var title_f22_44_23232="Osteochondral knee fract";
var content_f22_44_23232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteochondral fracture of the medial femoral condyle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This coronal T2 weighted magnetic resonance image of the knee demonstrates abnormally increased signal in the lateral aspect of the medial femoral condyle (arrow) due to an osteochondral fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD, and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23232=[""].join("\n");
var outline_f22_44_23232=null;
var title_f22_44_23233="Patient information: Persistent pulmonary hypertension in a newborn (The Basics)";
var content_f22_44_23233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8163\">",
"         Patient information: What to expect in the NICU (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Persistent pulmonary hypertension in a newborn (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/persistent-pulmonary-hypertension-in-a-newborn-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6903482\">",
"      <span class=\"h1\">",
"       What is persistent pulmonary hypertension of the newborn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Persistent pulmonary hypertension of the newborn is a rare condition that causes serious breathing problems in newborns. It happens when the blood vessels that carry blood to the lungs do not widen like they should after birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6903497\">",
"      <span class=\"h1\">",
"       What are the symptoms of persistent pulmonary hypertension of the newborn?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fast breathing",
"       </li>",
"       <li>",
"        In babies with light skin, the skin or lips look blue.",
"       </li>",
"       <li>",
"        In babies with dark skin, the lips look blue or darker than normal.",
"       </li>",
"       <li>",
"        The fluid that surrounded the baby during delivery is stained with a bowel movement (called &ldquo;meconium&rdquo;) from the baby.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6903523\">",
"      <span class=\"h1\">",
"       Will my baby need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The main test is an &ldquo;echocardiogram.&rdquo; This is an imaging test that uses sound waves to create pictures of the heart as it beats. But your baby might need other tests, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chest X-ray",
"       </li>",
"       <li>",
"        Blood test",
"       </li>",
"       <li>",
"        Electrocardiogram &ndash;This test measures the electrical activity of the heart. It is also called an &ldquo;ECG&rdquo; or &ldquo;EKG.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6903538\">",
"      <span class=\"h1\">",
"       How is persistent pulmonary hypertension of the newborn treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Oxygen &ndash; Oxygen can be given different ways, including through:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        A plastic hood put over the baby&rsquo;s head",
"       </li>",
"       <li>",
"        2 plastic tubes put in the baby&rsquo;s nostrils",
"       </li>",
"       <li>",
"        A mask over the baby&rsquo;s mouth and nose in a treatment called &ldquo;continuous positive airway pressure&rdquo; or CPAP.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Breathing support &ndash; The doctor will put a tube in your baby&rsquo;s throat. The tube connects to a machine that helps your baby breathe. This machine is called a &ldquo;ventilator.&rdquo;",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?29/27/30131?source=see_link\">",
"         Nitrous oxide",
"        </a>",
"        - This is a gas that is given through the ventilator. It helps widen the baby&rsquo;s blood vessels.",
"       </li>",
"       <li>",
"        ECMO &ndash; ECMO is a special treatment that is done only for very serious cases that do not get better with other treatments. During the treatment, the baby is connected to a machine that takes the baby&rsquo;s blood out little by little, adds oxygen to it, and then returns it to the baby.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6903553\">",
"      <span class=\"h1\">",
"       What will my baby&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many babies with persistent pulmonary hypertension of the newborn have normal lives. But babies with very serious forms of the condition or who need ECMO might have hearing problems or &ldquo;developmental delays.&rdquo; This means they take longer to do things other children the same age can do, such as walking and talking.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6903570\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"       Patient information: What to expect in the NICU (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/44/23233?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83452 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23233=[""].join("\n");
var outline_f22_44_23233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6903482\">",
"      What is persistent pulmonary hypertension of the newborn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6903497\">",
"      What are the symptoms of persistent pulmonary hypertension of the newborn?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6903523\">",
"      Will my baby need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6903538\">",
"      How is persistent pulmonary hypertension of the newborn treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6903553\">",
"      What will my baby&rsquo;s life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6903570\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_44_23234="Classification of distal phalanx finger fractures";
var content_f22_44_23234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Classification of distal phalanx finger fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distal phalanx fractures can be classified into the following categories according to the location of the fracture:",
"    <br>",
"     <ul>",
"      <li>",
"       Tuft fractures - simple or comminuted",
"      </li>",
"      <li>",
"       Shaft - transverse or longitudinal",
"      </li>",
"      <li>",
"       Intra-articular fractures - palmar (volar) or dorsal",
"      </li>",
"     </ul>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23234=[""].join("\n");
var outline_f22_44_23234=null;
var title_f22_44_23235="SVR genotype AASLD";
var content_f22_44_23235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56726%7EGAST%2F79643%7EGAST%2F67449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56726%7EGAST%2F79643%7EGAST%2F67449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sustained virologic response rates with peginterferon alfa-2a (pegIFN) or interferon alfa-2b (IFN) and ribavirin (RBV) according to hepatitis C virus genotype",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 329px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the American Association for the Study of Liver Diseases. Hepatology 2004; 39:1147.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sustained virologic response rates in recipients of peginterferon alfa-2a (pegIFN) and 2 different doses of ribavirin (RBV) for 24 or 48 weeks by hepatitis C virus genotype and viral load",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 357px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the American Association for the Study of Liver Diseases. Hepatology 2004; 39:1147.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sustained virologic response rates with peginterferon alfa-2b (pegIFN) and ribavirin (RBV) therapy for 48 weeks according to hepatitis C virus genotype and viral concentration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 364px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the American Association for the Study of Liver Diseases. Hepatology 2004; 39:1147.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23235=[""].join("\n");
var outline_f22_44_23235=null;
var title_f22_44_23236="Pelvic rt field";
var content_f22_44_23236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic radiation therapy field with vaginal marker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph (A) and computed tomography (CT) scan (B) demonstrating a radiopaque vaginal marker, placed to aid in localization of the vagina for treatment planning.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23236=[""].join("\n");
var outline_f22_44_23236=null;
var title_f22_44_23237="GAVE Light";
var content_f22_44_23237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric antral vascular ectasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of gastric antral vascular ectasia shows vascular ectasia, spindle cell proliferation, and fibrohyalinosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23237=[""].join("\n");
var outline_f22_44_23237=null;
var title_f22_44_23238="Dexmethylphenidate: Drug information";
var content_f22_44_23238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexmethylphenidate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/14/44261?source=see_link\">",
"    see \"Dexmethylphenidate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/9/17559?source=see_link\">",
"    see \"Dexmethylphenidate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Focalin XR&reg;;",
"     </li>",
"     <li>",
"      Focalin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Nervous System Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of ADHD:",
"     </b>",
"     Patients not currently taking methylphenidate: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: 2.5 mg twice daily; dosage may be adjusted in increments of 2.5-5 mg  at weekly intervals (maximum dose: 20 mg/day); doses should be taken at least 4 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: 10 mg once daily; dosage may be adjusted in increments of 10 mg/day at weekly intervals (maximum dose: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conversion to dexmethylphenidate from methylphenidate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: Half the total daily dose of racemic methylphenidate (maximum dexmethylphenidate dose: 20 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: Half the total daily dose of racemic methylphenidate (maximum dexmethylphenidate dose: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conversion from dexmethylphenidate immediate release to dexmethylphenidate extended release:",
"     </b>",
"     When changing from Focalin&reg; tablets to Focalin&reg; XR capsules, patients may be switched to the same daily dose using Focalin&reg; XR (maximum dose: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dose reductions and discontinuation:",
"     </b>",
"     Reduce dose or discontinue in patients with paradoxical aggravation of symptoms. Discontinue if no improvement is seen after one month of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F158424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/9/17559?source=see_link\">",
"      see \"Dexmethylphenidate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of ADHD:",
"     </b>",
"     Children &ge;6 years: Patients not currently taking methylphenidate: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: 2.5 mg twice daily; dosage may be adjusted in increments of 2.5-5 mg  at weekly intervals (maximum dose: 20 mg/day); doses should be taken at least 4 hours apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: 5 mg once daily; dosage may be adjusted in increments of 5 mg/day at weekly intervals (maximum dose: 30 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conversion to dexmethylphenidate from methylphenidate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: Half the total daily dose of racemic methylphenidate (maximum dexmethylphenidate dose: 20 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: Half the total daily dose of racemic methylphenidate (maximum dexmethylphenidate dose: 30 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conversion from dexmethylphenidate immediate release to dexmethylphenidate extended release:",
"     </b>",
"     When changing from Focalin&reg; tablets to Focalin&reg; XR capsules, patients may be switched to the same daily dose using Focalin&reg; XR (maximum dose: 30 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dose reductions and discontinuation:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3268365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No data available. However, considering extensive metabolism to inactive compounds, renal insufficiency expected to have minimal effect on kinetics of dexmethylphenidate.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3268366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No data available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Focalin XR&reg;: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg [bimodal release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Focalin&reg;: 2.5 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Focalin&reg;: 10 mg [dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F158431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Focalin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088600.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088600.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Focalin&reg; XR:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088601.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088601.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F158401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: Should be administered once daily in the morning; do not crush or chew. Capsules may be opened and contents sprinkled over a spoonful of applesauce; consume immediately; do not store for future use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:  Should be administered at least 4 hours apart; may be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of attention-deficit/hyperactivity disorder (ADHD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5707763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexmethylphenidate may be confused with methadone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Focalin&reg; may be confused with Folotyn&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Actual frequency may be dependent upon dose and/or formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (25% to 39%), insomnia (children 5% to 17%), restlessness (adults 12%), anxiety (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased (children 30%), xerostomia (adults 7% to 20%), abdominal pain (children 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (adults 6%), fever (children 5%), irritability (children &le;5%), depression (children &le;3%), mood swings (children &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (children &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (children 9%), dyspepsia (5% to 9%), vomiting (children 2% to 9%), anorexia (children 5% to 7%), pharyngolaryngeal pain (adults 4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal congestion (children &le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Accommodation difficulties, anaphylaxis, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Also refer to Methylphenidate for adverse effects seen with other methylphenidate products.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexmethylphenidate, methylphenidate, or any component of the formulation; marked anxiety, tension, and agitation; glaucoma; motor tics, family history or diagnosis of Tourette's syndrome; use with  or within 14 days following MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Cardiovascular events: CNS stimulant use has been associated with serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems (sudden death in children and adolescents; sudden death, stroke, and MI in adults). These products should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Visual disturbance: Difficulty in accommodation and blurred vision has been reported with the use of stimulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential:",
"     <b>",
"      [U.S. Boxed Warning]: Potential for drug dependency exists; avoid abrupt discontinuation in patients who have received for prolonged periods.",
"     </b>",
"     Use caution in patients with history of ethanol or drug abuse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Psychiatric disorders: Use with caution in patients with pre-existing psychosis or bipolar disorder (may induce mixed/manic episode). May exacerbate symptoms of behavior and thought disorder in psychotic patients; new onset psychosis or mania may occur with stimulant use; observe for symptoms of aggression and/or hostility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use of stimulants has been associated with suppression of growth; monitor growth rate during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Safety and efficacy of long-term use of methylphenidate have not yet been established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Dexmethylphenidate may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Dexmethylphenidate may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Dexmethylphenidate may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Dexmethylphenidate may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Dexmethylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Dexmethylphenidate may increase the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Dexmethylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Dexmethylphenidate may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F158413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: High-fat meal may increase time to peak concentration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid ephedra (may cause hypertension or arrhythmias) and yohimbe (also has CNS stimulatory activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit to the mother outweighs the possible risks to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F158422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10278045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if dexmethylphenidate is excreted into breast milk. Dexmethylphenidate is the more active",
"     <i>",
"      d-threo",
"     </i>",
"     -enantiomer of racemic methylphenidate, and methylphenidate is excreted into breast milk. Refer to Methylphenidate monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F158406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Focalin XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $723.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $734.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (100): $755.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $755.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $793.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $793.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (100): $832.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $832.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dexmethylphenidate HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $68.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $97.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $140.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Focalin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $75.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $108.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $155.65",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F158396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure and heart rate (especially in hypertensive patients), CBC with differential, platelet count; growth in children. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, or depression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dexmethylphenidate is the more active,",
"     <i>",
"      d-threo",
"     </i>",
"     -enantiomer, of racemic methylphenidate. It is a CNS stimulant; blocks the reuptake of norepinephrine and dopamine, and increases their release into the extraneuronal space.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F158403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Extended release: &ge;0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Extended release: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release: Rapid; Extended release: Bimodal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.54-3.76 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 12% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via de-esterification to inactive metabolite,",
"     <i>",
"      d",
"     </i>",
"     -&alpha;-phenyl-piperidine acetate (",
"     <i>",
"      d",
"     </i>",
"     -ritalinic acid)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 22% to 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release: Adults: 2-4.5 hours; Children: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Immediate release: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Extended release:  First peak: 1.5 hours (range: 1-4 hours); Second peak: 6.5 hours (range: 4.5-7 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90%, primarily as inactive metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/44/23238/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Habel LA, Cooper WO, Sox CM, et al, &ldquo;ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,&rdquo; 2011,",
"      <i>",
"       JAMA",
"      </i>",
"      , 306(24):2673-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/44/23238/abstract-text/22161946/pubmed\" id=\"22161946\" target=\"_blank\">",
"        22161946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, &ldquo;ADHD and Cardiovascular Risk,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354:1445-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/44/23238/abstract-text/16549404/pubmed\" id=\"16549404\" target=\"_blank\">",
"        16549404",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117:2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/44/23238/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8667 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23238=[""].join("\n");
var outline_f22_44_23238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708694\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158416\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158429\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158419\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158424\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062915\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3268365\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3268366\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158399\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158384\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158431\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874426\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158401\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158400\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5707763\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158427\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158404\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158388\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299158\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158392\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158413\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158394\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158405\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158422\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10278045\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158406\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989308\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158396\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158387\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158403\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8667|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/14/44261?source=related_link\">",
"      Dexmethylphenidate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/9/17559?source=related_link\">",
"      Dexmethylphenidate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_44_23239="Glycolipid Glomerular podocytes";
var content_f22_44_23239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plastic embedded tissue showing in site deposition of glycolipid in glomerular podocytes (toluidine blue stain, original magnification X80)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 369px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFxAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyO+024tLN3lyu7LBR0BJ5H8qzbXywpLfxYXI7GvVI9a07V7Zre+CTRjB3KQJE/wAfpVGbwRp92vn6bcxsud2w5VgfTFet7Rx+NHnezUvgZ5mqAq21vlbKkHrxzTXjCO67g4U8H1HrXXar4YutOtX3IROdx24ByCcdfx61kaNoM+sXXy5jhjP75yeR6496rmVronlknZj9GitrewW91aZvsTylEgjXLyFcE89hyK9T8O+JU1Tw9cz2tsYEgbYdzZ28ZzXNQeGJr54La7soU0SMMYDFIFkBI656knHNa+sS6X4S0U2ViDAJPnZS29yfWsJNTajuzeK5E5N2M2+1K4eWVoHDTJhShJHJ55H41BqHiy70uzcSL+9RgCucjmqWh3UNxcPNFIzqSSVA+99fStPVNMk1a22vAywytgOy8g+1aystGZq8tUc43jmW8D+cGXaMhQ3BNVLfxLqQb/SsxxPz5pBGBnjFd7o/wos7W2klubySWdlzHxtCH3HeuO+KltFpU2naXEMvbx73c/8ALQt3/SsoV1LRFzoOOrOwsNej1LShbSSRm7VSYHHIdh0Gas+H30fULmPULc2dvqs6hbuFnIkDZ5wPciuA8JhILWwnclQ1x0P9K6HXbJYNbvSE2zSMJY2TA+Ujr+eapwi9FoJSaR2viC5ht51kn3BFXAVR0PrXC654p+1yfZoSsMRbarbsZFaXiG8ni0SwVmaQzQY3s2TuGd2a8wsdr3cr3J+YHoRTpQSsKpJs9i8IeF7FES/neG7nc/fRgyqfr611d7p8ckZbarIR90jivPvhNObO31O7uX8jS/lAZzhd/fH4V3NlrmlauGtLPUY5JCDwnynHtXPUjLmbWqN6co8qT0Zzl1oc9zMiW8LgMRvYHA49far2vWsNr4Wm0+K4R7kgBhu+ZvaqHjLxY/h66+w2CCS5K5LN0UfTua4S0ju9WuZLqSdhI0m45Y859K2hCUkpSehlOaTcYrU1fA2ipLdTBE2hCcsRya9NNkDpE1uny71KZqh4Z0w6dbNLLgyvg4HtVzVLw2sHmSfvAclUHBrKcueWhrGPLHU47w54WXw5NdXN1MspI+UY5A/ya7rTYEghijXCxgD8K4vQtAvIWmu/tLz3crg/vydqrnk4+nSuuu7pba3LzuFAHJHGTRU952TuEPdV2iW9vVhhklbYoA454VR3NcLd/EPThMEJupImz8yfLyPbrU806ax53nTqLWInbEG+U/7TetcRqPhd7crJFLGq3BYxgg7to6n2HPWtIU4x0e5nOcpapljxD47muYxb6NGbVMksSfmP407QUb7PjUlJkmQybm759TWd4S0O31HVJmmWW4tLYZ85OFY/Su61+S003w+98luZljwE/wBnnH4ValZ2I5b69Tz7V5l02aGGw3RTAmQH1yeM1o2Gt6xe27NGSEjXbKUHLH1NXSmlavax3+psLe5EIcehXHcfyq78OLG3ikuArrdwsAZH342Z5Hy/TrVOTSvYSim7XOQ1rWb9QtkJHWLO/OSC2agtdd1SOVYLe+lJLbQS3Fevv4f0j7dd3t+lvLZbAWUp90r3zWZa6d4Vj0O71PTLfzYIizMSu509hntWftm9loV7KK6nLWuua8x3y3wFtGCWcAHoOn1q3pnibVLjRri73GUwyAEFcfLiu48P2mk3+kQ3Vtbxkznc0UgAYEcdK2nggSJoY4IljP3l2DFTKtraxUaKte55Xo3ibV7m7jIkH2ZvlYsg4OccVFbeNtVtdTW0vgrc4J2YJHrXVXNpothqIR5pRhhIYVHC+lbd/oeh6/5dwqxrcBNqSJ1FVKolZ8unoKNNO65tSvYaybpEcL8hz8w54HXitKKS3mPmod/uDwfwrCvvCs9pAo0y5dCoYklsYJ9PrXMQSaomvND5YsSqAMqH5Gxxkk96lRhP4WU3OG6O6tdK006supxW6R3kRPzJld2fUdDVppEQMZ7mJoyeFcYx7VQtLmf7CJGljduhI4bPpjvVoSh1RXK5P3g64NZ2sy1K5K1iHjAMoPcsRjNR6dpcOn3El3byyB3GGjHAY+v1qcsMAFEdB0WqommgnbygWt16I45B9jSVx6Fost22wuZJUbzGRjyn1rkfEFtqQmaaO3SSMtnHpXRR3tvNciRbiKG7BCsrYyc9FNWbqxlluYbgXJgI++g5Vx9KuLcGS0pqx5LfmSFZJplikDHlS3C+wqtphjvsoQUxwOegr0LxToVrcw4h2qeW2no3vXCILOwMsbEqynHHeuqE+ZaHLOHKy5JZQxBFjlAdzjc3OazrqKXzR5MnK8MTxxUM9xLxOi/cGdpOcVYhd54ElZMFjjH0rS1iL3HW0KTQTRy3KxSMuQxPBNc9l4odrkEZOK6X7MXjJcD1HFVLy3+1NEpXaE74oCxhqm6AsfvNgqB3qzp6s8bL82A3QD+VbVzaqHt3jh4AAJXuapSNuuHjR9hXnJ4xQhMS3Z4ZnVQRlSVXPeqMd5P56yPll3Yx0FazxmTy5AnIGAcZBNUbKxlmJCHbhuKBWJrjUW24jHlgcZPU02x0+5v5xJISsbDk1rRaBeSsJLpAiDlmJ44rYtrGW5ZE0+SJbcHBYdfepc10KUH1Odn/ANGsGNpHsfPDKeaNP8U6il1BFEdrNhM0R31vDjzHV1HJFV7zUdMiwdMsv327d5snOPYChjVj2nQrn+0bW3zskul+RvM6Y6/qKk1vTreKIKEiicsCQgAVR3Jrz7wDr5l1CGF12Iw2llPQjpXeX8aQSNHgyuU+R2Oe2cH34rinDlmdsJ80DlfE/iae03Q6akLiIbWDnB6dvWvNL+e9vr+SfUFlaV8ckEDHoB6V0uvzWk+oxwS4SRiQQTxgdPxrC11SkwVNxjUcMDXXGKitDkk+Z6ljwpYTR61bK7PCruPunkjNfQsWjW0IBwz7R8u45xXi/wAJdFutS8SpdXKs1nbLvLMOC3YA174enTNcGKn73Kjuw8LRu+pHFGiIAo57nua8o+L+jPcXVvdx2RuAgCuewXPHNerxjaCvpx+HauU+IepCzsUt8DNwCGbGcKKyoX51Yutbl1PFLq6iVRDbJhIz8uD90+1dFJcT3Om2WqSRNLFCjJMynOBkEE/ma5WYL+8cKPmYlgO1dx4Hsbibw7G6bkSOUtyMggjkY716c3yq5wQTk7FqHSRrHha0un8wOsbGNB0OWJz9a801XTJ7e7lkff1+Ud2Fe0yX8NvLY2zPFFCQQmTsG4Dp6Vmap4fttVmFzaT8B8SAHIH0rGM2vi2NZQT+Hc8z0063qscVpHFPJDAP9Wq/KPWpL+Ce0ukMazQXMfK7eDuFdjHqupteG20zS3jtI5cD5SCwB5JI711ur/2PdXMbNa+ZqJUN5K8Nj3q/aSjpuR7OMvL9Ty3Uri41m4iu54mF48YSQbfvEcZ/Guj0Pwpq1jEtw7xeWg3lGbke1aC6ilvfSRHSY4JYgHCyMc4/rWrBrz3lu8X2N7hpGKhEOB09aUpTtpsOMY313N0XYt9PXzAHk4GAeKzJoItS1FLq6DG3tzmGMfxH+8RVLTdKu59We+1QDZF8tvbq3yxnHJ9z71d1S+tNFilmuZGdpPnEWdzcDoPasEtbR3Nm7K8i9e6jb6fb+ZdyrHGemTj6D3ri/GniGKAWjwF5YpgwZVI6Yx+B56VWuc63eW98DLcwkCSMRrnYR/DitxPBn9oWklxcK8E+4PCgPK49c8c1paFPVvUj36m2xPb6dZaJ4MS/Np9qdYgY0ZQrFieMj6mvIfEWr3epao1z50q5BVU3EBF6ECvS/Fen6rpvg1JFuxJcWU5ZWfB3Ie5z3HavLnvc2glmk3TFijx44wepxTp2abuTUvdJo6HR9dOlaHe29nCscTxgJK7/AHHI54HXmsOSfUZdrS3Lyx3EmVG8kE+uPxqkIkKuWl32+4K2OM/59aZAzx3iGzilcnckKgk8njI9au6jqZpORp3t+iSfZb21kRlkAJDclQMYx0NdD4csH09Yb7SRLJ54eJ0dcHBHcfjxUXhrwHqet3sMs8m2GNh5hkB3Ef0r2vQvDNno0ZKLukIALHpx04rGdaMfU3hRbV2YnhmwtLOy+wHequpJSZtxJPUDP8q5vxTaw6W6Wmmp5Nqw34TozetW/FWp2z+KIQ8rqlrIHOzq3BBH5GovF+r+attBaQhUxncy5OfQVVOLUlLuTOScXEi8B3Ev2ySV4pZkiXCheoyelejzQxyLkD5z+lYvgKFzo4lmhWJgxzxjcPWm6hrqpM8OmyRzEt5Wc5VD3+prKpepN26GsLQgr9Tj9d0C5uNUmubN45Ii5+ffgDH3ga6vRdMii0iNUuYWmYZ3q4IHfjHWuI8dw/YfDgjjD7vN6LkAZzngdjXA+G7C/wBQ1COHT1leZeQEfGOepNbP3opNmKupaI+j7iB/L3gFowOfeud1/wAOy66riAiB1/iPR/wFWY9RXS/DbQa9LsEa/vnbn8Pc1xeofEyKysZhpcj3jzysVMqbPIXsvHWsYRmtYs1nOO0kJd6EfDvk3U99l0ZR5DNhS3qPYVrt4q02SGL7RJHD5reWrRnv0IJ7V5LqOv3erXcTaiWdEffjJ6d6sra29/4jsxZo/wBnkbf5bngY5IzXRpJXepzpuLstD1e18Ov9sS5fULyKKZsR5b5PYCty70jU4U3w3sT4GQHTGfat0WKXPh1LdsKPLUqfQjpXMHxCb2Se3tnIe3byzhd2W74Nc6nOb06HS4xgttzmLjxfZ2d4bXWLM+ahz5gQMD7ium0vWLLULMGwmEsZ7A/MKy9c0Cz1izS0lt5I7pSWDuQCx9K8rn+1+Gtc8m2MkciHjP8AFWyUZeRi3KOzue2SR/vBJIPMVQSFI5FZ0/h3TfEUX2xl25XIZDgn6ip9C1GLUbRS+1blRhh3/wD1VYjuobSRpHYxlSFePbxg9CKhpp26lppq/Q811DRbjT7uSJ42aBOVcfxj1qtpdwWd4gEMS5O7pg969P8AGEQk0ssDjC8EDPBrySSQrNLDF8isOSFx0rqpTc1qc9WKhLQ6X7VY2Ty/bgShThgMqD0x9arMI5zvt2DxEDBAqtdwQNokEU0h8372M/lTrS0aZhboJFt0jGMt1Jpqy1J12KF9My3RjV3DRtwuegqMkyXDOy5cJywHBq6uizyzzSyJIoY4XdycVr2ujeS5M7gQ8fj9abmhKDMVZfPtliiQnI44ra0XTWjMZKAL1565re0nT7UKCqAhj8rY4p19qthp16bS2/ez4JLH7qms3NvRI0UFHVsvahdLbaSkBiwG5IYferl5dW81fLSRE25yiccVT1LWJtQRn3MwyBkDAx3rmJsfa5hAxEz5A/LkU4U0lqTOo3sV00uR1JYhcDOCM5qGW1Zf9Wyv22jhvyre84IAUOVKblZiBuI6r9f51Ut7g6heeXBaiR3GAxHzIfUEVdiU76F/wZaXS3sLLGwEsgXkV6p4h0/UpfEWjzW0cjWUMbGcIRhj2GPxNY/gjQLzTFbUdT86V0UskQGcf/XroLDxQJ9X0+OSM7bveIth4CjjLepyDXHUm5SvDodlOCirT6nEeLrGGCWa3nh8xQRjAyQD39R+FO0L4fadqipK17LFbr8mwMDvJ9DWh8Tp4XkZ7JwLryiCQeeO1ebQaneRWsLyXrvNgMse/Cpz94+9aRTlBa2Zm5KMnpc+jtC0m20axW1sl2wr+ZPua0PWvMPBvjmXy4IdVcSpIQqyL/Dn+dei3l3FZwmadvk7Y71w1KUoys+p1wqKauiy6K2Dkhh0I615f8WrordQxE7vLTORxy3/AOqug1LxvbQ2s8kAAERwS59/SvNfF2rnVLqG4LHaylmJGMgZArow9GUZc0jCvVi42RzNvbyvfR28YOZiAB65rqtYurnw34k0SAyutrHGrMqnhssQxI/z0qh4JjWfxPbb1G0EkE+uOKvTaVJNeXGp6xcGd7abyRH/AM9SM4wewrqk9bHPGOlyfU2e/u7i7u1jS3ikdYWmGBtzxsXvnrmtTwsimQPYyuyP8rYXHI9vyrCittT8TXkX2qRVt4QVj8tflHPT/wCvXcaXpp0pEFs0eV+8pUgE+pNROSiuXqaU4tu/Qt2e9YiQMSu33fSpWtra2umvZIv9LZArELuZgO1SLPK7NsCqO7hcA/SnmXZETIcnpha5mbrQoz2EOpT2017agLAxKRA84P8AeP8ASrtzcWmn2xeXybaBOfQCqdxq9tGWUSrlPvnOdn1rzG31qbWtXuGu43mTJESjoB2GK0hTcviM5VOXSJ1fiDxisQhWxwZZpNiqwO5vcD8RVbTtF1HWrss4dn3bXml+UKPYHrXZeF/DECWkd5qNrC94SJIwRkw4GBg+tWJ3k09ntdNH7xn8yRpDyc9Tn19KXtkrxgV7LaUzV0jSbbSLBLW1QBUHJPUn1qyVDoRyAaisDceTieQSDJIZhtOOwwPSq2qaxaabGTczIpB6Zrls29NTdyUVdnn3xouIrezsYZHky6ybYlbA3cbWYdx1FeR6VbSXd05WEXBGGaEZBfnsR0717dcXGmeL9RNsZVYW7YcbRnnpg/nT/DXhax0TU57eKZWkmjXbuTOAMjr75rqT5Eovc57Kb5kzmNK+Hn9qSwXj2klvbkZMbtk8HIz68cUy0uobOOY6Rocj2cDYknkyFUA+vauy8Mrrmg3t/a3xnvdP4a3fqU55X6Vu3FxNd2dxZS6WWjkXBRgPLYH1NTz2d9GiuTS2qGp4p8PWFvaj7bbosxCosbbuT9P51q6xcsirBCwE8hwPYdzWF/wjRltoEaOziWMgqscKkRkVuQWcFoS9xKXkK/NLKecf0FYPkXwmi5vtM5nX/BFjeyQ3YkaOWPvng+9XdF0Kzgs1t5lFwu7ersP5VptrulAD/TrYqVLA7xjHrVDT72ZY9QmuUQ2lvue3aIg70xkDHrVe/azF7l7o4v4u+JW0+1XRdOLxF8ebNH/D/s8d64bwrr9np9uLUQ3HnSzAvPuyM+vtWDqmq3GqandyKSqzzNNtbqD2rMimZWcMWAIxx+ldcUoJI5ZXk2z2HXtWWKylEqrNHtJRj3OK0fhba2ejeEX1S4YRsylyzn7pPYf0rxR766NqluZHZD0x29q9U+Hk9pqXhCXTLiE3ggO94i20huSpB9PWlUSashwlJO7Ohn8MOPDY/tK4e8eZjI/mksF3DgfhXhl4kCTXItZSISuSvXBHbNe36L4pvtUlSxu7NIWgmClIm3fKBlRWxL4NspTLJ/ZVjiVjI6AYJb61m5OHxmkYqa93Q+coGeaWJUVnI9f6+1aejp9p121+0CRYkfcxiHTviuu8UeDL+11G5n0ZY4rHG6WNmAZCoJIx3FcXYXLWN3bXMqMkauGJ678VtCV1uZTi4s+kb8XMvhDNozGYwcHvnHFeJeHJ9f07VFhtLSUvLLyHU9e5Jr2rwNq1vqejI8L7lPIz6Vp3U8EbMrBFXGGJ4rnjUlTbjY3lTjNKTZ5jd+N9IS+K39s5vQNjSx9MiqBWz8RSx3UFxHBJEwVjL1x+PtXO/EjQZLWeTUbMq9m0hUhTloz7/WuT0qW6a7jiiZmMrhSpPWt4yjeyVjBxna97nt+saLBpNsNX05yghwZOciRT1xVtpDdLBLCgmWQfKwHGD2qtoPha8ksAl3fNLaNGcRHPesfR57vw9qcmm3xZrXd+6Y9h6j2pK0tE7tFO8bNqyZsz3Dz28tk7bWPyoT/CfQ1zT+HJ/O3yoxQLjKjrXUXtsLmdpIYSJOHDq3Dj/GrWkXK3KFInVmQ7ZBnDIfQinzOKugsm9TkbXQJLm7T7SA0a/dHT863br+y9LhC3U6K6j7o+9+ArpoYLeS4DO+Co2YHUGvMPFGiXlr40SaMhobiQGNmOSB34ojP2krSBx5FeJ1swJW2aODiTHzHjaPpUPiDVrbSjFAvlNKeBvGce9c3451S5h1DZZXMuyLAIUYGRXI731GYtcuzSt1ctkgfStIU72bMZ1WnZHS6x4luEmEUErFxwUAwK5u/u5Du+0R+XK5LKwPUdxUIu2tLh45AHKvkMy4fipdQZ9Ts0mUpvi3bolHzAZ+9W2y0M7Xepd0tlmtDB58cYYbgHbHI6jNZs/wA8Et0siq5kACg8g45rQ0PShr+nTRWo26larvVc/wCtT0+ornGDxyFGB3A4IPrUuaKUHY9D8M+CdQ1CFTcJ5UKjaXfow+nf616T4f8AC9jpQDRRq0wGPMYf0qGfxZp3ll7N/N25BH3R9Mms6XxkhjJMKowPBMvH1rjkqtTc6ozpQ2O3lffEyArgjbxXn7XFhp+uW0Vwhhkt5MA44Ax3/wAadbeKyq4mBOX3pzz6baW61Ow1BnW7tfLZxt8z7xH0NEKUoXutBuqpbMuanp2j67OWSZftDD5ccZ9x615xrfhsaZrDi5CurLtHHHWux0bQrWyYzQ6wZFQ+ZsxkFhnt269BVnUY49bjEcuxrxVzlQQD7jNXF8r8iZLmXmecIrRXtuFYLDuVVUD3616DrmsS6qRFb3LLaxgDHQMfU1zK6NcLO2VYGMhVyOvqfyq5ZaBLbl/9InaIKwQdwT0P4f1rWTi2mZRjJHPa5NM2k3f2QQSQ79xcHnb3+vNZkyu7wxnICRqArEnPFdjJ4TNzd2ssJliEIyFVeGbuT+NOjOlweIksQv2u+J+YqfkQ9cZ9aFNdAcNri+FNKltXW5kVxM+fJAHIPdj7V1smi2zWsUV2EeBTuG7ux7+5NWLdjHcEzIoYptVR2HerP2dG2sclu3tXPKbbudEYpIbaRR2sWyGNAnYKMACi4uY4V3SMAPfvWRr+uppkZhtY3urw8LFGM89s4rkr/wAP6/eWwv75vMndj/o2fuDtj1ojBX952FKb+yrnR3fiy2jSRt8EcanaGd+p9MVh6ZrMeu3UpnuJDGhysattX8az9K8Dz6hP/ptu9tbjOWlONvuBXdQ6RoXhmwEZhRtx6tyWNaOUYvlirkKMmuabsc3cadbSTy6k04trKBS07AnHoOnU89KvfDTStA1az1B9NFwZEPlyGYDIB6EDp2Nc/wCIPGdpqUMukyWaxaWJCkgQ4c47r9DWDY6jFpGv2P8AwjdxdWtvOoVpZm4bJwTjpxSkpNWegRlFO6Po+yykKowwFGF+lZ9/ZK06SgDIcFSRnmuf8L+Jpr/xFcad5RlhiUfvy/Xjr/Ku0fBRuMY6VxSi4PU6oyU1co3M0VuuMhc9ea8i+IV7Bb3SGcsscxI3qMtge9d7rxdLpGY7VyevevHPijfRz6rBBGXPlJzzxyfT1ropLlXMYVffdmP0DXFtdShNg8rCRwrEx5Yj0OK9vtvMlvbczwhN6b1OOVHvXl3wg8GXF3dHUb1WitVyoBGC3Q16V4pmu0vtthcLbyoqgbk3hh3GKKkud8vUdOn7NXLeqzXL3Mdrp4Jds73DY2elcx4ilu7NJLdLiRJjx5n88ZrR8Q/2noU+kXlkj3ELybb1VXJOcc/hXHfE7XbK4aa3DyC6kZQuDgKncn3p0Vdq2wVWkmnucfqerXltcOItVmu2HG+N2UZODwPwp+uanqFrDpqieQ+fb8/vvM83dyc++Dj/APVWC13G8CLDC6yKWXzN33ge35U5rNxDLMrJJbQNsb5vmz2x7V1N9jl5UuhY0W+Nnq1nNdgvbwON0bDcSM5wB6V1I8cvFrss8Lu1tK21oggAK+uPUVwUN88UE8SgbZQAWIyfwpEBaF2Rl4Gwbh2Pepun5lWa8j0LVvA0l1O11ptwwLZIQj15wK5648EatbBnMaEhgyqHDYBzyfyr1Hwk076Dp0kbrKRbKWYZ+bHA/Grsn7wyCaARSuMbgc4I7GsnJ3Nkk0eK3/hzVbbyQtvI8pXewQDA56gjrx+Vdj8KdHcSz615pFvAzRsoON544Ndra2AnWJDEgj9COnqK1SEs9Mu0uFiiUFiojGB7fjSlN7Iaglqzh9aP9leIoryxZXTduyDy5zwDXpw1iG30hbq9byiFGfc18/XGoXratJFJMHt1ctnjC+mDXpe7T7i1im1+8iTTjt8qNnwSRg5461dammlczp1Gm2tDM+KWrTw6FuEO2LUsh3IOcDoB6Hv+NePM8PkQhQXcH5wx4PpXW/EbxPN4h1CRYiP7IgJFoNu0EcAn36Vw6LzgjI74qVeKSK0k7ntfhoaho1kzKzODblokT5jnHAA9BVnwxDrbeFZG1csTM5ZPOBLqPfPvV7wdLKNGttRMaskcIj8vPIx71taT4gttYvGtvMSGZDgwtg/gaU5Su7LYIqNlc8e8fCY6wJMGG3aEAyD7shHb3IqHwDMJNXkuJLSCYRRFnA5k4/iUd66v40x2On21vaWw/eyN5m1DwvXJP1zXI/DxCL+UyF0iljMe9fQ9quL5kTJcrPe9ADfYwyuJIm+ZG9qzfHujjUtEnaNcXUakxsvXNY/hy7u9Muljn2/ZZH2YU8KP4W9q71gskZDcjp9a5pp058yOiFpx5WeJ+CfEU1rdJp16zNGTsRm6qfSp/FdtcaX4ji1HTZHQ3OAwHQsOxp/xY0i3094r3TVK3JfdIE7eh9q00im17w5ayFQl4mH2uepHb8a61NNqZzcjScDo9Dvl1HTVndDHMx2SjPRhU9/plhNLBLPIUMbBi279M1ieC1nRb23v4/ImaTiNj1GOorob23E1m0BIXGMHGelYTspaG0buOp5r8RLyL+0XigBXbwWxzXCBtuHAO8HO4dK7Lx3f2c+oCG3VZZMfO+ejd641o1WR1RsADLeldsFaKOKesmNupHup2kdvMlY8mi3muLSUTQs0bDIzjqO4plrcG3uFlKg4OR7VqPeW88TZxyO/rTWoP3dDTg1aLT9b0bUII0hlKAzhPunJx0+lY3iOSI+IryeAq0TTF1I6HPNFl5LKiuNzZOMU64top3wuEPfNHJ1QlPuXNLvIwJraZVMjEtHKx+VO+SMc+1UL3UElV3Inmu+FV3bhQO+PWq8k729+Zbdsbfun2xip9aiJ1KTyzuEgWQHH94A/1pNjS2LGmNM9vJfXk0n2OFtpUHDSsedo/mTVe+165nRVQJbRK2QseavXSLJptpZQsdkO5zxjLsRk/kKpNp8LxlSfm9c0WkO8bgurTxiExEqVOSefmPfmuo8MeI5rrZb6nE1zErbRJnDKD2yOaw5bdba3txmZIyPmIAYEeuOx/pTLab7LHBh42iecNJNswfl6Aj8aGrrUFZPQ9x8Paei7VS+eSArvWOQBmwehDen4UeLIzo+gajqMVwS0MW5UKjBPQD9axPBurJJYtMxKLGw2lu4PUfTiuX+KHi/+1pIdM0qUS2zriTA6uT0/DFcKpydTyOx1I8mm5r+Hten16wZo8xTrwQSNrHHOM1H4a8JJpeorfSjfKCSuW4XPtWl4J0VLLS7YTIplA5Pqa3boN9oKjCxAAgd81Up6tR2CMNE3uVoYWF5dXEsrO8xAUdFVR2FQXb3txHLFpxVG2kCVxkBvakkla9vfsdu5CoMyuOw9BXKX99czTuyyMtuDtEQ4AA7/AFNOMW2TOVkX9G00aZfnU9avHnvnG1cD5VHtXdrIkqAMBuC5BrkvBtimp2szXis8MTgR5Pfv/Suturqwtp4rKeaFLiVMxwsQCy9OKzq6ytuy6ekbvRHLNe2+tWsn2+C5tPsFx+6XfhZ+Oh46V5nf65qWu6p9g1OONAJSTIuVZfQZ6Y6VneM9cvb3xDdeZM6pFIURAcAAcdKxIZbqDEwMgjYFSw7juM1tFqL0MXeWrLOrhRcOqh1ffxubOR659/Wuz8L+CbnVY7EXUzSQJ86RAYwGOSc+hxxXH6PYS6/q8dvDgEr0Y/wj0r6e0DTE0zTooV+Z9oySOenSs61S2qNaUL7keneHLC0gwIQzkYLd+lV7q9GhTpbzSTS2sqHy15LIR2B9Oa6JDj3zXEeO5WjvbdhgBVJJJwByOawpXnKzNqloxuiW81Wy1FDGzmJlPImUrXkeqWFpf+MLYR3EDbplSWIZJPP+fpUd5rl7Y3txHeESRvuKSZ5bPQCue0u/ay1i3v1Bkljfc6nv612ciirI5Odt3PrDTrWKysobeBQkcagAVl6jpn2rXIZip2gAk9hiruh341DSrW6CFPNQNtJyRT7u68lwK89c0ZM7W1a5X8STNFprrH/rJCEHtmvnXx7EF1a6fZIx3BQ54UAdBj1r33xKzSWAmQ42EsSOo46ivnXxBfPe2mZ4RJdRnbJMch1wcAEV14dWizmrv3kZHml4BEBwPm61cvbd7a1ti08bb/nKIwO36/pWewAdgFKhepweeOhqWdfMCPHuCoBycHknv6VumYtDbaGS9kRI8ctj3JPetSLQLsazBp7bTJMQVZWypGcVnwfaBJIYFJdhuBQ9PpXceCfDGo6pNDPqUM8FpbkSNKx2l8dAD1zUtqO7GlKWyPVfCtotmZ7DJb7IiREk55xk0l88a3swl4AYHdj2rR0SFVF5cKPmlfLHPUgVzVzcXrTanqNrNHJbwROfscij94y993bvXOtZNnQ9EkWkvDFdxCFxsLAsCeMVy3xRv2FmLaJ22tINwTOW9f6Vf8O2eseItOOpXcnlLK4cKibdqeg/nVw+HUvPMaXEs0eQDnP5VsnGLvfYzcZSVu5574F0ePULid7ossSAEoV4I5OSPwrJ1XUW8U6q6Q25SG2hkNvFHwSo5yfwr1pLKKyuYbclVuroFEAGPqT+Ga2bPwPplhIJ9OiSG4biRyucgjkD0pVKyT1HClpY+a0iml/dorELycDOB34rU8O+HdS166eHSbcyqDh3fhV+p7V71qvgmzvZTJLaW7uAPnjJjZvYkVr6WLPSrFre3tEtfKxujUD5j0Bz3zWbrXXu7lqkk9djldZEnh/w/a29si7cBX29N3euO0B1inubmcncuZZNo5YDn+VdH8R59Sit0Zo1EDPu+UH5a808P3txYeIA8su4SSeWwbvmuqkvc9Tnqu0/Qh1bVU1G9mD3EzWbPuQyH5gvPFX/AA5qFrY2rFJVBHzFWGABWZ430iTR9aeJ49kUo8yLByCp/rWDvKnoCPej2i6idN9DrNa8VX95cqkEipFG4KsmefrXvPhu/N9olnOWDFoxuYDGTXy6JpMueit1x0r6M8CHHg/ThGfMOzqO5rGs1KJpSTjIv6npUF48srqjPKm05Hp0rlorAxEBbh4rlO3Yfh6V2NokrZMqldpI65yPWpLjT7W8I8+IMR36Gso1OTQ2cOY5G1umlZY7raJkbKuvSugs7kzxyeZHtaNsEZ6+9Ra3o9qNOnFunlyqhKkdsVHpBE1tHNwGdAGPqatyUldEpOLsef8AjjTEXUmkhgB835gqjH1ribm3O8iQ7cdgMV7lf6UmoWc5T/j4ThcnvXk+tWNzb3sxkiK44+ZeBXTRmpLlOWtBp8yOeNofnIcbR90YySKqrAAhd3A5+761dlLAt5hCnHGO9VCAxw3IrSSREW2TWReKdHjJAByGH8J9a343juLS+PmRswYFcLhjx2Fc5ETEwIwVBztPQ1amlVSJodq7hyM9PaqjsRJO5durVJnXJCY4yo6irEcXyhmIG1fvMew96dCp8o9cjHFVrq9ZWa1jjQkOAWY5w38u9Axt1PHIXFs20ggfM316fTHX3qnFNfSlRbo0hibcGjTJz71u6Da2d1q5t7+3kt761bLx7QEkA6jGOP1zWze3lvqXzRafHAWGFlH7vjPXC1m5N7FqKW5yuy9vf3s0aB24+YbTgdSc9BV230Upc27XjIYJP3ipbkZI79fT+tTzaZFExmbzAScZXJrb0+3N7ZmOBmkVBgjPQHqPxxRJ6BFam5oFjH9jO5s/OGVAePasew8C7dRlmvp5EYSh4mQABuc810WpXMWk6EJ5A0YChSyAAjPTrS+G76e8s1knJeF3Yq2OMA8VzuUrNo6UkmlY3pmNtb4XaHGCOMA881Q1a58mIEEeZJwM9KtTSGSUlxtjj5Gf51ylxf8A9q601tDHlI1AD55HfIqIRvqVOVtDVhvoNBskT5Gu5gGYu2EBPTP+FYVtpjapqk0IdYVHzkgEjBPb/CtPVNPO92YRvFIAXMpwFI4/LiuL1DxdNpGqGXS186BAN7SqVWQ+oHYelax2bW5nJ6pM9m0nTrTSNNW1hk3HO4serGvJvFnhTxFf+PHuokeS1mlDRz7/AJYk9D6Y9K7fwZr669YCaQoLgf6xF6CunhnSOMqyEjsa5XzQb7nQuWa1R8x6/DPp+r6haTlHdZWUt179RVO0WUW87NuFsfldscA9se9eh+MfBV5eeIr+8gkH2NyZGZuq8dK4q/1C41JLawjQLDD8kMSDAJ9T6k+tdCd9TBq2ljpvhdLpVvr0IYSyXjD5C/yr67QPUjvXu761YsH23AV1GNrcHNfL1os+lTmS5t5Y3IKqzLgqfUVq6J4uuLESpdb7tZcKWkbJQZ6rUOnGSVylOUXZanv6eK7GWKUWxZ5kIXaRgHPfPpXCfFpL1tD+0q+8M6iTZ0A5wBWXL4d1O+1O0n8PHKud0sgO0Fc8Z/WvTb7Qza2vnWq+fIqhWjfBBXvik+SlL3XqUlOoveR8xGd5pUErHavanLJGLt3K7ot3I7Gun+IOnx2viCdbO2SKFzvjQDlgR6fUGuVkJKoHQKVGAQPve9a3fUysuh9HfD/Wft9qGgQJZsitAn8SjowP45rodQAkmwjBiDgjuPrXlfwfvpILKZJ4pI1ikCh3BwQe34H+desLHE1086Ku6QDcwH3sdM1y1UlK6N4axsyl4iUJoM0cbYlkXao75NfOMt79n16d2wyGR9wdevYcV9BeMbpUSONSd6K0vA9Bx/Ovm69YHUbs7ACzkgntzW9C6iZVrOVizaxW91qojvrgwwP1mIJ7cGlg0yOXXBZLc+dbbyBMucFR3xVOCbcH8wbxwApr0nwboWkXt+lxZ3Uy+SEc7scMRyvuK2drcxkr/CdF4d8LRWemfaY7aERKhZTPyWGOvtW/DpM2raEsFvdRw2bAAtbnJIHbNR33ijSNA09YtUmLuzlBAg3MVzjOPStTRvEmhT6Zu0WaJokPMSDYy/VTXLJz3SOiPJs2VBqa6ZMdOWI+TBEBuLYOaw10nUoEmng1CE2kwMjjYCy8g7R+HFUfElzNPqiNbwEyzvwQOgHr696ytb0vxZBKI7W1kmhYA/IQCM+1bKKik27XIbbeiudXq3ipLDTbO1sWVJNwVwDyR6AVHaeM9O0m1db2Uecfm25+Y5rF8K/D28MxvtTkMdwxGEB+6O+ah8e+F/C+lXam4uNRkvrgBktoMMze+SOKX7p+4tQtUS527A/j2HVfEMDQuYVQbVhkQEO2eG3dR9K9esZhPaxSZB3KDXgdtp+kTXVi+m2txaatb3AMtpPJvLxjq2cDBHpXrdhfT6eyia3MltIAUdOqE9QRUVoXSSViqMut7nTyHCk9hXHrqS6rqNyloVZ0/dkf7SnP+Fb7atZyRshmVSQeGODXnFzd+R4ljj0gqGyGYerE96ijTbvcqrPax2OvINU0mSzugIbo54Odp9CDXjcukTjxAkhUKgmBYn2PX8a94kh82MrM3mY4rkfFWjx2thNdRQyuB95YlyxHtWlCoo6E1afNqeffFu2u5Lqzu/LL2vkhQ4HCnvk9q4m10+4uNx8vGBkF/lFemX+o6hbWUlpNb+ekmBFnksMcgj1rS034ZPqWiRTalK9vfyMSRG2Qi9lI9q0bjDWTM0nPSKPKrTSLifcivBuxj/WDpXu3gO1ntNAtVN1vXyxiPaMJ6896828T+CU0K9s7GC4mvL+6PyRIu3AzjOa9T0zR18NaHYssTxHb+/i8wyfNjPB9ampJOKt1Kpxak79C7rpvBHYvpcuMTqZ1Cht6dx7VDqviO1067EEqsWxyV7V5tq3xJVNWhewEwtomJkjIxvqT+17LxJOslvMFuHYDy24xRCivtBKt2Ov8ZanNHZQ/YnKJdDa7+imszwdfM6z2EhJMB+VvUVr6joL3/hQ2oYNPCu5CD39M0zwZHa22nNpyuklwpLs46k0KUVBpA0+dNmqzt9kuWT924XJZhxxzmuS0mG78TadcXtzAV/elIiy43r612UQWSJ426MCCParljiCJLcgbFX5SPQVnzuKdjTl5tzxXxF4a+yBpZTsc9PQVx5JSTKkEg9xxXp/xHv2m2oiggk59xXmqoZZAq8MT6V3U7uN2cVSylZEiRW80meYyR0zxn2qnPCYyyDJ57VfNlNHNGx25DBTtq1cpFEQXT5CcE57VdkyLtEn26MKdyFdp+Y5GB/8AXrKdfMM0qglAecnkZqybZmDzwEiNjuCN254we/8A9atDR7SaW8keKLdhDuBOBjGDx3pNgk7h4dvjLMttJJLK0g2sWOdoHQZ64xVjU7q6jZooNw4x5me3otWtKs7axt78TWccxkfCMM70AHQD8a6Pw9o8l5It5doVQEbEcc4rNzUdWaKHNoiHwjpJvNOE19EzzlsguO1dRoelraPdLEEUE7gfatYCNY03rgrxxS2D/ZobieeUNAhL5fgqPT3FcUqjlc64U0rCahpFpq2nm2vk3xFlbA45ByKz3EGk2ggT91bRKS2T054Fbt47IEkReO615/4mvJn/AHK/OucHH8RPaikuZ67FVHyoq6rq11qimG2JhgY7dxOCOetc9qGu3mi+K49O02BZWQpC7SJl5ie+fx4rrNP0a4lJ84rHEDvdg2fw9hXL/EOWxtr1ruFJZNTMaRo7YCR+jDHO7HQmuhtbRMEusjqtVtofDVi0BvnMV6ZfMkuX3uMrgAD0z3rxy8e8kAtXVnZDhiMsWPTOe9aWlma7u4I9ZaeW3DEBZJCGB7471raZeXmm61bJFaxw+TBmcS/OZI2OfzPGKOX3dBX97VHYfCu1j0nQprm7hlMlxII12jJz2HtXfR3EMyM8UqSBTg7TnBryjQfHdlZapep9kMVtI3y+W/yLgYLYPrx0rq/AuuaNqRuIrBTBcyfPIjjBb1we9Yzp7s2jNbGR4v8AG9taXEtlGm8b18w+q98VR0+Lw62pQXtoE+0ONy88An29a4XxZGZPEd9tcEGZwvuAcf0qHTbxbKW3Eu9ArBsjk49a2Sjs0YOUt0z2C6sRfW7oFh8xWDJvGRx6j0NeQQ2cQ1ma2lUNKXMaIh+XeTgc+lej+f8AaVV0nBVh/rfb6+teZ6pGsWqyvDKZCrg7xxk9eKHGw+a7se8+CNWistNuP7RuY1ZZDxn7orUvPF9lI32Wyk3SSoT5nbHHI9a+frbW32zfasEMOdvGeeeK6G5u7bVfCckum+fFdWJBYE84PUj2P9Kl0qbfMNVJpWNi70Vf+Esn13Ub2RbC1ZHQ7d7HjhQB2Bq1q2j6X4p+xTWN2ZGjVgjRJtLHcOHz0OSKofCjWJoJz9oKS2zOVlMpyVGOCPXntXZzGO1vb25txBHHcMj7IU2pkZ5x688n2pNa2KjLQ6TRvC6wWcS38hdgBlAeM+/rW2LdLdCEGATmsHw34oTWpZYogyvEAW3Ljv8A/WrqCu9ADXHU5lK0jpg4tXieX+JZLi51R45N0IYMqOwxkD3rxBoVeecSzAOHxvPIxnmvdPi+0EWlLGX2zEHGDg/SvCJVZFk37fMBALDmu2m+aCdjknpNomuiiyIkbrJEvO7G0kdsj1q5pWp3GnFLiFsOwaMKeMDI59+9YzFd2eMmneUw+c5AxkVfMyXFPc9Cvbo3+q6RHHZw3q3P+tJOWIGAckdAM5rorSGw0fVZrLSpNkisZHjdc78dBn+761xfhS6+y6e08GWnTJxjPIOQPYV0Oqsbp7fWbY7ty7ZCvykcfMCO2M9Ku13rsKMtB2meJp5/H0f2uRTbMTbRhBwrk8N7816h441o6B4Zlu0kjW+OI4QwzvbIyMfTNeD6XNa6brENx5Et40DmQK52oSDkHPfmuvm8fpe39rLq2mRuInzGSdzR59BUVKLlJNLRDhV5U03uexac8k1jbTTp5cskau6f3SRyKxPGPhePxDAhjnNneIcLcIuW291z1xU1p4jhupIY7W3nmMibiwwAv1z61JqOrulo7QwyxFfvySLgRjufeuFQmpaaM7OaLjrqjnZ9E0PwpYAqqrJgNcXUpy7KOTz2z6V5hc/ETX7jU52gkhW3BISEINoGeOT3xWX4n8U3OravcSHc9qhxGjtkAjjcfUmucBMiyOrquecdxXXGKXmzlnJyfZHo2h6jq+u3cN8xLW43RzoPuqRjHHqQf0ra8I6Ddz30l4sideTnAH/16pfCrWdOttIlsbqcJcSuzbmTAwcd+9V3bWdO1IrFNDJYu+FVm2sPp3rROTuthe6rNano/iHV30myZ4oZLmY/Kqx87j6n2rK8I3Piu9gnm1KNDG5zGjjbgf3R7VH4U16W5u3ivUjDKo+VvvMc9MV2viCPVP7IdfD4hS9YgBpjwq9yPeuad6b5LL1NopT97XTocRq2m3l9fzfaLMWhiKPFIpyGOOQa67RNS8m1hivQ28gZlU5TP9KxfDuny+H4Lqe71e1v5p3zeSzT4WLHYDuefaob3WLdnjk0VEubGRgGYPtVRn5uvpTa5/d6Amo69TsL3TNObU7fV7pFFxboY0kZsAA1xXxO8YW1hp8kNnOGu14RQMncRwfoB3rmPG3j2OC2Sz0q5N255D9Ujx/M/pXlmo6hdX92bm8mLzFdpf1FEKXLrIU6vNpEZeXHnGMuAGVeSo+97moYJpIpTLE7Iy8hl4IPamtGQMggqO+afC8kaSQZ2I7AsSO46Vrd3IsrHsvwz8SPfwfZriQsyKAzHjca3Lu0/szVRcWqbUOX4HH41454PuZrfVluhJGFzg7227uewr3XSNciuDPDcQsPLAVmYcGlNNe8kKm18LJI5SyCRQPmGSBVpZzGiybN0e3Dc8j3rK0ySKUzpCfkDnA9BWxCi+UYuoIPFYyVjaLucP8AEGySOM3IIxtyK8sWfbcK5ALhu3Q16l4yimutPkiClsDaR6EdK8uMK2twq3Lc5wUXk120dInHWV5GwxAcnqOvFQa4I3t7YpncSd3pVfUbxAAkAKk8H2rSsmS5sDFImdwKjaPunsa2Zmej3Hha18uMuCuwYGeKhj8I2u7fE7l1OCQcYFdJq17FBAEmO8SqxRlGRx2z607TYLe5EnkXTi4KnfHu/JiprzfaTSu2d/JFuxiXNmmjQgxWMlwSpOUAzkdAc+tXNLuo7+EfZx+9jPzoOin+7XMW0eqG8u9Ivsl3PmQXA5ww459c8V33gzTLOw0WIWkqTs5LSyr/ABN3/LpRVtGN3qwprmfYW2t55wzPEsYydoPOR6+1KEMM2JVSSTYS2Bxj0xW42EUnHAGa5JtRWS3lucmOOQs7DvheMfSsIXkau0Sn4o12G1i3SOIt42Lk/dHqa5uxsrXU9YijhvJS8SLN8oyje1c9fv8A21qctzMf3SnasRcY/IV3ngG1K6UkinALkgY6D0Fdso+yhoc0ZOpLUh8e31ro3hiWJ5fLnuFMUZHB9zxXilkW+3teXLx3Lqd2yZiRIffvXoPxM0y71rXJHa4SHT7NNm5jwrEZP4mvO9Qs0ikg+x3AlWSIMQTghh1GKmCtEUnd7mnqGq3dysNvcRRfNN5rMoG/A6AHsACeKkGqXtpMlxBOkkdtIPKaaPLyZ7fQVLovg/UXuLa71CHy4GJk2FvnYDpkdQM1btPDGtySXEF1h4sF1A3MGfoDwMjFWppidNnPX89jJI8kdmEEoPmbcgK/X5fQe1O8Oaj/AGFrNveK7FQcMFH8J7Z9a2dS8IalYWsYj81v3ZknDoVUEdh68VgWVqJbpbWN2fzF+8pwFPvRo9UFmtGdH420Z11w32njzrW4Pmrk8hz1H51y17CPMYTLNHKvB3LnmvSTpV/Fc26y6iyIkKbY9gYqR1Jz3/xrsLtrAWRubu3jnijT7qw5J+g9amTsrLUqMdbvQ8IEt/BGYoGm8pwAcAkcdq6XRvBVzfzRJcO1uJVEgIUs2Pcdvxr0/RdX/ty6Frp1mYIhkNI6rlT9K7yxsYbJNsK5Y8s7clj9aynVcNGaQpRlqjymX4VW13YLHBHcQzhAvnSEDJH8RX3q1o3gCTw7pl9HKpupbgAGVBnao7Y616vTZQ5hYIQrkcHrisFWd7m3s1ax82SwXPhHUVmwz2kvJBUj8PY12n2nUdZiiFpbyBJwuJZAANvtXqMmkWl1aiG8t4pR1YMgIJ/GrcdrFEoVI0VFGFAXoK2eK8jJYfzOV8N+HpNOhRg+2R/9auB83pzXYx/LEBjpxTCgXLY5rGv/ABDZw6RfXYlBS3DBsHncO1YNyqO5r7tNHkHxDu47nx5b/arkxRISCW5QDOOn0rhfEOnR6bq08EUomts5jlXkOpGQRTr+6fxDrU0xIjJUsN3GQP616fb+E9M1jwtpjXkMkVxDGY1aNsErngtkdea7m0kciTbPHo41kXIIz3qewhe9l+zp5jSYJUIpbJHavRJPhvB9rDJPM9uvzOiLukx6DHrXZeGfCsWn2wksLB4Mjd51yMSHn07UnUSKVNs4rwZoF3aNEZUkEZPPyEbu/P0rr9QtJ79ZVjgSOJSS75Cjj+ZrbWN5I3aVnZFbKydM/h6VyeuX6QW8FveXiWyzynJkzjjvx0yOKIycmJpQRystnYBcaoRCpJYKr42j3PrVa8l0zT5lSFMkj5GY7j7fhTvHUEI8VS2ulASRSxJsEbblPH86kh8JXtxYW09yFWaAYki6nb2z6cV0c6tcx5Xsj1fwFeQSacmwQhduV2AZxWD8aNbEHhq3tbd2VbyUq7A4O1RnH45Fc2C9rbSR6fJNZlCHgETEH6E9xmiXRrvxRaQ22tXLxTWi7obnaTvDNyGHc8DpXNKlaXObxqNrkZ5crlDzynTBpscjRTh1CHngMMqa2vEWgXWj30i3haSBmOyVRjf/AIH2rKihR1Us6kLksqj5sDrTV3sLRbnQ+BrP7d4gt4pRuw+/Yp44/wDr16f4ttpEFsl1G6fPlWRMbM+9cn8FLeS58QTXEduPLTAyOAB3H8q9N8WeONE0xbq2WXztQjBUIqbgH9zSc5cyUVcailFuTseZmDVINTiltkd33E5AI4HTNewadr5axja4t5TKFG/YMjPeuY0DVptR8KLe6nbol08rJEUXaXHZsfnWtpsMsUEaycsD87L1+n0qaz5tJLYdKPLrHqVLDRvD9gt28SG5eZy7CQbjz2xXF+LraZok06zQ2yStu2xDCqvp+Nei+WhnllQZOfmOO3aqmpwRvGX+UyqOAoy1TGdncqUE1Y8Um8IzRElpMKOuRjj1rJj0xPtf2drmMRsjN5h6ZAzivVLvKE/aFRAVIBnPQHrxXH61pkMMZkskHl4yzDJAx710xSZzSbRxd0Qrgxx7EAwOc5Pc00NvIyST/dNTyLFLA8iyEShseWR1H1p9rYyz4IHz43KP71TZ30LuktS5oNhFq17b2p3wbmC+Z1BPpXtPiCy+y6LHPGW8+OMRLhsZJ4yfWuN8B+H76PVmu5BgYxtYDA+leleILRrzSpIlGHUBl7cjmpnK0kioRvFs5b4fRtBHdxvnfkOdx55rtYm2uhIwM4rz3wNqCX+u3hjckIgRge/NegSKPJLMSOeCO1TW+Iql8Ji6qk0mqXFuIG+zyxZEmOjV5JrVt5F/K0hG8HHNex6lcRXeuWkMMz70UlkTkH3NcN420r/TpHdQFbkEd61oytZMzrRuro8+cSSENtJLHjPeum0y3aG1VXXbgZNYaxmKQnO4RjcM9jnArp479ZoEMsYiCqEGB8vFdLOZM7Cby00eKKe4AihUGVyCAT3P51cu1gWW2aG/SC+wscDJks6kdD6g9ap6G3mbY7kLFP8AKWb+/jt9M1ftrSDTAXltSbaSfzkCqWKsT+gHYVxS0djtWqKurMNJifVr+F3mhX5FAK7mx356ZrM8MatfS2c9xpdg9rNKxmAMzGNj3JB6Cu0vPsWo2sttcNG8BHJI5Hriren29tDH5dvGqxqoUADjHas3UstUVyXejMzRvE9zf2t3HqVr9kkhB3SEHaV/vA9+hrLvpYbvS5JbIq8U6iGHHTbnJP8AOtnXdNhu7eSENtkkXazD0rnLi4hlvYNL07DCEbcJ69zTppPVIJXWjOO8JeFJ9Uup7gOYrHeyblbmXnnHtXXeJvFT+F9X0+zt7ZZrLy99yFHzqucZ9vxrtdLs47GwWMY4HzE8c1majoWjzzXGoXEC3DTqqvlyVfHC4HSpdXmeq0GqfKrJnnXjrw3f3F4l/pEk1xHeFAmw5DB+enYY7mq2jeEGuHu/7Wnlgh2jAIXexHT6fSvXVs5HjD3MotrZVGIkxkAdie1XNOj0x9yWiQMV+9gAmj2zSBUo3Ob0PUbLTxHHcriMRrHHKT91QMYOaz9T+IlrZXk8cCyXIUkExoAE9OT+dd3cWEE6lJbeJ0PXKivNPE3w/ne/lbS5CInA2x5wT60U5UpP30OpGol7jMoeMZdW1sNdM6WscQVYR3/2m7E1q+Hbnw7c3/7q4s7S7iUqBKAme/fgmq2n/Di+ilEc00UbOuST8/A7cVxPiDwZrdjcSz3VlK9svJmj+YAe9bt05aRZio1I6s9Q1G50O1vBDf61avcPgZQg4+pHTrTrq9tbYCJ2BUfKWU549a8W021S71WztAcGSUKSBkgd69L1exkh2GBUeNF4w3TFVyJOzYKbaudt4b1LR45iLZkRnGNzYXPr/SuuUhgCOhr580KSG91dvLRhL5mSpJHHrXr1ve3kCrEJopEUYBdSD+lc1eik9Ga0qra1Oox3o5xxXPT65LZD/SIAw6/u3yfy71aj1oOgY28wU9OM1z+zkbc6NWMnJ3VJ9a56XWpPMBS2lKe3X8qyvEviK4hEVrAy2k87bEaTk59MDp+NNUZSdhOokrnYzTxxRl5GUKO5rxz4lyO+iXUunQCC2mmxM27bgDvjvurvNPs557NTqF2biYE5x90fhXNfFSxkuPCsltY2++RZUchOuPX37VrSShIzneSPKPhxpH9s+KLWJgphjYSSBu4HavcNRkEV5HbwRgx7NvXpXMfC/QBo+kS3t2ojvpwVRSo3IM9c+9Wdb1FrWC4khUvMAfwNaxTk7ESkkrnUvr2i+FbJBqV4iTSH7qgs304qw+qJqq+ZbyH7ARwAMF/fPpXh9layahdJe6xKRAreYzTZzJj0z2rs7DX7jVLV4dGjDRA+WrDsfYd6qWHSd0TGtJ6P7jd1nWltIwiSgIo2gDp+NeX+I4LvW9REcA811fjPGB/hXo1joZeNDqq7nYY3N13Y7jtUPh3Qo4NQPmuMyy43A547fjxVRlCKdiZRlJq5D4M8LW2jpHLIhnvW5Axz/wDWFdiwKSu4s8MceY6YJOBxkDmr9ytnoenSXExWOBMs0h7D3NeT2fiayh+Ji6jbXjrpjIRcs2drDBzgfXGKxjerdo0k1TsjrdV0qC4WK4gCtEXw6jsDxVnwp4eOn3DSrczThW2KrNkAYHUeoq409lqemLqGjTh7RyUkG3ac+uO1bmkZeyhlAxvUNipnOSjYqMU3c8++LtrJJZMGRDB5LSyYHzBl+6R+eK8R06ylv5THE6xkgkFshTjtmvpLxjcW9vcpJelfs6wsJcjI5IAH414r4rMV/qsy6b9mUIu0RxHYCvb6mtaS5oq+xnVkot23PTfhLe2On+GxHK6m5Ubn2DJ69P5VNqzaddak91DY20EpPzzsV3Mf5Zrw7Q9SbTdUtppA+yN8sgOMj0NdP438RwzuttDDFLCEDo4Y5Vj9KtQjfnJ55W5TptV8VWFlrdgsk7PDC4Zwhzxg859Pau0XUYWMU6sWjlUOuDzg9MivnBCJpVDgg8ZzzkV3/hbVlgvsiSSWPIWNXPAI4/Km4Kauiedwep6TqtyI4T5riOSThU3YA9zTNIvbKZfInZp3wRhH+QAe4rMeOxupxdNKLmRGKMe2fTms2a7mZ1W1KJbhjvKgDJ9DURgmrGjnZ3L+vR2dtayzTQbliHzkc4BNY1xbz31jbf2dZvNag5bLYOT7V2ugWsd9CzyI2yRRujODuriviALiy1e3t/DzvHFMS5kR8pkcEewFOL97lQpRvG5lXfgmcTK17AsKn5mKHj2wK17HwtlNghdliOd54BruvBlrJc6aj6i6XFwigMwBwW749frWzd2s85VQirGOWUHAb6modZxdi40U1dmPoGm24sx8riTpuyanaRluDayuZFJxnuKuK96r+UlsiY6fNwKLOymW9ee7UbiuBg5ArJy1bZoo9EcrpHhq30TXrq5iO37U2VHZR3rbe4dJ9joPKCnDZ7+lSa9OlvPCHGd3SkuBE7hk5iIDD2NVdtJsnRaI5u8tXG3UbbMc4PU8d6d4ztzeaCGTDtuUhs9PX8K2lhgmikhlX5Qc9fSsGKG8sXntljW7sXTdFEx59xWyd3fsZuP4nCXdssKvthbyCqkk9TUJRpo4WlZhHgEIvrXaS20GpwSQxI9pJEwAWcgAn29qSxt7GxkFsk6XNyjFnVRkJXQqmhz+zEaKeCeC6umS3tUKvLvbGEHOFB5JJFcz4t8eajd3i/2a7W9sc7QPvEetU/F1/JqviC5WPzDHECqJ1+6K5cJK8Uss27GMde/oKnl6vcd3L0Nzw/4nvdO1tJYZmNtI4DxyfMNp617tcKZFtLi3fYSd3HQoR3H5V5Z8PfBDThNUv22QqN0aMAd3uavePPFM17bT6doUbSAYEtwh7DstYSTqS06bmyapx9R3jPxz5f2mw0ht0ykrJcMeh7hfX61b+D0CG21PV7vOM4Ej9wBlj/KvK4raK3ukbUZgAGG+NcliCO/pXrMGox654DmtNBQ2eF8tY2HYdeR681U17vKtEKD97merKnin4hy30r2nhxEngaJg8jDDZ9ACa5vwz4sltra3tmYlVYbnY4AbOQOe1Y9paXGm3MMN3GfKiuFZ9jDMbE8Enpir3ikWVnrV8+kzQXbysJECgMqNyHHp15pxSWiREm27t6npdtqY1aZ7a6uk3NxCA2MEdTj+Lmta3sLqwWO4tIkmniXDlRt8wd+PXvXgMWpXMN99uad5LmMYQtztPc8V6P8ADzxxM7lNSkCxvJhCzcDjnOfzz71nOD+z9xrCaXxHp9nr1rc+WvzxytgbHUjn0961xjrXjnjTx2ul+KYo7SzSe2hw4cnG4kc7fasvUfi1fyGRbSJ43Jwu7AUD6Yzn8axdC+2hqq1vM9v1C5js7WSdxu2KSF9a5r/hILm4MqwRW+B8rIXJP06V5d4V8T6lqOvva3VzLPbuplCs2dvGcV7lpGnxWdhCvlp5hUM7bRktjqaUoRpb6jhJ1PI8+1Pw8lxqVtqd/Yx2s68h4RgH0yBXH+K9Wljm+zsywoCOhPbtiveLx1EZjkDBWGN4GQteTeJfC0l74piIikSFHwC3WT3HtW1CrfczrU+xT8Ixs07POVeRnGxlAwwxwCf1rYl8RWWn/bHOpRzSGUsQj7ig4GF/Kna14Rv/AOynttMmjgLsDKozlwB0BNcovgS/BR75DDC3BVBub0zmtVKE3dsycZx0SN7V/F6w2H2qwRbiIDkt1HvVXQfGtvc3EUFw/k3Ej7UO35RVDUvCyrELa0KJCo2/M/G7OefrUWgfD7UbjUraXVImt7CPdKZVKt90jC4z3pvkjEEpuR2vi+XUJNGWbTGYXMDM7KCVLDaRjA689q8o8I2ep32pts3KCCjzzk4iJ7/WvTtb1Zf7RKW5G1pCBjpj2rpdRsA3hK6bTEjjvZEGJCMlWzyc/wBaybcEvM0spNmL4fhbQNJWyguZLrc5Z5G5KZ9Knezu9Vum8jzDgAbieB715mkmsLdSxXuqz20VmpaTDncRn+EfxZ7Vv+HfHV3HfQQRmTyGG0tJyzAdyfWtHSa1juZKqtpI7HUbGTStAnu595lCgCPcN24nAxiuF1S8ltJpAT5gcbpBnGxR3GOtdNqGuy30X2YYMQwUUj5h7k+9cX4lgvZdPf7LDIWDjcinOV706ScU+cdRqT905q61PULuO6DgGKYcLIckD/Z9K9W8Gyafpnhq1umUBFRWUgHJJ6nH1rjfCPhaXUNRQ6k3kQgh2iPJI9/QV1/xJSbTYLZNCDusPE/lruMWfu8Dsefyom4uShcIJxTkdHqU+11bfjLE7fXjrVG5vQlxG8aKqOQ2cdMfz615v/bOs2kkCztHk/OySLiQL6H0z+ddJo+vy6400cwWIRDChe1L2PKg9rdnrXkW+oaWLa7RZ4ZE2sG5DCvO/Hvgi1tPC040Kzit2SYSynJLOgB4BPpnpXbaDfxvaRRFgGAwK0byZfLKqUZmHCN0NcKcoS0Ot8s46njXgG2uLDwnrWrEyeS6rGkZ4DlTnj+X416p4a1e21Tw1bajbApAY8lD1UjqP0rlPipJnw9MkPyLHGMqhwASapfCed5PBWsW7cpHMQOezKMiuiovaQ533MYPklyLscZ8UPFH9qSC2tpGGGJmIPBI6KO/H9a4ATDymHlgybt2/nOPStbxnMsnia+MIUJvKLgDoOKx/LIVGJ4fpxitdtEZ76stQStdARSKryBNqP3H+NQPFlgiAlxkMCe9RRsyPuU4Kniul8NeH5/EMVzNARvjwCinkn1xVXTWpNmnoYFrCxulRmUMB6/pXeeEdMZrq2je2dYnA/eNjgEntVPS/AWpm+RpnSIL8xIOWwOuBXp2m2lsCgjR1WJNoLHtU81loVyOTuxlxGlrcpa7TJGuCBjGT7VWwbHKz20ZBctsA6k1o21tNNaNBBNK0qDeJpBkkE5xmsi8+2S27vcgmVFORjA/D1rNb2HK61I1ur1YJTbmRXlOAFHTPbPYVL4Z8FJHcPd312ZQ6keQh+UZOT/Kl0iX7RhGhkjiZdysxyWPsvXH1rp1upFs9sVtIjA8NsJG2nKUloh04rdm1aRoltHDCgSMDhU4AFMVpI2LDd5ecc1zL6v4lt52MGi+fbnAUmQKQP8A6/WpfEHiaew0i4mmsHjkRfkXOcn1xWHs3fQ25lbU6m2Z/OkWTaFHSpXKqMMQPrXzlrPjDUr9rW6lna2EMgKiJvvEdSRWgPiXdolwIrdZQzs6mVicZP8AnitHhvMhV/I9Z8Zaet6tou4Bt5AOfaqohOm28MZkLR8R4YdPeuO0n4kw3thGdaKR3kUmFZVIDKf5VW1v4gRyX72fk7rYEDzA3P1q405JKL2IlUje63O+AEc6DH3lJz6muOt2uLia6uBeyq+5hsByFwensa7K1mjubOKZDvRk3KR3FYOqabZpK1w03kwt88secBgOpNVTdnZimrq5znhTSrmXU7u91JkWwjyDKzE7j2ArqRawXNvNPpsG2YZAldSBmqel+ItJuLhLa3ceSHysbpgAV3NnJBNFiIAAcFaKs5Rd2h04xasjzDwF4curvxHcavc7Y9MjMm9m53j0/wDr1iRQDxP4wW0ht1tdNt3LpEg/hz94nuTXtdvp8GieGJYAglWKFnkB48xsZOfrXHfDq0SeK+1KWFUaRiAq8YUfw/SoVXmUp/cU6ai4xJPH96uj+GDbWR2SOPKUKOffFePz3b6GpggPl3bcu5HzJnkY9DXovjjVYrbVtPjuVMsSn98EcKRnk9e9eUa4bKbUriawklkt3ckGXhgPcVpG8IJIylac3cgdmby1MTNISd7nJLnNe0/CCW3kt7m3S3dSijJY5BrxnTFLXiSyhmto2y+09vT6mvZvhbqmnSSTfZsIZCfk7j2NTPWDsVGymjrfFvh+21DT5WEYDbSHKjGV7/iOtfOt/braa1La7zPbQOUR14LLnqMV9XoEePaBx715N438DTLq0N9pZcRsCrxxx5I6nr2rGjU+yzWrBvVHk1rHHc3kdqrGKNnIV5D90eprZ/4RjVxbB4bIzoTvDowyRkgceh6g1u+FvCatfCaWMkwyFikq4xg8c9MDvXdaH4g0W71mawHkvHHEfMuGONzD+7/s9a6G5dOhilHTm6njvibS9WXUwbqCVndAyuBlcexHHHStrV/DlpKU1GzilgtTbl5vNJDRyhR2PJya9D17VotP0a8e38qRIgWi55AJ6qa5XQbs3zSTSoWimUsFbnOetEYuWsgckrRicd4W8QxaPfeYLVHaT5TITyue9fUOl3BvNOtrhtu6WNXO3pnvivmPw1p1nfeL4I1tZRafaMGMndgZPHqele26L4li05rmG9YrbKd0Qxyq988fjWNWEprzNacow16Hb4yDnB/CsK6ljfWZZZV+S3Xylx1LHk1kN4+s2uCkSER4GHb3PpVXUtdssalNmXYjxOyouWXf8u7Hp71nGjKPxIt1Yy2ZraxLEkEdysvlqDtOeSR6fWkttTt7pUMLZYZBWub8ds9v4XWNX2SDcQSeo4Gc1z3wyWW5MkxcmNXAyT6df51tGlFw5mYuo+flR2mr29gbfymkjinZw+ZG7mq0+vppUn2GS6hHnAumGBZV+lZk1ujanfhRudnP3uQw4wfyrhPGVnaNZrIsqC6VtoLHnHpmrjTVtdSZTfoX/E63SeIYLhFcrEwaPZwGFegaJqENlAquYsS5d4Hchsnr/wDqrzXwpqLyaPNpV7qCweYyx28oG9omJ6e49u1dbc+H5NNvw2o6xHNMwGFjjxIc8Z21c2mlGQo3+KJk+N/ENjfzSW0FrulVstOMDaP7v51jeF4IbvUowiMJwcku+4Be/St3S9Bil8V2b3iyG0uAzLHMMEMP4WHvjNdB8QH0zTtPFzaLbNdxSLEoRgGQ59qfOotQiieVu8pMoromqT6nJmeC308DLOBh8D+RNbMUCKGSBdyOOrfeqSCV7q3hWVx1yBjqcDr61dg815WigtQrIOcc9O341lKT6m6iuh5/qWpr4d1prqVlJkVV2jk4GePpUF3cXut3zaho15JE8iiORI3KHA7nJ561r+LfDT3V5500YEeNgbPKn6VY8IaRDpTrPcXAbgloyOeOBWvOuXmW5g4Nys9g1nwPLqGm213a6hG1/FDslllBxNg5U57Htk1xGj6T4gsNfRDaSRhmAkI+ZSueTkda9b0vULMRXNrNcBUfd5ZP8IPb8K47xVYa/EGmspfMiJAjMTnntwKzhKV7SehUkre6rm5arNGj/Z3eIxtkH7y596ZHrN010iZIkeTLEHPTtin+FPB9xp+gXkN3P5t3ckOzlj+747f1rNtLCK01eAPI0kxU52twzDv+Qoi4yuNxatc6LxDodzrvhy6thKIrmZg4bGRx0FcN4Xsdc8NWWrW1xmIXC/JGMHc46NnsK9Xe4MGkNcRYJRNwBryLUPGMlxrlzBJMstruBjmTA2+oJ7ioo80m10KquMV5nDX2lXMMH2ufdteQoT1Jbv8AnVG4kMoRQPlRdq46kV7tpenQTWTwTQo8Ex3kH0NeTa14curLX7lDCws1cuJBgDy+tXfWxKWlznY2zKoQZPQZrsvhnJNBr0kMEoSWWI4GM5P9K5adITKWt95j9x81ehfBKzdvErTSphUUAEnnPXpTfuptgveaR7hbaHaRF5fJ23UsSxSSBsnA7fnXO/2ctlfy+a58wHcMngjtXb1h+J7MyW63cKq0sP3gf4l7iuKnUd7N7nXKOhTVGUZXjPpVPUftLP5WnhHu2U/fPbNN1DxBYaXEP7RnWJiuV4J3ewo8JzfbruW+mikjeVFaNX6qhrWzS5mZcyb5Ua+jaTHp0AV2Esx5ZyMc+3tWp5gC+9c/4n1NrTyoomkSSRsBwuQvHeua8O+Jr3+07y01DlY0QrIRx06Z6ZqFSlNcxTqKLtY6DUPF9pYawLC5OJGHAFWYp7XXbeeF4xypUg9RmvIfG2o2M2uRXRLvOx2/u+cHpmvSfh/DbrozXImeR5XZWkY4zjitZ0owhfqZU6kpStfQ8O8ZaPHo+szWsLFhuwUcdB65rnyq8soGAeVHpXYfFC4tLnxJcmBnLo+1j2x/+uuNicq3lu2IifmxW3a5G92gxuXoevFaWp3Iura3kSLy2RBC2BgHHQ/WqE4gaVBbeYo6kt611nh0tqmjXunRrFLeqCUYqOn+NUuon0PQfhvfPc+Fbfz2LNExTJ447VW+InmRaS7gFWkkEZ+nWl+F1rPBplwl4CjpJt2H+HFX/iIr3Xh8RwJvk84Nj2HWpTtUG17h5lb3MdqsflowlPDmvUPB2rrcaaCM+dFheD94V5Rc4MYA+96d6ueHtak05oxnBc8+1dNSHMrHNCbi7np3xi1ea20i305HMcl25L7T96MdvzqLwndpp3gUXEhAUEkj0Ucn+VM+OFhcSw6beQAlYy0bY7Z5zVfV4orL4YRGFgPkO4H+IkYH8zXHTs6cV3Z1TupyfkeZ+ItUfVmjeWOD5y0zEA71BJ4J9OlYywxtI4UnYy4BB6fWluIik5imDnMYbCHnkZH4VZ0x7SIia+t5WQRMkaR8B355Y/56Vq3d7GaTS3H2slmb9FDSwWgkBeJW3E468nqTzWnp16ul+IxNpTMNOlfd+8P8I65x0xmsm4tM2FvJ5UiYGW6Yxxggev1qG1hZUF3CcwwyBX3ep5x+QotYL3PUpPideJGptYI5oo/9Y4XOBnj9K0fE/i3UyulG2tjJDe4IijViT7H3rx6BZnaRLFAI5AzMobIAHTr3Fej+GPGs1r4XVbm2laK1XyzMSNzdQcfTipcUtYpXKUtPebLfxG1P7L4fu1sleDzp/spzwQoGTj6+tedafustHe7DEPLIIoz29Tn9K2NE1JtZ1JtJuYnm0++m+RHbLo3UMG/yK6/xPaWFn4eTT4rURGLPllhuAYY5qo+60kJ+8m2c74X8+eV7a7kF1HIpJ3jKdOmKufD+B7xJY5x9ktYUOydxhTz0Ge/ep7TTZbLw3JPZs7XvmRfdPLbj82PTj+dd74Y09X04z6iitLkqoJzsHf8A/XSq1FFXQ6cL7hoqaPpySPatAzk5kn2gEkn+prmfihq9usC2sc6wTsDklckn6+ldboVpbeINPuw0CxCC4McMwHJ29/evNviBpMapG15IzTxsVUbvvHOOfyrOkk5+ZdST5PI5zSbeW5dYHlLDP7wk8Eexr0/wrpAj1qbULFfMmeHyZTI/yEcfw+vH6V5E9zcwALAIhlgAka4P0Fe2eGLKSz0Fbi8UQSmIuCWyE45JNa4h2VjKitbmJ8SLuR9JkiaORLpkKCMDOckdPasvwfrOl6alnpmqJMkbRBjMDt2sT0YV1txbjUybnOVVdqgdT7/nXH6poEl5fOz4aMKCjDjYw4IP1qYcrXKy5c17o7KbTtOlvLeYOt1bzYRH3YKnsOPrVXT/AAdaRHWpdUljvI7psZIwI1A6Y9R2qfwlpQgs4IVeRxv86Vm+6rgYAWt26jhj1CyYkeWXIKg8E+4rGUrPlTNorqzyvQvDEOieLRcTWz3OnRDzIZJnAO7tlepxXaaiI9c1+G70+8hWa3GyeMMBI4IOF/DjjvmoW1afWda1qzulggjsCBGW4YjPJz6YrAOvf2N4nv7e6jE+nygSq8CAO52jad3f0rRRb9TJzS9BPBfhfXV8VTrq6zxWybmDFsjnoVNWdb+HkAv/ALTHJN5K/My7txJ9STXV+HvFQ1SzkdElZISI5VkAEsYPQnsRWvd263NsQAoDDBJyeKzdSpGXvGkYQcfdOY0myknlFrFN5aKuVcHOBXS6c0dmzwWMRlY8yTn7u4ep7/hWHb2VroULtPchLBIwAg64HXJ61Wk8RvqmlTtpsDx2yKwVgvDY9Mdqck5vTYSaj6jPGevta21w2ILnCFSEBIyewNchfSzWekxX92W3su0KX5Jxn9ARWnC0t7FG0p+QKHOE9Oox9a208JaZr1tHaam1wDExlR422nDAZU/kDW11SiZ8rqM8te5OEnjkkCkFlkDHDnPf3rs/DvieWK6htL5FVXTcWY5KZ74q3qvhqyEP2XTEMcNqdqGQ7g3+1+dZVzoE+lXdrcXEUcsBUgzH7zyHjGO/UDFaOcZxszNU3F3R66lzEdOklBViIyTg5GcV4t4mnum1ONrRCHVtgb+6BXrEln/ZeiJvQvL5QV8DABC81xumQQalqVxHMmY2I6dziueg1G8kbVk5WixJ7zUdS8Jy28Dos0mIFdmwOevNcFeeHbXRQo1u7O5SCyWybioOepPuK9Xa2SwaG3hTIL42fewPXFeYfFHzf7bE4VRDNGAflx8w61cXd6bEOOnmdn4T1rTbzSpLXS5pvOQFgZwAQfQVFdwyXkDq0RmfBVi3Q15PoV9/Z+qW1xJnbC4fA9vavYNK1F7ycNBFiwkjEgkwd24/wkelNd0HkzhfEumyJHapb2Jib7r+UOS3qRXc/CfS1sdRQSCWS5lAld342jBwuK0ToTatqFrPKTBZ27+aSwIMh7D6V1NjawprcM8DqgdCOB98AdP8+lZ1aitYuEHe509YfizWLfStMHmEtLcOII1Tklj3/Cp/EFyYrLyY2xLOdi/1rjLsW9syyOBLMDlQ5yc+2a5qNPm1ZvUnbRHGeIPEsNmt9aXFnHdyiExRSTY3DHHbuAaw/Dfjm/0mVppRm2dgBGvAUdwuegrN8WMs+s6hNJE1vMw8xQWBV8kcj6jmsWKSR9NeCSMlFfzVYL8wyMHn06V3aLSxyavW57aPG+k6vaGUzJC2Nxil6gd6y7id9S0yR9PUolyd6MqnJXoa8iiuvs+17cFJApXdnPXgmva/hncx2vg20W6hLuXby8HkqTnPNRpFe4ileWkmcydBi00m91DcYiMMT0Uj0ra0y9DaZaW2lX0bwRjd5QOG2Enkn8617Tw9DqOpSz3t2/2RXLpC0nAyMEY7jFYzReF/DOqStDMS4yVRucAjkcckfWnzc2nUThZXex57rOpEaxql4nl3EMshjAcdB2x+Vc6Ruh3DAYHt3r0PX9G07VrYS+Flttwy08TOd2PUA9K8+DtCzowOOhFD7MF3Qnl7PLYuOevPSuz8FQT6ddzapdQtb2CRg+aynDEnjFcpHFEMTTFWXdkx+1ehaR45g1CI6XNp6RxMm2PnKjHTIqkrPQV77noOjOk9s1xEMLMdwFUPFRR9PkDMV8p+cHBIrX0aAW1rEr8JGm4/Wua8UkjT3AIDyuXOe3pWcNZ6Fy0icNJbrMxFvHmZeoP6UyPQ2aN3uRskP3PQfWuos43+xwtKu1mX5WPfFYeqXkqT4Ztw/uA9q6076HM0krnqXxUkjbRrSycMZLi4XZt7Y6n9aw/HiLovhSw2W6yw+aFdJehGD1rU+J7JE2lXxaJorOfEy7hlQcdvwo8apHrnge9aEFgI/PjIHdea4Kfuxh2OyfvOXc85msbe+lhubGCK2F1taPv5WO1V/E+gvY36S3THCneTCowzY4O30rofh/a2d5okcN+dh3sI3Jxk57VqeMlubePzRp4lSNdhY85x3rdy97lMOXS55Vq9+stkkFp5oiYgyiXbkt/s46DFUI5TNaXFnGscKgiT5l+YkcAZrY8XWrW4iuZ0SOSUg+T3Udv61kajq13emOWRiZQgQyBQCQDxyP505NXCN2i7p2hXAa3lupxaK5Ux5YAtk9gTWnr8Mmn2bQy3CzyB2D7GyAD0Puc9a5q81B9Quo57vmRFVSR/ER3Pue9dXo1o/iPS7y6MMXnW06ERoMb1Ocj6f40RkkgnFvoc5ol5dafqVvd2RXz0OdoYYI7g+ler39xdeJvDqXFhayISwDlhkDaTkZHrn8q8x1WJNOvJESFYkk/eLubdgeg9j703R/Eur6UQdNvJ4Bu3+WrEqT3yOnala3qF2/Q9M0557eOFmQbNoDbfuiuq07VoBobW3knz8sFK9Dk968s074japbQlb6O3v5Bj95cJk4JJ7da6M/EXw+kUUselTC6A/wBWGwgP1+tTNc26KjLlOs0TUtT0vTXiu44ypZxGYz9zrg8/1rifFMUN3bPJrV1slll3WzR5LA45JH19Kif4sXTy/Pplq1vg5jJOQfXNZGsRXfii+XVNJk3RSSiPyZZVBhbIAGDxg9vxoguVtsJO6svxM200m4XXbcXU6suPNSVD/rAOR1r0jwve6hqC39h5QWCGEBizb4ixI+UE84x/Kua1+1vNItWXVlSK9lBRIgOeDywPYVb8JSapp2ha1epHIQYwIN56sRnvWkknG6Ii2pWaKXjrxM9jcNp9iZYZ4nDiUcDnsP8AGslfF97/AMI+iw3CC984qQYgTtI6g1zUklzqL3NxfTEmNdxLjksTwAKZZwF7i1WUMI5pAq7cHuB0/Go5vuNOX7z6D8M391J4Ysm1G2khu9pRol6so4DkehrKa/1WW+33tqIIElAUZwVX1rufDVikMD7clI/9HQnrtTjP4nJpdRs7XWLSdLeaGWMAoxjYNtYeuP5VzKolJ6GzhdLU891m/wBDh8SpcXflSJKg5b5gxJ6cdRW/4t0CbWbXT7vRTBFcWp3rEwwjLx/KuK1+00yy09orxoxbwnCqxzLIc/8ALM+oqFPHHkz21jZR3ksc+0sGbBK46evauhw2cXsYKVrp63Nee4k8N6bqd/d7Li8unRZVtwfLUA9Ae59a2fhf4ql8T2GoR3NvFFNbMpUx5G5Wzjg9+K8U8W69eaxqs7Th7eIHatsDhYwO2PX3rr/gkt//AMJEXjlZbIxnzk7P2H5VnUtJM0gmmjvfE2lapr9lHb6TCm+4kK3M0pwkMY/hA7k/0rqtI0nS9Ks10u0UeUkQQqTyR3b6k9ak0qRLA3sdxLt8uQYDEAYPIOa4rxo1reeL9Ni07UZ7PVZx5e6Iblx2zWavN8uyLlJQV1uddqmn2sMkVykW1PuOFHAGOK5jxjer4f0ya8SMhQojjUP949M59K7OxtJU0Vraa4M84iKmU8FjjrXiXxS+3SWFg1yHQQs0UiFjjd1Bx36HmnR1er2Cre3qZeoeP9Smhkjt47WNJR+8dE+83tnoK9B8J6pBq+k6PNqMwOworh8YLAkZP44rwqNgrglA2OzcivRPhVPZ3Eg069KAMWZVY8ueOg9eK33Rj8LR7dqtwtxYXlv5Z3qp+8OCPUV5h4evJLWebMYMyuyoTyD6Zx3r0VYJLy3urHzQC8Xl+Zj5gDXNeINH0nRbCKOW++xxwID5rtzI2e47msqTjG8O5rUTfvdhNCuL+38ZSm6kRrKSLcAVwV465+tY3jy3j1a2vYYALieSYeWV/gJPc9h71095fQz6VBNZuqts+WUDIZSOMGvP7TUdRsdS33Vq6wzzbTOSCNx749a0grvm2ZlN2VlsecavFOmpTfaoRDKjBXQDGCBj+lez/BnWY73SDZCE7rIAOWxggk4x/wDXrz/xnp93Pr887wMYXAYFE45GBn3r13wJoSaH4Wt0eJI7yX97LtHJPYH1xU1bKPqXT1foct8YtfvbW6soLIEQkE52ZUnpj39cVa+Fuo6hLp5lv42RIJlCMyldwbOSP/rV1us2dlNFFPeWsc7WzebGr9mqHULt5baOXy1/eYVY14JOOKlSvHl6FNK9+pqeK2fyYhHnerBlNeO+JF/tDx41ulzK8anzBgFTGf7v046+9ejwau09uVum3SrkHceRnt9BVP7LHeSPdafDC14JAsruc/L3xiqpXprUmdpnlniPTtRnt3k1BlVoz8hPJYeg+lZLpqnh66tWA2l1+ViAVcHqpz/Kvbtf0e01fTlsnlMNwkmVcDkn61xHj7w3PLBasJdpt42DK+TuHqPetFNS9SeS3ocLp2kS6h4nisEQEPLkhWGAmcnB+lfSnh3RrS001ES3TykyI48A8V4J4Ch/tLxnayQxhBCvmOoJG7aME/jXt0viJLq5m03TnMNzEgy5A+TPTGeCayqpvSJdNpas220q0O53iVS3P09q4LXvh9b6lqJuYdSgWWRuUZf5V0KQzMg+0XMksg4Zi3WqFjooTU7m6N/NJAw4hZ8iM+1RBuGvMXL3tLHn+q6JbaJqsi2kOqXE1rj7RdQDai9+Bio/G+gWNxpKazpCeYJAJCSew6jHrXpkhkSV1tLjdlcPHIcgiuO8R6ZOnheTTrALboHMm5n+9u6it1PmtcxcbPQ8fUMkQkMYMf3c+9dR4V0CX7bYzTMALhwVQDnb1JNT+C9ED3e67VGXO5QGByV7Ee9dxolt9r8Q+eGOIUK7cYCk9vyrRe7qyN9EdrIoFoEQjeR09PSsrxZpEUlnsJHypuxWvY2olmN5cDasLFUGeuO5rC8W6whglGApYbVBOCfeuaF3KyN52UdTy6+1Se3WW180bVOEBHP4GsK6ld518xyzoAuc/pWle24nuS/nISDj1rZtPDq20aTSgvO5BXPIFeg3Y4FG5zd9fXF5NNNPcM00hLu2ep717H4L1CM+EUheWOSbYSVXnH4VxHxW0a1hmj1a0i8tJjiQRjA3Y4OO2fatb4X6ULXQbvUbkFxJEzBRnJGOmPWuWpJTimzppwcJaFuDTba11ETxxv8AZID5qopIUMTzx2GRW9dXJvUjkMhjtQQZJMfp/wDXq5pEMc8+nqYWhaWBvNUnOCQG5/EVzfjvxJbeHopNOBSWSRWVk+o4rPm5pWNGlFXPMPFdpa6b4rvrQI9zZ78odx3BWwcqehPP0rn71Tb3Dw7WXYcHcMH8q9Eg1LSZLG3u7q3je+igVWgVi2xVJAIJ4HHOKW+mtLu+M1zaWwTb8tw4B7eorblbMuaKPOSLdUATc0hHXsD6Yr0PQ7q58L/D/UJLoiG5vmAtUGBIAR94+1cVcxadZayEHmXFoACcHHUdq6v4j2sVta6HZWYlbERky/zZzjof6VFujLvocTJKZGknmxLIxB3HtiljG6dQsZUtjCHrg0WxT7TH56bo0bLqvcd66jw9bGe8e6RIms484Z1JYnHGFB4OB9KtLqZt9DmLmF45lQsWb7pUjkY7VEyHDMVxz90jj8Peu58W6DawWyy2j+W0bncrcsQe+e/J7VxE4aMhQ3C88HPNDXUafQj43HcoQE+9dl4N0ex1u3urH7XNFMsf2pnC/c2HGBzznP54rjl3MzgHIA3detejfCS0Hma1Lt+5bBTL/dJYcD3OP0qHoiluXtehi1u90m01bUg88IEbyBuTjAye+eK6bx/eW9n4LurK0kUwhAhlPG5uwHrXlf8Awj93/wAJB9hmcoZJCyzHjK9ePetX4g21+DFBIshsjsMe35tzBcZP4VTirp9iU3Zo5G5heSyluI7jzBHtWTJwWz6DvimaNFPLe2gt5VhkadFWRuxzwaR4NQa3SGGG4Nu5yoVDhj07da1/D+hrcaolvdanDZXSuMRsCTx79Aalu7KSstT2/WbvxDBp7QaFaRzCSaVJJGIynToPc5rmfAM8Pg19SufEl6lp5gGLTdvkZic7io6V1Wk6yLWa+NtMtzBE4jmjPDI+ByCeD2rhPEfh6fXPFVzfwzW1lDKQ2+UHdngZx3NTBXThLb8SpbqUd/wND4l6VbXtoupW5P2dALoHGG8tuox681wXhvUGXUpEiQSW3zBZ5RgjjjJruPiBczXGkQabpl9DNOIwkgJ/fSheThRXlV1b6kLQhraZLdXwxVGwW96qL5Y6ktc0tB3iMxi9xG3mllDGRhg59PpXoPwSumkur22deI4wVZR79DWD4M+Huqa5LbXN9BLBpbZLSt8rEDsAfX1r13StL0bwjY3MsMAhhUbpCWJLY7ZrOVTmbt1NI0+VK/Qm8bWNrfaA0upSPHAuPNdGw20Hhh6kfyrMt/CMtlDbyeGXtfOZPmvbkFpcHuOw4ryTxVruo3uvnUIdRZreRj5JDYESnqhXtgHHvXqGmeLodKMWmPe20l0FGLeIMVAPIAb1x2NHJJRsmTzRbuz0LSrU6dpkNvLO08qLh5W6ue5rjPHdjZeIIJbGSRRMFLKVxuVhypx3Hb8al1DXp5BaPFcQIr5Yx5yWB6AntWbcyW93Ha3simO7t32uD1ww6/TGDUQpNO7LlUTVkecJ8OvEElukgto1yCSpmXNXPh/aXOna7LJcWYAjBUu4/wBWRkV7NosL6nCJNzRxR/dI/irItdIAGpBkR7t5dzADHymtFV3UhOns0St4htNKsAZWQ3xByBzk/X0rxfx/4jPiDUlYSs0SfNyMAN0wKd4yvJILy5tGJLK5VWzg7e9ciQwBcglegJHFacsYbdTJOU9z1HwX4hvF8O2tnZxQTRLdJbyKyElEIJyfqc4Ndx/wj66g0LXlxsgi+Yxhsc9ia8h+HuvDR9bhi8uM2s52Ts5xkdjz0I5xXU+N49ct7yc209zPYXCq0PlcqBjpxRa70dgvZbXOh1a1u7EB7OSO8hzjIG8KPQ9/xqKTxSoijAuTDdISFSQ9D6ehFcPoPhvW45opzJJafNuViTz68d/xpviVop9QnjjjEnluFEm7GfWtIwT31Ik3HyOsvfGgurfypUCEY3umSpPcD2rc0TUoJ7O2e6YZiYkBuvHQiuJ0/wALrfwNvmOSNrcFWU+wrf0rw1JYQw20jS3CBtwJwSv/ANalNQWiKhz7sm1jVITeedED9nYYJ2csT3ra0SSKGGWe2cHH3hjrVK4s7GJ5Y5X2yIPmQkZ9sjORWVpt2kGsCzRZBFj7x6MM9KhxUo2Q72dzotbvWiWC/sYWubd32TmPkpnowHseta0fl6jasjhC6jhiOG+lV1KRXIt4nSKObgjH3e5NXZtFjRBLHO4XqrKc/jXPJpJJmyT3Ofh03RvDe+6ZYreWY7dwHJ9hWF4h1a9hQzadJAsUgJ2qBlgOnPXNb9/pJOppfSKbpwnl/PnAXOenSp549Jntmtmt0jeQFcFORn09K0jJJp7kSu+tjC0bxGryQRyv5RlXf8/TGOpPaug017eZJpLZmy+cFujD1HqKwk0+1tUFtFBH5arjLDcQM9Ku/bPsulXUghdkgT5fKHIFXNJ6oI6bla7fypp4ZLlUljGXIbkCuN8QeI7eBZYrWU3DjjJOQD/WuW1q8bWL8PapKu5QHG4kuR1JrIlURjgFj2z6VovdRlrI6zwX4ha38T2xngDRzOE2qvIz0xXr9hbxRz3UsK7d74+prw/wZayXevWrJFvS3PmuSeFAr3bTITDbWpIxmRWYE+uaym9LmkFZ6GjrEq2emLCuQcV5J4knluJ1HzHkg8da9O8YlktS69gK8avNRuXmVX/5Z5AAXpVYVaXJxD1sW7Gxgvb2MohjWM5bB61s6vqSNItssvknZhG25ya5uyuZrQb8DYw3c9Sfeq95cv8Ab4ZJCvzEFueOexrqcbu5z81kdh4n0MqurXE9wqrPGxtrVXLN8uDn8q7Lwk8Nt4as3mZYgUAHmEDPHesjSLCS8dJpt20HCrjB57Vr+IvCtldxwG+vZkkwfKt1+706YH864ZyTtGTOyMX8SRopOltNa3BI/dt82DkbSCP8K+ddfuW1LV766uWm2+e+Sx3MMt0r3O3smtdFltvMLeSOo6jvzXjXjLT7jSPEt5BKyGJnaRCCGOGORnuD9acEtUKd9GRTXu+JrIxKomjjRyE+YBDw2foTmonsIbO68m21GK4jcDOVKrknHJPHHBz71QDx7WKqxnB4+brk1dl07U4pFW4sLmFMZ2OhA+vPbitW1fzMkpNeRr/Z7VJp7O+jt9ttk+ZDwZOOoJ6CtHV9dXV9IhubiLbJpE6RCWBsGZGBGfblR+dcbcyLCR9meQpKoyXTH4D1FdZ8OdPk1DWpbG+tj9hu7d0f5cEDswz7gc0pNLUIxk9Di5gv2hzbbmUsSu4ckH1rZ0bVZbCKXyosnaAZP7hHoOh/GrviXwrrWkGOGe0LQI7iO4iG4MPU46fjXPwW1w0qLEkrOx/hGTn8KIyW6KlB7M0fFGttq1wrbWSHAVO2B3/WsRs/MG5PHQ9a0zpWo2e5pbK7jBBUFojg89KtaLoGraqoW3tWFsWw0rLhV9TmhyT1YKLWiQnhDSbzUtUiWxG10+Z5HXKIO5OeD24r2TwvYW3h/T5LBH+0TTMXmIUbpT2OOwFchJCnhyyhgtbvMUakSKBhZJT1Y98YwK2vCGnNrHiRLya4eGG3jMmYjjzWzjbn0x1/CpnH3LvYcZXlZGXqOq3l94huLJIIFktSHiZuN69CQfxrrfDlo1/bM96CqxLt2Drn2NZvie3m8P6Pf3N9cRSTSOzwMVG4L2TP1rnvh34vj+2Layo6jDFFL53DqR9euPpQ3zQ90F7sveM2HUNTt/F95p8iyxwFnRUZf9UMHDCqd34JuLdftcWoQTfOoVACJGJPTHrXqHifybyyS4s7aNr1l2B92Pl69ao+Boojextq6FNrfut/GWzjJo5m48zBRSlZbGraeG4NP0ia7vJorMFVLSNgFsdC3r6Vy+kzwpqN3d20ct79vkRWuM5FuoOSAOwPrVP4h69NrviO50+BZFtbGXyhGCSZGBwz4/lVmyhuNKt/+JdboSRuZd5LMfX/AOtTjF8t5PVg5e97q0Rwnj2/WfxfcPp0BtfKxEojOGYjjdkdSa9h8ETtF4Zs4tTwLjbliwJz3G4nvXLR6jp9qbrUrvS0kvrZVyrkDj6+ld7ofiVNR8HreXdito8rNEkAXIb0I46H1rOpFrS2hcJR3L+ra5ZaLosr3U0fmFCY4iwG4noPpXztca/ruu3EqSzTzJtYtGvCgde1XvG2k69AzahqCmSCWbbGytuGMcDA6Diuds7+8tLO4SCRoxKwDEcEfSnBRg7JinzS1kiHT7a5vb1ILaJ5p3PEYHJx14rrotNgjvpLgyi31GNs4U5jBzjIHWqvhO21WXSNU1HSmlE1qV3lFBLg5zg9SR6dwTW14NWWXSNW1PUrdnmiKRIxTaTk8lj7cVUWloTKMnsibwzE+ua9c2+7bb25Ug5wQe59wT2rsNZijE9s5AMKqA8bAjLZOD/9auIt/GENhKZYtPjF2spYusxwUHquOTjvXZ+LLgTxeZFsVZfnUg9OjA1TTciY2UdD0Hwxtj0G3JKjgscfWsvXN/8Aa0F1buEjfCO47fWsHwXrIEslpPKhtJQSGPBV+uPpWF4n1650rxdDAsxjt4+W9CDWEaL9ozWVb3Ect4/0S4j1S7lljd4VQeXMy/K5JyQCOtcJKrR5V/qB1r6huNHtta0ItcYcTRhmUfdPfgdj7141478LG11FINJtbqa2aNZDMq7gCTjaT6jFXGopaPcTg1qtjgIZDFIsgUMQc7SMjH0r3Twzrhj0OxfWxEm994gAx5SY+UH0z1x6V5j4L8KXuv6ykUULfZoGDTu3AAB+6fc4xXsUmlR6h4j1HS760ke2uE86O5RMImMAIT6/4UnKOzHyt6oPFupW+paS/wBkfDRxFgsY+ZweMDFeTJpM9jA0ssc6xnvIOM16HrXh6LQLqG4jlcjAQpk4257D1qzBYW91G0ol2mdAPLyNpIzyAfWtacowjeOxnOLk7S3LXgdINSQiUhZJFV1DHknHNal4W027lgkUSZRjHIQVG7HAz9a8n11Z7C+thBcSwm3YyLGrYwQeDXtNhLdeI/DEFzPHHbyy4kjwc5X+mayrLlak9maUnze71R4JPBra63Nc3dnM011LubyznJznAINeyazoC3Onw3VvGsd0FEjFccHGTmsHVvCuoo03leYoblHjYEg1t6E1zNps9m0u11i2yZHVsdaqc7pOL2FCHK2mtzz+/wBRmVDLczbXyUC7WwSOxboKl8P6jqa3oks7mUWwyfJ35T6Y7Vh+JFvba6uLee6klsJGEoUHKhiO/v1rU8H3c3h3RrnUXgR4SdvluCSRjr7V0P4TBX5rHaWWuTXMbgGK4kK5ZY2yR2qV2Y29ugjdbhCC7yrw3tVD4d2Oh34l1iwha1lXKyxbyQmfT2NdFf8AiHSNOm8kqj5G0ksBx+Ncr+K0YnQrcvNJlKWOCWcpeQy204/iXlX+hq1GloLRIceUJAdw3DJ/xpt5LEVElnMywkY2SgHax+vSuafxdYzy7Lv7IjxvsWbjI9TkdqFGU1oOU1HcqXfwxt7tZZtP1B4nZiVGPXqKwrTwTeWkbyRqJGVWTy7pPL8wH0z2969N0XV9PNxBbQzbyUdgR93jk5rL027uLsXN5qRiJkkJj2ndtj/hFOLmm7kvlaRgeHNLGmakmnW0UMhwJbuZG4B7IPXFdBcau39uz6ckYHlIHSTOct6GnaHZxxrPKAUFxJkYHUDv+NWLGwmQ3Fw0MDPLJ8hb7wWiUlfUFF20JtSu/texCCFIw5I6ccGvOte0h0u/PjJLEntXTaBqct1q11BdIUiikKlmBxx6Gu1kispICJVRhtyDjkCmpuk9ELl9ovePCbqOVbhop8J5agkKc5qossNzGZIgxAOCrd69R1jwzZ3apcRRnB67DyarQ+Hra3t2hjsl55ywyc10KumjL2LDQNX1XUdZurDU9J+zi3OQYs/unA4Hoc+tdZcubOKOW5lV5sAGSbqufWuD8XeIdRs7/wCz20rWunRjaDbcs/uT2/Cqtlp2q6zpzGS5fyXKiNpycsfbv+NYezulKTsjTne0Vc7e3ghg0iaCO+N21zO2+UL91m5JPoBwK8a8QyXM8skGtRA6paf8th1lQEABsdcDofSvavBfhm80qxdZZGeSRtzGQ9T9K4rWINL8Q6tJHb3UEWqW8h/eE4zj+H3xU05JtpaoqcbJN6MxvCGgQ28lreIGubuRciJVDeU3B6f3sEdele22ehWp+a8hM8hAJkmkLE+1cNY6kbS4iaSKKC8ikwYi3yuDwXVvT+VeopIjIGDAqeQRWGIbVrGtKzOc1jwfpNyjzCzRpY1JjTAIDDpjPTmuFg1q/h1PytRsJLK6UhQCFPBGcAjt9K9U1DULaxtzJczRxL0G9sZPp715P4ztLjW9SE1rKVZsKgUZIHsB3NVh7v4tia/93c6/StcivYSk+FmC5MZPbOPpXEeONa1DT1D6e42g/djQcDsTgfWrl/oeu2OkqtnbhrmRSGYtuZePWl+Gug6lbDVNQ17eZANqRyHIPcn+VaXhD3lqR70vdZS8H69qup2E8l5EVEY+R8YDH0INTX3iqO2tmt7qaKzmkUgHyywGf4lI4P41saX4h0+y01ptW8qwucsyxOfvpnhsVgTa9o91eQSXr2TWsxYnarM6jPBVcd+9Wrtu6JdrWTMLUrqPXbiOxsFaVANzXA+UD3OeldVpM39gaHfXNxN5dpBtjMm377nso7npzXVaNo2nTxQXVsrfZZU3IgQKxB9u3415t8TbltT1iWztpDFpmnlYio6FyeSfVgKaqe0fKkDhyK9zmvE/iKbXrkxiSY2SgHEzZOR3P+FYFjNJBcxSwOFkR8qwOMHsa6XW9K0yy0+3ka4dfOT5Gxyxz3HauRchnKxj5AcinLQmK6H0B8Pb26vdEE98ySyy/MQY1G5MnHQdP8K6e1W1ngkijtFVjwwx2+tfOfh/Xr3SL6BrSbEasMoThHHoc9M17loF4s1imo2qNEl2PMEZbOw9CM1jUh1RrCbWjLsnhuxiv1vUjX7RsPy45Ofes3jQ4ZJbqGMltx+Ucj0A9BWumqK8W+QHCkqspIw2K4rU9Sg1rXGsYrhmMKbmCDrk9qKak9JbDnJdCOKC31NZTMgCOclGxzUGr6HeajbRw2898kMQAVUJYYFdvoMGkxYlucLKP4ZBjGOn1rqYdRsGUCG4gI9FYfyonWlF+6gjSi17zPIWvZ7Cyt7WMXNzIg2N/okh/EtjmotT0PVdQvFfRtJeSLywpea3EfXqOe3SvboplkXMbgj2NO3DPXk1n9akuhaoR7s8AvNL1zw15Vxrd0bGyyVjt7RkMkhx2GMAe5rrtPv7TXvDc7WkctuFdFkiuSGDMDlWB4znByK1PiRoZ1a802/W4gCWbYkilbCsuck/pXG+N/E41GWTTrBEjtofvbVChT7Y56VvB+1S7/kYT/dtmbP4Pl1bxM8jmG1tThXSDliMYwoxitzx3bTW+iuAfK8oKEZTnA6AGuFtNdv7G4hmuxcHTvOyAMplh1wRXSeLNb/ta2iijuI5Y3Iby0ODjHBA961UXzKzIlP3dUUrCWSHwpfXL5EhTdv/ANsdDWjJqWh+IbCyudXkls72K3Ds2MrNgkYH5frUOj6K2r6bFp0zyQxSOSxXGc54Hua9A8O6Ro3iDTvsV5pySRaS32VHbhm2jnp71NWai7sdODlojb8I3Lav4Lt5jGLTzYyoA5AUHAP5Vy3iLW7jw74am1CJXuFEvkxDH7tsjIc9xjGMVJ4h8a2VlO+i6QCHt1IYRj5EA7Z/wo0Wex8ReH9T0tWYi4XaUJOQx789ORXOoSSc7aG3NFtRuc/8NvG1xrWuHT7y3ghmmBdJbZNgJHUMO/1r1S9mS2TdK6jA6dz9B3rzjw14Nh8D6m+oXFz5021gh4ConHXPf3/Kp9R8e2FtJMTF9qud4PyHClcfwsaXs3Ud4obnGno2VfGFzLe6usOH+VTIo+7gdP616FZ2Fkujw+fEjBIxhj1HHrWA89l4l0+1uxay2xnBUqSNxUeh9M1zet+J/wCy71tPBkeAbVJ3/of/AK1aOLqJRWlieZQbl3G+IPCGqeIHgutMCqN23MjY+Un71er6baLp+l2tohytvGsY98CqHh/ULa/t42tWBTaMD0FO8V6kdK0a4uUUNIq4UE8EmuepOc2oM2ioxXMh2rava6fEDcyKpY4Udya5+wu1tZ7zUZYyqSKdqnj868M1rXL+4Ci5lLPIxLbmJI5/SuusdYSHR/s0txOx8tmYyNkDjt7V1Rw6SsjndZt3Zh+MNY+16yrwOQGfcV7dePpjFdx4Yt/7R0P7NdJsWYEcEHIPevNIrebUL9ltrdmkLADgnI9a9g0yzfSrO3geSMXjJvZBztHvWtWyjyoimm3cqTW9r4V0K6t7Fv30mZCpPzHH9K4Lw3o994j1pZCJDH5mZZuo+les6jpx1G1MjJG8hXGcc/hVzwiI4tOjgtoo4WhO2RVGM+/41iqzhB23NXTUpK5zXxYW50nQ7O7sWx5Uq+YpGVYDpuHevCbiRriaWdsKzksQowM19O/EGwXUvCt5Cxx8mea+ZSo8x1fLBVOOwBHSpotyjqOolFnW+BNRFpa3bXTbnmQwwKMljxzj0FaXw7N9d3ktqGb7EpzLu/h9AKwPC9s1tYzXLRE3bH/Rfm79yR6V6t4M0949HhluXVZpf3kjAYJHat5S5YXMlFOQ++1EwyXG1XjjhAhhQjG9u5Ht0qqmsSy2qo3ySDtnn61Drl8lxqA8vkL8u4jpVXW7RIY1mgyp4ByclgaUYqyuEnvYuyaq+1gFDL64yDRcaxC4VkTEzqEbn+H6Vgs80MYQSBt3Y9/aqc0bx4kLbiDwoPJq1TRDkzv7O8RLUKrAjqF7r7VfBTULZY2SVA3BZG2mvLX1O5hu0jZMseQR2H9a6zwxcSXLCGVnDNzuz6VnOlZXLhUu7GBJ4im1e++yafZ2k0TLlnkUj6k131vboosU86NL9sOpRSVYL1HPbFeF6LqkunXkcsAGcjrX0HcXLf2RaX0dv51yVG1fu7c9ST0xU1layRVHrc6kMCAynIPIIry+b4WC48YXOqy6htsnn89YkX58k5Kk9AM1fmvNVdJF8PXxmnRwjgqrxjPPU+g9K7Gw1KGe1DTSKkqfJIGG35h1wD2rkcJU/hZ0qSlujlfE+hRBiqJ2L25zkqw5x7g/1pj3t5Y6TaX1g0stmy5eLGfLPcY69fyrd129stkVzHcRfaowRCrnCyZwCDVO0d4J5SUEdnc5LrkHaccMp961Unyq5m0ruxwfiHxFBrj2Qubh7NI5MlkOc46givQ9DuLKbdgwqz8hMYOPXFcT4p8OadaLcajCXViAo3KNq57/AFrz5vFE2n3qRSI9wYCUPm5QgegI5rVwjOOmiMVKUJW3PpC7ubW3iLXMsaL/ALTV5z488cQ6TBFBb25lWZiApO0sB3PcDP515veeOLm4VDBbQ20iDHm72lYe43HANczM7XbM87SPMcuZHYsWqYUYx13ZUqspaPRF/XtRutR1AtqhXzpDln29B2Ax2HaqFtd3FhI7WkgRz8vmKBuA9j2ou7iWR5PtKr5zEMSMDjHTioJ33sBGpCqMY9K1k+pEV0Po/wAAyWP9gQSWl0ZkZsu5BA8zA39fVia8U8exXFn4m1CGU4EshnChuMMTgn3r1HwHp14L6DSpomXS7S0UsyHHmuwD7ievJOMe1avjfwbZapapCgLOCXCGTEg9ShPX6HisVNQk1fc1ceaPofP9xcPLaW9u+ZIlJfGeVJ4xmmXNxiFLdIthjzuBXByT/hWt4k8K32hsruBcWjnbHPHyG4ycjqp9jWJL5kzbypPHLAZ/Otua+pny20Gq2NqEbh1weK9S+EOnXV6txqM90YtNs4zDszwzHnp04z+tcj4U8K3us3K+WrRoGzvZcqfYe9ezxaHbeHvDEdm11HDCW3BdvytITnlupPSolK3u33LjFfEeQ+MfEN/e6tOtrOwsI2KRKhwMfStjwbJbaDo8muaikjqziPKgFjnsP1/Ks/WNHi0uWS8umlFqZcpGv3mOc4z6U3WvFFlqfhg6fY2bpIhBMbjcDz94Y9K2lZKyMVe5o6j8R7htQ8yPTYTp21vLEinc/oxP9Kz7bxrAqmeSwtkl84fu4wVPl45w3rnFcXv3RbVG1jwQavvOjaNFYvaqZ1cuk3RsH+H36cH61C8imu56JonxLi89YLyK5tLfbgSRS7tp9xjkV0VndI+nza6l00llKp/eb3VyVPQivDHDiJd8flsvGcYLfWu78D6pHc6PN4enkdJJsyQOG4zjlfrxmlZD23Leo+LZWnK29ugiGTiQks/41jx6Nq00kl3bKZlufnkV/lZQfr6V1MOnf2dotpGNAW+1m4mZVaR/MUKuOdoPH413+gx6nqRhfXLe3gvI4yGjQDaVzhc4zz1/KqnVUFeIQp8zszyxPCGs+JLqE3s2yCMBfubcD1A6Amnaj4dtdJ1DyEf51UoHZtx9iD2xXuF6oiiWGAKo/uqK8i8YlpZXg2H7U0ZKsvGNvJH86mjUc5XHVgoRsjtfhPc2l9oBWC3kSS3co8ko5dvUGs/XPGX/AAjWpXumWWnCfUmkUjAwshb1A5zip/g3NM3hjUGiTOydhFu6MdoOPzqh4Y8Ia7deLIvEWutFFIJmd4WHJ4wpGOAP8KxfIpyci1zShFROYk8A6/Dq0WpyxhYLkmSZUk+aHdyVPrXp/hTSNO0z7UbMq10cNIMjdz/jXS3TxCF1lICbTuye1eP+MPE9zpctvBaalHZORmaSJA7Yz8obvnHNKMpVlZlSUaTujoPFf9v6idSg0rT4po5dsRZyNw6dAfxrj30RILu00jXNPktdRlBZbmDDKQPVRwelelW95NLFaX2luLm3uVDNuGGZu5/+tVy5f7RIhvo1QAHC/eJ+pHQe3enGo46W/wAyXTjLUpackJSOQxiK0ij8uInC4A9q828QeEW1XWmlh1CBImfc29sFfwPWvV9NLX155gUG1h4UlcBm9qZ4r8LWPiLT3glHkS8FJ4wNympVXklZlunzLQwfBoXS9QktUZ5YThFlI6n0+lVfi7rEcOnQ2gmCs7bmwew9qi06zvNFhnsnma9toSTHMcKwA55PauQaOfXnlvJrdBJkiPzXLY9+vNbxgpT5zGcmo8hwdhEdQ1XbO+8uSQWOAfr7V6Np2kvehLSKLAMZUDGfMJGDz6CuOvI10PVY1EGZAdzZPGD/AHfTvX0D4StIJLOC+8pRNImAQfuj0FVUn7ONyYR55WIvCnhODSLSISgNIBz/APrrV1eOO002d1Ub2+XcRk89q1cVleJEd7FCjqpWRfvd64FNzneR22UVoUrSJ4YQhXGFzuPA+tcvBr2m2fjDyIrxPPYmKeMkgeuR2OD/ADqD4k+JksLKOzgdHklBWUDrjHb0/GvFri9u765jmlK+du4YfKc+p/SuunTury6nLOetl0Pp7XTHNpE8bsqrIu3OfWvnq+8NHSbu5j1WVI/mxGgOS65+8D2HSur8KXF9400W701rloprPYVkDEhxnv8AlWG2g3+veKL6ORwIoZNkk75wMcYHrVUoRg2rinKU+hoaLpqy3NskQd1jHzspAVVx39a6+81u2t7Bo4HBnA2BR0rndYuF0aBNP0/5UA2s5yC3vTfDPh64127cD5EiwGZj3NbSs1zS2M43vyx3NLw1oN7q1hJdswAZ2Az35rdPhTUfv+YsgQZCt0FbkmqaV4N06ytNQlxK4wqRruP1+lbrXbMVKfcYBhx2rknWqXutjojThs90eJ3QRZZjdRt9pyVC+nOAAKsX1m2n2VrHfrm4mXdhGyVB6V6m1tZvfR3L2MZnzkSFOQai1jSNMuLuK9vSqyRDGCQoP1q1irtKxPsVrqeT6rZ/2csZbDmRcru6qK6DSYXi0O6urVGMoj2bh1BI5b8BVTxrdx6jqCW8EaLHFxvB61raVPFpHh0wz3cazyAsFY/MQeBxW0pNxV9zJW5nbY8f0e0+1Xe3yw6rjgkgYr3LTGjg0dY7lwE2rE8cmTgY4x68V5x4WtbhYF1G4sUi09VMglJH7wg/KAPrWjrHi6a5RzbxyQO2FdkPLkD17d6c4ueiFGXJqztx4i0bRIpGWCFGkbd5cK7ePfPesWHx1Z3Osi4ggCzKjLsLnkdzxwa8y1AGeWK4heSe3cYLDqh9DWraaWLN9OuZF2yRvmUdQRnj6cZpewghe2nI7pPiDp11crFPYROwbuASpH1FdZp2u6fq8XkArG5GFVxj8q8O1mxKancXEDAROzMoA6ADkk/561p6JcR6do8FzcXEsryybViXkhQefxqZ4eDWmhUa009Wera7pI1XSpdJupCjMwMb4weOce9fP/jO3Fr4m1CJlZFWZhhuteyaRr8d9ILC/kYnbhH3coT0BP8AXtXMfE3wrO01zrFqGmnZAk8ITJIHWQflz+dZxTh7sjRtS96J5YVV4giJukJzuA5+n0pd7fZkCZyN2SRnA9qcyhLx/Im3bWAGcgtV2yulika6m8pip/49yuFkzyRx2rVIhsy4wxUy8bQQCc1YtD5V5HiRU6EktkY68/4VDPKrTPJCgiVmLbF6L7D2qzaFGuPtMiRsM8RbcBjSj2G+59MeCr611A3d3DKjtPsfAPouDj8c1p3mnpNrVrfmTmCJkVPUt3rxb4b2+qWVnNqRl8m3Zj5Qb+Ir94gegHGPeukHje9h0uVtSZYbh5GWEKuTs/vGsHRbleBoqqirSRbuW8Rx6q1tcaB9pR5fluLaTYjJnq2cgHFVfFfgfQrW5Du8q+bIWZI3Knp1PbH4Vc0DxxeXem3V4Ehe3tMKdzEM49fTPtWbqWuw+IbtLiJHjVPv+ZwpA9vrWijNy12XYhzjy6fiZdxq1x/bcVppgbyrNV8yKE7ScYAUtXXTXM2oWe3UYkjtlbO9jxGMdcngHrWT4S0m+l1qZ4IYlgm/eS3YwSewG0+tegvoFm0YjvFa5yOfMOQfw6UqtSMXYdOm2rniHxQ1Cza1s9Ps4QwH7z7Sc5PHAB7iuFtXFkBPDIxuM4UqMBRjnPvXv3j7wlaXmlSGOIOyIzRKSco2OCD/AErwi00i8mvfs3ktuzgg9z6U4NStKISjy6M9E0vw9o3iW2F3bRyRX5QM0WcLLgclff2pW8PxvcNHfIXkbaBujCbAO3AFZXgO01iPVpJpxNBFAMjcMAMOgH4V7RqKadeabFd30kUBeMPvZsYGKcp8j02YKN1qeI+MtAgs4bu7ilbYxVdmMnd9fSm+CPBt1qMyXrySR28f3BGMSP7g9APeu+WPwzrf2mw/tX7XtAYxgkZ7gg9/wrtvDVpBZ6MlnbqqymLcQR27VNSpZXtqOnC/oec3+t3Q1JIdMZg8bEFvfpk+oxmuv07WrLQdJN7r12ITcNsRnyWfHcDrisrRdBksdcnn1GFNt2+xSM9BnH0Fc98VNLeVJdTa4M8cAWOO3IwqKfSnJxnaPQmPNBc3U9D03VLHxFbzDSb2KR4zyv8AF9cHt71xOtWzaVqAV8SHaV6Z4x2rzPwtrsvh7X7S+tlDOrFZE3cFDwVr1LxvMsd8Lu5ZEt8iVGyDgMv+elOnHlnZbBKXNG73E0jxzbeHLU6bHpudspIMfygk810Vl8QIL2W1jit5TJKDuA/gOe5rxnUpXe6jW2szMj/MsqscsD6Yrs/BmlvHe27SqyIOzHJxjPNaTo07N21IjUqN76Gn4w8Vi1vVgSOS41KbhIdxSNVzggnueK8t1q803VvEouzFNHHPMDPGZBhBwDg46V0XiNta0rxFqU/n29wbcCVJ5wpZFY8BAefwrjJbS4uDNcKqTdWfyiPl98DoKhRXLoiru+57r4K161vtONhpVs1pDExhtixJLJ/fya7NdGtDEFlDSHOSST831ry3wo8Xh/w3pN3qUcot+jSbeQWJOMegFdbeeK7O/DwaPeefcmFmRYlY9BySccVjOm2/c2NYVEtJbmx4i8R2GhWvzPGGXgIDwPWuR07xudeuZ4bJ34PCrgbh2A9K8w8WX851eKO4z5a87txJbnvXc/DvSba2me9uSInk4RBwce/p1rVUYU433Zk6k5y7I0bW4uNV1S90qTbaWPlNHI68ne3A5PpyfxqqnhR9ItoorK7W5EZPRsHP68Vurops4fM0lEvJyxw11L843HJyT2FbI+1QW/lm2jaRjyykBc/zqXUs7xNOTTU8w8R6JeteWdwYFvDnaYFUn8Sa9l8PQtBpkEbgKwX7o/h9qpaFcxXqyqyKJ4X2MPbsa24lC9OlYVqjl7rRdOCWqJxXIeNtWghU27SRh0wQHbALn7orrHbajEDkCvKtU0e91jUpHi1CKTa5cxeUpKH6+tKhFOV30Kqt2sjjbbSZpNSur/V0RYhmQpG24Nkevaub0PT5dQ1NHsLWWaGKXDF+VXPAzivXtO0WW7bdqbG2s4/vno0hHYA/zrTN/Z6fZE6VDBZ2KnbvVRuJ/wAa7JVHe0dTnUEtzP0LRn8N2DxGZFvJSHl8kYUfWrF3qFrZ6FcSW8YVyxyzLglu5qC4uPLWW7ut620Y3BG4MrVwuua1PrU266YRwp91F4FKFNzd2KU+XRD7NH1Gd5zvuBG24qq5H09q9i8L20UVms6Qi3M+GKngnjivN/hZY339rT3kCu1gMIwPAc//AFq6jx94gudPu7Cy0oH7VJID0yAM4xU17zn7NDpe5HnZmfFHTri11iLW0ZHiCLGFPJUj0r0LSpGurG2uGXaZI1Yr1xkUl5p8Oq6cIb5FcMPmB9ar2kFzp9xBbQRq1kE2ggkmMD6+tcsp88FF7o6FDlk5LZmjcxYid4wS4UkD1NeA6y1++oTS3wuFdpC/OR37V7jqmtWmnoTczLGT0Bryq6ur7xBqrKkxliUnZxjIrfCXjd20MsQ1Ky6lTw7Cl9eqrMJN5Gcg5GK57xZqEl3r81tYwrvDeUkg5cgcYHoK9LsLC20xwo/e3rL8sMQyF+vYU7TfCtrZCW9uo44JGyzMOWx9T0/Ct3VSdzJU3axxes6mzGKKzJgtIABHFwpHvgd6zoNcWaSWKeEu8gIVyuG9i3r9ayGnSUgMZluhwUfkH/PpW5o1hKk6MrM4ZQHSVMlM9VGea3aSRgryZJ4c0SRr1pY8hHGWjX7uf8K1vEI+zSmO3w10kZkCFS2ce3+PFdVb2PlpbpGQi7gZcdTjtms3VNFS9u5LyKWaG5K+VlR78Vgqicrs35HayOfgtHuNPW5LP5cvTdyQOoFYN9K5mitItskqFpMkBVQk5Jbtn9K9atPDyReGgss7O4GdxArgPEGj+WJT8qHqxOcceuOeaqnVU2yalNxRzNlfSWc22I+cqsxLsACxPfNes+HtXTU7ZILicG4VRtYHJJx0z6j9a8pt7KS4hg8hFVZDtLMeM+9aGmvLo2qiEujRZySpJbPY/nV1IKat1IpycXfoS/Enwk0E0mr6fCfKdv8ASEQACNv7wH90/oa864+YgYHTGea+nbQJfaSkoVJA0eGRxuVx3B9RXn3iX4XQ3sP2nwu2yUHMlpNJ0H+yT/WuPntozr5b7HlARfJZvM+c/Lt9v8K7L4f6M93NZ35WFYrSblJB/rs8j2xXP6voN5omoJZ6vttZWKkg5YbT/ECOCK7zxhqF3oGj6fFbSW8wnGJJoQArYAxjHAz/AFrVNMzfunTeI9O+xfZLmK7UW5BDxrGQodiCAMdAefxrkde0a9NvcXVosksjOSEb+EHGQPauXuPEviEWKRTTzpAx+RmUjd/wLvXcfDbxXcauw0XUtsj7QsMuOw6g+/vTU3FaMTipPVFTwzomp2du9nZyZuncSOpOUix1bH8WKq+IdYMXic6Pb26yRpKqA+bkyE4OSfx6V654O0OPTJLyeSQy3kzbWdhyqjoo9BXPal4Wsb/x3GltaJGuPtM06HB3dMCs1W959kX7LRGhoXiO30+zEUiEALnbj5s7sDHqKh1T4iWNjeeRdT2wYpvVQxYj2OOM+1W9Y8K2+nQvqEEk08iMPkkxjbnoDjPFeEeNLWOw8UahHbRBYt+drc7CwyQffmpSpz95Ib546Nns+meNbfxJcy2FtIqkDP3cCQdyCfSuXv7jQrDWHexuo3kjfDIV+63pmvLtLe+W6RdO88XJ4Xyc7j+VeleG/BUmm6fNq2rqsuqMrG3spWwCfVz/AErSLjDb7iGpyWpe8ReKLbTrTZEVe4dMiMAkAHv9K831bxFfatdNNfzFoinlBVXCKvoo7V01v4dvdZ1G5vNTmSCeQgNtGFx6L6CszxroQ0hLcRg7HYvt6j04PSrVlsRZvVjfhigbxlZlWCx5IwTglc17R41v7qx1HR4NIZIby/nEDTsM7UGDjB9c18++H9R/snVrW8CEhG+b3HcCvoJW0bxno1rK9wUaJxKkinY6MOtYzVmpdDWLunE2vEyqlhAzl95lVV2jkn0rxH4qXpfxReQ2sr7URRNEG4DAcEj8cV7XqN+sy7IHzDCQZHPRsdh618/63Zzah4kla/lgglfdI+BtL49velh00FZpnMgbmVc7Q44PavYtdtH1Tw5psrIGzaRZRjlV2jBXPr3rzWLTTnT/ALRPEkbMVY8ELz6da9yt7FRpdnbxybo1QYxyDx/KtpvlszOPvXSPL106404pc3uoR2tsVBUQjdtweBjHFep2uiQTaPDqVvOLg7PMEgXAYe3euJ8c6SqaaHTCxQtuKgFuvHT8BXofw2lMfg20guXUyRbk2g5wueB+tTXk+RSiy6UUpOLPIvipJDFqBEUSfv4QGkwdxYY6/TFZfw001LrxWkFw+0JGZSB91hx1P416H8QvAsWpX0d1FLJCgGC2Mgj09BWPp1vY+F4ryZLuJw0YwJGBbKj7oPfNEXzrQUlyvU7+A2F3p0ml6ssclkT+7cHg/wDAh3p+n2fh7QrW5TR1hEpAEj7t7EHtnsK8zvtee1NsYlZLeRfMZCvyknFa2halpjSqkV4JJ5G3sRxuyc7Rnt7USoO17iVbWxt2Xhez1C6luY44fMjXcokBIUnJFdX4UsVj0nddCN5JT82FwoHTj2rkLnUbiHVWtIsyxvGZHkJClVyRyRgHPp7Vq6d4kEccdq0YO0feB6is6kZyRpGcYsd4o1H/AIR6EkGTBkBhCDdkdwal0jXxd22dQMEF0zsVjV85XPBPvW5AtnqlnvbZLF33DpXF+J9F0m8t5BaN5TbTwMggDv8ASohaXuyWo5Jr3osv6DIyeML5EkBieEM6+hB4/ma6p9Rt422eaC391eT+lef+CopL22e6ZN1xvMP7tvvqCOSev4V3l5pvmafNDYv9hllTHnxKNy+4pVlFSsyqd2rmFruv3lvLvkaGz04A7nmHzMP6VwEXi2K11G7TwzBLdXt5IMyzL8o9Nq+n1rF+IU91q3imS1hmkuVjcRRoOcnp2713HgjQLXw3ZNLfmE6jIuTnnyx6CuhRjCO2pi25vfQZf6s1hCq3UqXWpFfmZ8AL6/Qe1ZmgTX+q6wg3RyWUX7xwqDYrdse9Sah8P7bUtWuL281VoLaQ7lRBlvf2FddoUVtpmkw2ul2u20VeSxw5OeSfUn1odRJWitQUG3ds8/8AGGo3N7eGMBvKQ8Litr4eabNdXrXF6kTWsa4IZep9qk8U2Bedri3jXaeTjvWLFq9zBYtbwO1uDndhq1+OFomfwSuzsbrxdANWGkafEIEWQIzou0HnkCu1hs4JFjlljR5F5ViOQa8d8P6fYX2o2r3V8qPGwwpUgt+Ndb4i8eQ6XqLWNtC0oh+V3B4z7VzVaN2o00awq2TlNnX3+sw2shijRpZF4YL0HtVf/hIrXBW4V4HxwHHB+hrl9LN1cJvijeVnPmZJHGf5VN4osJo9Oea4kRWxwqc59qj2UE+VmnPJrmRzvim5TXL7Nnl0I+92Fa/hzT/IgjhjAEjH53HVV/xqDQbExQJsj3TMMhcY69z7VY8WXkfhPw2Ug3/bbltseBuLN3raUtqcTNL7TOrH2Sxhyqoo9B1NcJ4q8UM0rQwcKjfMeoUf41y9reXdjaSm9ldtSnXLBmz5Kf3QOxPeuc1C/ETkJyxPIz0rSnQUXzPUznWb0RQsZpluI9jg7TgFucV694bsg1tNqU77mjbIyeSepyTXjunwyPeohiY4b5lHXjrXqeoai+l+FbYRRqJZZtpdgSFG3kfU1dS8kkiYWjdkvhjxLqOp6obN7JI4mUsrLzt571U8YeMV06+e109laVCfNduVyOwrW0ixMWhPqemRMtzcw7kBXlSc9a87l8P6lrF8YTYi3mGRuXoxJ6tk5/GoXI5OXYpqdlHU7TwR4jutbnljkJ8lVyOeQe/H8qj18alNfLbW9s0sDNgsQc/nXR+CPDp0CyMksIaYADcAM/j64zW5qF9DaYe5MKtjJwMk+9Ze1tP3Uaclo+8zin0ZNNsRPIqmNV9a4DW7ueTVVlji2K6+WjkcH3H0r1y41KHV7GeztsCSRcAkV5N4ptvL1FPMJigQcsOT+A9a3pSbvzbmNRLS2x6Z4Nvy+iPbRzEy27EiJcBmHp7Vs2U8dyqOnmQTgZ2SfLInsR3H6V4jaawtkqf2fB5HzZMzSsZH+vb8hXdeH/FEWoeW147C4ibCTJkkf0I9qidG92ioVejO11uy0zX7QWfiGzR1A/d3MYw0f4jkfyrkvij4NSTRYr3Q5XkhtEVPsceCoUfekHcnpmuquVmntPOjH70D7qNw3+6T615f4x8WD7faS6Sk1tqNqWDSEbSM8FSOhrGnT1unY2nPSzRe8DeB7vxJYW02v3Fx/Zce77PDnGc9SPQVoW3hux8LeI5bi1lItUOEll5CtjO3NaVl4n1ybwdHNpNhbyzLH+/ijyJYck/ME7qe2Olc74c8X+dfjS9Z03LCQbRgklumGU9aqKldtv5Etq1kjpPE00/iC1UaXc/ZJomG6VGJVie3BFRafqc3h/VbVr+Tz3kjMKyAEF5PQ56c10enXcMFnLKuntACdxV1C98Dj8K5DxXc/aNTWy8lRqDBbiLeCQpxkfTgU4a+7bQUly+91PSbnV7K7sZbcOWlePGwL3PQfWvGvH/grVm8QGS3i8yK5USvJkAA9CWPr6Cti08Uy6VNmeJULANJuXG/1I7nGDXd6VqEfiG/t5IwfsqRiUc53emahwdLVbFxmqjs9zO8JeFX0zSrSC2hhiccyTsMyHPU11kWh2isGmDTyf3nOa1FAUYAxQa5HUkzoUUjM1HR7W7tHhMQUHkbflIPrxXn2v8Ahe5uNOudMugJom+a1uH6o/YH/PNeqZqC9gS4t5I5FBBBqoVXHToKUFLU+PZ4mjd45CA8bFWHfPT+lX/Dx1VtSig0Z5zeSNhVjbAY+/bH1r0PxTpHhi4v5XvbqW21GQnctuAQxHG4jHU113gvw9o3hnT47sSgzyJua5nAX5T2z2FdcpOOttTmSjLRvQwfib4kuvD+k6fptkY0v54w9xIpDeXwMqOOpPevM9M0u71iTDMQWyPNfLfN1xmtz4tzWt74h+16fdR3Kuu1zHk7SOg/WrfgW4uLexR5wfJLZ3hvugdOKqCa0Jk/tIs+GfhzLeIpmlkUhsSNjgewH9a9UZIdM02KwRvNmRRHH6t2zVTQtQSBQxuLi4Wb5lDR4WP8e9Hh/QnudWuL66lkkQzmSPefyC/7IrKT/m2RrFdt2Z/jjSng0omOTy12FGO7G444PPevNvAF1fwa9bwr57QiTJJJxjvk17z4n0wahp3llFkKMHCsAckVmaXpun/ZA6xqrABXz/CR7U6de0LMU6N5GjqP7zRpvIkgkLY65K5z0NeE6rZXGo66+ltbOksbsxTkxsB0bPBHFev6vpMU1uywXBt3yCAjYNZuoaPatpeTJIk6rsEm7DZ9jRSkobdQqJy+RwWqXk149ppdnbx+bkYaYfIVHVRnvWbLoF/a6uxtoYZ42bcgXIEZHTNT3V68OoCzjAmki7sDx2Dcd67vw5aT3EcMk7MWC4Oe9dU3yK5zxXNocd4luNZtrO3wTHuwHlIXKn+7xWZ4SudQvtZa1up2ZWjYNIRkqPb3r0LxithY2bm6RPJkIEoK457H3NcHpuoXmk6wuy2jaOU+UqxoRkE8EYog+aN0Elyux6lrBl0Xw/fSwMTDFHuWPON7dOa8nOu6rqsyrc3vkyRLvjSFMfKeoJHTiut+KN9PJoqxxykhG3Soj7SQRwSOuPauF8Iafbavq8Fs3nRyEiWTaxIeMcsD3rOn7quy5+87I9e+D/2pPDTNdBId8reWHGHK+p/pWz421W4XSriy0sSf2jOBHEV4wT1OfYV59qmpyX3iBrW1aXz1lAIU/Ki/4AYro57m00eE3F5dSO7YUmRizMfT2+grOVL3uZ7lqp7vL0MTT7O08PTRQW0P2rUyu5myMj1IJrQbV1liLmCNG3bX8wZYH3rB1+3a9la/tn8uF8Bio5THTHtWTdxm6trOy0idLy+kYsybsFuPWt1BNXZk5SvZHYSah53+rlUn0HfFNn1G8ijeMI0iFCUbP3Wx0PtXLeE9H169u5o7eCSC5U43SrhEPfOa7KW2e1vPs8s6zTBcttXAB7ge1S+VOy1GlK15I5XRde1GC+xq7K0EjbfLI5jPrW/r+mQJB58IKo4wSq5xVma2tJ72LzYEkdcHcR09K1LkxPFMEOQVAbjhT7UnLVNIcY2TR5y++3Uy+Yu2MZBHVjWdHJ9qnMSIzTOfvHncfWux/wCEZNxE7JcqEQ5OegzWNq13Ho876f4di+06l1ln27vLHt71sqi6Gbg+pt6Hc3GjwQme6jtV6t5jY3Vtae8viFh9muDLEj8zODgf7o7n3ryqXTtT1BluNWnMKHrJcNjA9hXpnhKzktvD6Lpsu+GQFlk5AfnGfWsqiSXN1Lhdux29laW1jGwU89WdmySfeuR8eXlgr2tzPEr3Vvl7dXPc9yKl1PU7bSbYxAkXLDrgnn1rzjVr6W8ldmYuW4+bk4/pWdGjd8zLqVbLlRRu7r7RcPMNzAtliRgsf8KyNRs3uLskYGMZrYfcoQyKoJ5ABzVvQNPe7mZjKqQqQZGf+FfWuyVranNG99DZ0nTTDZPqF+QqxIDJIV+bHvjqaz9P183Wryi5jeXT+ixHkA9AfrXoM2nQXHhxUlm8jI64yM/T39K4bUNOltLiOCwRmjjfcZsYG4c9u/NYwmp3TNJxcWrHoGh6hJqOY4VMLwqFMZG3HoKfe6udN+0Q/Zyb5Y96sVGDn3749K5eG4m8OaXf32q3Ei3F8f8AWE5YEjsKq+Cre5utPubtbmS/2Zlg80ZKMARnnvWLprWT2Ned/D1Ok8GeINS1C8uYdQAlt0Qv52wLtYY44rlvFurG51GUWgeaRs7UUZOB1Na3w9l1C41a+srwyvDJCxbnhDnrVq98JQR3AnmuAypkjJJxz2FVeMKjJcZSgjmfAk811fRs6PjhTjofU1c8Z+Ep7q6EoSTyxxkDOa0kv9O0RiYlBYZ3HPOO9dRaa7aXmmTXMZG5Msys/QUTlNS5ktAhGLXK2eK3Xh9dPtpZJYpblgMoA20D68Z/CsuzumKbI9sXOSUHzfnXceJfF9le+aqQqWU7WwPvDvg1wslzBKxkghKSZz85yPyxXRC/UwlZ7HrvhDUXuNPjghk3Lt3Lu6g9war+KvCqawwvYF238S7WAwPMHX8/Q1yHgzxBJbXBFwPMKEFSOML0IwOK77xBex217amK6m81sTPFCoY7OuGzwP51zyi1O6N4yTjqef3uqyeG4bfyZZk1NM4YNho/r6j2716T4D1az13R7G+1NLa61WLIecxKJAwJx0+vWsrxDouj+IbVbl7ad5pFG2SFfnUds9iB6VU8KeDDodzNdQaoxlwUUeXgAe4NTUaqLUuCcNUd54sSa70VpLOP5yck8jgZ54rzbRbhL+9SXVdYM3kcRrCjeUvbn1Nei6Xdz6ppV3Yz+UbpEKpJH8qvxgHHY9q5nVY7fTtJnX7MLZ4k5Ro8EAc/j0PNTSfKuRjqK/vGBrniDS5r1tKwCwYoS/K59z2I5/Op/Dniyy8M3kFpKkjWzOEeRMDyeehX0rmF0KLWc6tpzn7LNIfMJ++j98A9etWPDugmTxLbRXyFrWRjvDLyw9D7mt3GLi0ZJy5kfQcMxeJHIALDOAcipVINUZbi2sLZDcTJFGowC5qnD4j09p2QO+wAHzNh2815nI3qkd3Mlo2blZviG7W00uZsjeylVGcZNFxrdhDAZPtCOcZCqeTXhfj/AMcXuoapd6dEnlxFgiux5Cn27CtKVJt3lsZ1KiSsjhdYvZL3W7i7J3Evkc9cdBXqvxVSM/Dzw59qYx3RCtsXgEbRnIrkPA3gue/8XWVtfpvstpneSFg6Mq9tw468V1Xxq1Sxu5YbHgvbINhX3OPy4roV5TsZO0Y3PNb2/iLxR2CNFbRHenmYyTgA5x16V0ng27jvtRSC2typSMySRk/I3TOB2HeuOmtHt2Ad45EYZBicMD/n0q9or38d7bto5nW+jyV8v0xyf8a2TZm0vU+ntJtoxYRR7I+B0XkCtJWjt1AYqvYA8V5n4D1jWJ9NaW4K/aS5HkmLYPxz3+lVfiBrV9YX+nzalEyWrA7lib7p7GuT2F5WbN/a2jsetkhk9q5jWYynmyxLK8PHmJCMsTnrWdpHiny9NtmlSe6jmH7uSOM8Ajjce1dJDEstuskbhg3zVHK6b1K5lND7fSbZYgpjDHHJcZJrlfGarYWrxwB1iYHI6gHsRXcwthACeRXMeLrO41LSZxBFucHemODke9FKVp6hUj7uh5j4G0UX80jwz+cg+VWkHII5Pv8AnVv4j+JNQ8OSW2l6YRCZYt0kwHzdcfKe1ZXgzWpNKv57XyZYHMhZ9/PzE89qqfEK7mufE1re3Q2KYAFRsFeMg7fx9a7pRblfocqaUbHKT6pdTzMZZnmVRgAk7R749c10Wl+O543hF9B5hjAHmo20gfTpn3rjW+8xTIHp6j3p1nBNNPHDAm55TtA75o5nfUOVW0Ok1zVZ/EmtTLYxk28jDGBhsKOCT27muy0DS7/R7hrKwjga1ntwJr1CCWZsE7W6gDpil8M+GrbT9LaPUo8rLgSSIxBdgeEUDk9etdXe3MVpAN0TRW8SALFGMkegwOpqeboUkUbe3stKjaO1hVT1ZgOWPua4LxbrV9dXDJbIn2WJvlJTJJ9jXsGkeGF1DTRPqKywyzrkRZ+4D6+9SaV4D0yzuluJ2e6ZDlEfhFP071CrwjfuX7GUrHN+HvB93ffDoRXUkgvbpxcBGO0gf3Poaw9I+GOoTalDM6CwhifJJbJOPQV7d9KhubqC1TdcTRxL6uwFYLEVNUupq6UEtSSJCkaqW3MAAW7nFcF4jKLqtx5YA+YA4/WumvfEFjDCpimWVpM7dnI/GuNmeS6uXcZaSQ52jp+dOjBp3ZNWaasivFCJb6Jl5kPGc8AdzUWtJcz3y2FnbXDQx5OVOB6ksx6VrmOLRraa7v2TgcAck+2K85vvHl7eXTrBGsdsOkQOCfcmuqCcndHPJqK1OzvLC8h8OMkcay3p5CISQp7c96zPA2iXekw3VzdMgvrscqzZKj/GuPuvFd+6JErFTg5AY4qbSNWM29LyW4LbSY1QZLv2H0q/Zys02R7VX2OquPD1/qlyTfIEhHAVSGO3PNavg3VXnmn0+2s2jt7T92rN6DpxXLaVr1zp6K09wTI+SY2OcL0x9a0rCW50zxPDNaCSfT9S5lUKf3LeuamadmpfIuElfQu+NgsZiw/71s5QfzzXGWmmXlwWa2id2Xk5Oc13HiHR2vXaSJjIQ3IPWuh8P6ZJZaPEJkVW7gdqSqqEFYr2fPLU8zi8N3k2o26SrsRhl2HGPWtC7vNMls5tI0z5SvLztwGx2r017eOdmgCZZl5PoDXn2jeHbXUPGM1nblVsLFg8gBy0jZ6E+lEayldy6BKnbSPU6S0aWfSIWEMEtsqbiWbJZu4/D3rF02NbnWJnWeN43b7qZ49vwrb0vWNMsLF7KWDyIImMYaTB3k5rMWW20uO4vDbJDFGSVKsfnz0ANKndN6BO2juWfGiQ6tqg0mNw88JDr8g25x056nmrUNrZ6J4fttHkb7Mbs/vZkTkD0+tZmhPp2q6vFrk8nlyGTd9nDceYBjNdF4gkhubItLb5bs/9aUtLR/q4LVORV1XWbTSYZIrVmZsctn5mwOpNeY6744nukkhtgVVhjfnmsbxDqV3Fd3EMU8nzMVZt3+sHbP0rHs7Wa6lCRIxJ/IVtCnGHqZym5b7Fuxe51G/hh3SSMW7DNdlpIuDp13I7GRpwQAFxyRjGDWVpGn2Fgc3lyPOYfMM9u4rqP7VgtrZFtERkyMFTmqbZCSucBc6BqAujGUWNT03MKr29k8t6sAwkn3QGOFY/WvRdQvrO/TddMkFxFwV9fTNcNcPNqOp4RyzHaiZXd8o6H6U433YS7I3PClldDU0tWtYBztLEBiDmug1ZrV9S1OxheJ7mWQxgLIQwwBz7Y9fam2mp2PhjyZb9XubsjISMDjjknsPpV5NJtNQ16XW7MoBcxBZVfC+WrL94DHJPvWUpO9+hpFaWTJfA2sW2oeIbTQ7T9/ZwWxcznILSL7enNd7Po7Rea0ASZW5CudpX2z6Vy/hPR9L8NSzXdikLTSDbueY8L6D0rd1bWorm1MUd6bTJG9oxuYjuAcYH1rkqXlP3djpg1GNnucbqHibTNG1yK0lmms7iQbjKo+VeeN3fB69K7aLVLXULQQanHFJBMu3zQN0bg/yriPFXhvw5r8kV5Jd3EU6xhC6/8tAOmcjr710XgJLGLR1sY9iRQkogklEhI606iTjdoUHZ2uc3qPwrSXUDJoervaaXJlvIGW2Nj+HnkfXmtXQvC93otpZ/bbr7W9u2W2JjIz69Tgetdctlbx58i4MbeqsMH6ike3vY8vbywz9ir8A/iKhVJbX0L5FvbU89+KN1qdrpJ1RPMj3SBI1xnylznJ+vSsOw+JxNrBHcWECqDtlIY8DHXpXX+IPFLA3Oj+INK+yiWJlguWPmQlscFuMgZxXhut2GpWkvmaqgSSb5kfIYSjplSOCK3ht7yMZb+6zS1zxRd3gi+yzPCIznKdWPQkn8K5uR3kZpD/GeTnvSy7Mp5WeV+Yds+1b3g/QJ/FmsQadBshWPLyy7TwuR+vpVTl3FCJ6T8HEk0jwjqd/JlRcOBCWOOgxwK5vx59mSKG6ltzK8zbVcZB2jn8K9Z8baNYnwxb2vklYLeVGQRnbgjgE4rzvxhYQqlot5eAxrtCptyuSe4HU0qDUtV1HVTWjKnh7w3Y31zBqewiwEQkMB6scYCn8a7sReHPD9gl/rAt4Gb5YownOPRQOT9a5jwNqkeoSahbLE8NvE8YU4wMAkY9j7VofEPwVa6i0d6NTFpKg2sLlyY+emPTP5UqlnLlYR0jdFHWvGlrJewT2Gmo0cBzF57ld7HjO0f1rnPHWu3XiCVIb9liFuu4pGuACf8Oma2PDvhmaDWz/altu8uMNaup3xSHByR2NJr/g+6u72SWwIBZcncMj8R1FbR9nF2Rk1Nou/DKa/t9FufssbXMaEskR6sB2HbNXtB8eQSahNAkZiJcgxTHaA2egPQc1a0NNR0D+zoobX7VpRANzKi8wkDHQdu9Z/jzwpb3kEusaFIjxH5poogGyf7wx+tZ3hKbUtmX7yjpujqLvxa2nPJ9tspVQHgqQ3/wCutvw3r1lr8DSWbkshw6MMMp9xXFeEbK4u9Jkl1lXeM26JEGJO3AOeO3aq/wAH7eQa1rV1ACLTf5S57kE/0/nWdSnDlbW6NITldeZ6JfeHtPv0xdwq77iwkUbXX6Ec1h+JvCenX1tIot4mJjKKrDJUeqnqDXWISxIPWvNfF15InxW0GF3kjhVQOCQrE5/+tWFLmk7XNKjSV7HlcvhLWE1G7trS0lmjjJj87GAw9frU2kaW2j+JNPiu3UNuG9RyQ390j8RXrvjTXD4cNxc20HnkuoMY4GSOtcBoUY1K9ufFWtsIIzLlI1XLMR04rthJtXZzTSTsjrPOP2kl/nlHKEjp/hXReG2tI5VknBN0RnLDhfYf41xkeq2t0295Ao6kE4NXG1C3dMiQAD+JW5H40p03JWCNRJ3PU0uEYbgwwKy9U8T6Vp0btcXkRZf4FOWP4VxHk3SI0jXt35UowBvwOe4rKHhqzut8S4WRzjzN+Wz6n1rGOHjvJmsq0uiNTWPigDHKumWbLtU/vJ/l59h3rH8MLdahE2p6zM9xdzZK+Z0jX0A6CoZPCbW95/xMb2J4gM7RgMa1FvbO3iT51ZRlRsHp2ro5YJWpow5pN3my/wAYIUcVXm1ux06FmY77rptxwvuf8K5vXPEkQxDaSN5jcgp2+tcXcXU1zKzTSNjuD61caV9yZVbbHW6rrYkuyLiZ5I5gQJAeg6ZxXHEwxMwAyc8MO4qNH3YVASe2K6Xw74RvNXYMY2weduO3ua192CuZpOTsYq2N1Jam7WMeTjHUZ/KrGlzpp5F9GpmuOUVWGEjP9TXo+s6ba6PpSWmYy6rh9oBx7V5aIpLfVxZ3C7VLc4IOM1MZqauOUHF6EsQubjUlWNWeZ23bAO9d/wCHdVls7gRyY8tDsmUnlT9Kw9D0ya0uJHUyeYUxDMpwQfaqCBo9UDRyOzscy7h0bp+NOSU9AV46nrVwQ8f2iCYLKx3Kp6YrD8Q+LX0m2tzd3qBpMgJBFuHHXJzV+ysm1HTI8PmOOMjAOG3VxHi3SDPpE6xrIXhkzEDHg4/iHFcsYq9n0Olt2uXvFvifUJtFtLjRbxvs0u5ZJIhg59D3FaXwOs5kXUr2cPiQqilgck9TU/wj0Brbw/I2rwKwml81IpBnaAOteiS3FvbJtHlxqOgGAKzq1VZ04ouENeeTPKNc1CbUL8afc2MoiDlRMF5U/wB70IrP8VaLPZW8UK3hngjUM6LkYyeoB4q5Nq11b373Onri0nfdlV3DPcexq5Lqv2i5eGcx/ugdyOnJ9x9fSulc0bW2OdpPc5XSb+CEXEMNsJXdAkG5yoVvX3r22KC5Tw7YW8NvbzPIuy4ZzkIMf5/KvO9E0bR9S1CEpFNHIG3FIiCq+59K7t9Y07SYvstxc5cNjGR+VY125NKK1NaSUU3JnD+IPBBgQTSrCsMIKoygKcE9Djr6c1wWrXx0+R7eEk7wfmzj8c17H4znbVdGaTS5lkjT7wB6H1I9K8Ou9MvJLiWaSAsobB8r5sH0x1Fa0JNx97cyqxSlpsZiSObgNIxZcgkk81cnVrLUHSN2KqdyEN1B5B/I1VYxKSHGw/3Wrq9M0qXVYoohHuAAHmHrgdDntxx+FbX5dWzPfRIz7eyOtSJ+9PnnOW59OMn8xXZadoEuk6W0kCB7jaAPlLMc98AZ21u6D4eh06wIhQtIMASN0/D1+tJqF9BFdTzSahxHGWdmYIoUdVQep9etYOpzu0TVQUFqcV9jltLtr3XPIcb94GScn0I6fhVy514SyRiyCXMzqGmUZxkcY9OKwNe1PTtdkMlvLJayDhopXyrAHgj0+lXNF+zwmKM4XPIbH3q2tpdmd+iH6nr+o6dM0cUcQiPKu8XI9qhtdcv5s3V46yZYJFCRtVsnk4HYf1rdmhhuWlSd0yuBuPAJ9PQGuZ8U+ba3UFxvC7AFCqMBQOhpKzE7nVyx391HKiXKtFHkPMq4BPZV71d0+xgt42kZJBaIvzuzbQX6AD9Sfwrz+y8U3NrFtAhfC4XcPun+99an1PxNearYpZqFSPguF6uw7/pScJPToPnt0OqvtcXTGe4axcJOQIpJGAYqOpAph8bXttMstvujg5Zfm6rnGcHrmuQNtquqPapMJXhUfKzHOwd66LUdIa6TbNIsQ2JHGiD7iL0H68mjljsx3ludvaa3pvjDT1s9RASaVSUkIAAP9DXD6voWteGmRJbKG+0+3m86J5I/MCn6dge46Vl2t5caI8zRCN0hALeZ0OTjA9/pXcaL45b+zA0ro8a7VMci5DE9l79qh03D4NV2LVRS+LfuHgv/AIRvxj5i3mh21tfW20lo8gSrnsPr1FelW1rp2lBntYbW2AUBtqqvA9a4uyt9K1CeO509Y7C/DZGx9v1x6/Q1oX0f2aZ/MMclzKux22AmRe49xXLOClLt5HRGbS7m7p+vaL4himhtLmO5jyyP6cdf51ymv+FNO03R7y/LXk7xqXjlSQuUGCMDHbmq1j/ZVlp00FvHbWtqwcyqwMYOeDuz+npWpo96NJ0+K1tY1Fsi4QLJvyPxP9aFBw+EHJS0keQeAtSv7bUntI4TJaswMhWLcV54Nd54w0a1IfXby5me1mURTQg5KZ4BX6HBxT76XxJPqMtxpMumWkZ4KtGpZvXcQKsJJc3Fi9trsenOZDuIik+RvfBH8q2u7pmLStYf4aVbHwdaHTnnvlM5eEOAjdeQOwrp9U1W20sRteFlaQbsYyeByD2rmlaxDwrdT4WLAihgX5Yx2/zxVm5fQboiO5uQSeR5h5P5molG7u0XGVlZMhs/GOn+cbiGR7cnKmGQErJ7jHeregppSy3NtYTQwxXLec6eZnd7DPQD0qk/hPQzAJUvxFH94jzhtqovhCzuYkbT9RtjHAp+bbvGOpJ5qrU2tLoV5X6M6ttd0WyjmtJ9QgBwQVVs9fpWDoPiTR9FzYaeyeXPIZBIyMg3Hrk9xXCQiyuTJZafqVi8sjEbXR49x9eaj1Hw74iS1aKSJZYAp2vGwwR/Or9jTWknuT7Sb1R7VLdXdvIkxnSRSwDoq/KAfQ1rXFpaXDR3VzFGXiGVkYDK/Q9q5Dw5qtrJoFpDf3EKXCxBJEZwDkCmXd0LuIx+fM9pGflBbiT/AOsPeuV0m3bY3VREfieGDV7GZY9zztLvj2jgAcc/hWPdm1sfD62l1H8rLlkx834CsrXvFuo6aWt7bTEAZcLNk5HuMVz9lo+savN9t1Jpbe1H3ppmPT/ZB5NdcIWVm9DnnJt3SLP9kWmqXbpYrOu35m2fNxU8nhW0iRze3MscAGREjgyNj1xwKuy6xpmlae1nY3OxZf8Alpkb5D6+wrkzqIuX8iRsSqSN28g/WtkpPyRk5JebOibxPHZabDb2UAAVfkFyTIxH1NV7LxFe3N1t82MALvEagJvX0yOQayF0W/vgs7sMxnAOclhntVXWdLnsZIpUDnc2Bxgg9jxRaAvfZJqmtXBurlYXyucBmGWx9ag07U1eRorh3jWRg29ezeuKPELwedbSQfIzxDzVLZw/Q1mWhjF3GJfnTcMqp5YegqhWRsX9rI148ltKs7sNxKjrWU+S7K2dx65r1rwpo1vfyIgUQhz90gZUD6d6n8VeAzPKRpkaFyvLtgVk68Yy5Waewk48yPJdMt/PvI4w+0E9a97V10TwrEYgBJKuM/1ri9I+G95a6hBJNMrquDtA4Br03U9LhudMitGfYYwNp+lYVq0JNJbG1GlKN2zwvVtTvr/UmiWNpAG5XBwTW1p/h6Nphe3MXld9zdq9Bh0Gz03fcTsJZlX5d3Q/WuM1i+m1GWS0ZtmM4KEAAfStY1efSOxDp8mr3ItR1Im4jtLBQM/8tG6KO5NcE1/cw3kjxygZfkqOGwetOvLi507VXZnO8DawLfeWlXULa6kjiFskSl879+W9hW8VbYwk29z2f4fbbjRSQHUyHcxY8g1vXTWttF5czq8xBxuxk1z3g6T7FoE91gLFGC/J7Ac1w3h/Ub3xV4xn1G5nMVnboxO37qL2H1rhdPmlJ30R1xlyxSPQjezaPpJWWb7VdyMWUDAx7fhXms/iq8k1cxXZBO4jk9CelP17xLDZ6uhOZ44uMbuo+vrXFaxqSX2py3ICRh23BQfu+1dFOmo6vqYSm5aI+ktC/wCQRF/10as3Vf8AkK/8AH86KK54/Ezpfwmp4N/5C97/ALv9a57xV/x/t/viiiqh/EZEvhRueHP+PVv+uX9K55P+Q/J/umiirj8TIl8JU17/AI+E/wCuYrq9C/5Bsf8AvCiispfCax6HR6h/qz/1zNeV+LP+PmH/AHBRRRh9ia+5zx+7XQ6J/wAex+o/nRRW0dmZy6G3q/8AyB9R/wCucf8A6FVfWP8AkFt/17r/ADWiipQzj361q6H/AK9frRRVDR3CdKqt/wAfIoorKJcjM8Tf8glv+uq/yqLSv+PvSf8Arkf5UUVS+El/EbFp/wAfSf7wre8R/wDH1bf9cn/kKKKiXxIuOzOV1T/kXdW+q11mj/8AIOs/+uI/kKKKVUdLYz73pJ+NVYf9SP8ArkKKKpbEdWRH/j4u/wDej/rWTc/8f8H++aKK0iQ9x15/yD4vq1bPgf8A5Bk/+4/8jRRSn8AR+M4rS/8AkNQf9dK9S0//AI9V+hooqauxpDc5LxJ/yEo/wrqNE/5BqfjRRUS/hoa/iMgj++P+utP8U/dh+h/lRRUw+Mup8B5nc/fX/fpx/wCQufrRRXWzkR6Bpf8Ax5t9BVfWP+PU0UVyr4zp+ycNff8AH1+NVbX/AI+4v98UUV1HOeqeDv8Aj5X6muwPRqKK4K/xnbS+EY33T/umqj/6w/Siis4lSMzWv6CuVH/H/J9KKK6qexjPc5fxJ/yEz9KpQf6+H/eFFFdK2OaW56vb/wDIoz/9cmrlPBv/ACCNQ/3qKK5o7P1N30OU1D/j4m/3jWf3NFFdEjGnsf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81:122. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23239=[""].join("\n");
var outline_f22_44_23239=null;
var title_f22_44_23240="Disease modifying treatment of amyotrophic lateral sclerosis";
var content_f22_44_23240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disease modifying treatment of amyotrophic lateral sclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23240/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23240/contributors\">",
"     Rabia B Choudry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23240/contributors\">",
"     Nestor Galvez-Jimenez, MD, MSc, MHSA, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23240/contributors\">",
"     Merit E Cudkowicz, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23240/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23240/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23240/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23240/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/44/23240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS), first described by Charcot in the nineteenth century [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/1\">",
"     1",
"    </a>",
"    ], is a progressive neurodegenerative disorder that causes muscle weakness, disability, and eventually death, with a median survival of three to five years.",
"   </p>",
"   <p>",
"    The hallmark of ALS is the combination of upper motor neuron (UMN) and lower motor neuron (LMN) involvement. The LMN findings of weakness, atrophy, and fasciculations are a direct consequence of muscle denervation. The UMN findings of hyperreflexia and spasticity result from degeneration of the lateral corticospinal tracts in the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The existing and experimental disease modifying pharmacologic treatment of ALS will be reviewed here. The symptomatic management and the clinical features and diagnosis of ALS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33193?source=see_link\">",
"     \"Symptom-based management of amyotrophic lateral sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RILUZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     Riluzole",
"    </a>",
"    is the only drug to have any impact on survival in ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/2\">",
"     2",
"    </a>",
"    ]. The evidence that riluzole is beneficial comes from two landmark clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective, double-blind, placebo-controlled trial in 155 outpatients with ALS, survival at 12 months was significantly higher for patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"       riluzole",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      compared with controls (74 versus 58 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/3\">",
"       3",
"      </a>",
"      ]. For the subset of patients with bulbar-onset ALS, an even greater advantage for survival at 12 months emerged for the riluzole group (73 versus 35 percent).",
"     </li>",
"     <li>",
"      In a larger follow-up study, 959 patients with clinically probable or definite ALS of less than five years duration were randomly assigned treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"       riluzole",
"      </a>",
"      (50 mg, 100 mg, or 200 mg daily) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/4\">",
"       4",
"      </a>",
"      ]. After a median follow-up of 18 months, the primary outcome of survival without tracheostomy was significantly higher for the riluzole-treated group (100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      compared with controls (57 versus 50 percent, adjusted relative risk 0.65, 95% CI 0.50-0.85).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these data, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    50 mg twice daily for patients with ALS.",
"   </p>",
"   <p>",
"    Three separate mechanisms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    are thought to reduce glutamate-induced excitotoxicity: inhibition of glutamic acid release, noncompetitive block of NMDA receptor mediated responses, and direct action on the voltage-dependent sodium channel [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/5\">",
"     5",
"    </a>",
"    ]. However, its precise mechanism of action in ALS is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2009 American Academy of Neurology (AAN) practice parameter concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    is safe and effective for slowing ALS progression to a modest degree [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/7\">",
"     7",
"    </a>",
"    ]. The AAN recommended that riluzole should be offered to slow disease progression in patients with ALS.",
"   </p>",
"   <p>",
"    An earlier AAN practice advisory on the treatment of ALS noted that patients most likely to benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    include those with the following clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Definite or probable ALS by El-Escorial criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/9\">",
"       9",
"      </a>",
"      ], in whom other causes of progressive muscle atrophy have been ruled out",
"     </li>",
"     <li>",
"      Symptoms present for less than five years",
"     </li>",
"     <li>",
"      Vital capacity (VC) greater than 60 percent of predicted",
"     </li>",
"     <li>",
"      No tracheostomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with these characteristics are likely to be similar to patients eligible for inclusion in the randomized trials that established the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Patients for whom no randomized data support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    but expert opinion suggests potential benefit include those who have [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suspected or possible ALS by El-Escorial criteria",
"     </li>",
"     <li>",
"      Symptoms present for more than five years",
"     </li>",
"     <li>",
"      VC less than 60 percent of predicted",
"     </li>",
"     <li>",
"      Tracheostomy for prevention of aspiration only (ventilator independent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Expert consensus suggests",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    is of uncertain benefit in patients who have the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tracheostomy required for ventilation",
"     </li>",
"     <li>",
"      Other incurable disorders",
"     </li>",
"     <li>",
"      Other forms of anterior horn cell disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dosage and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dosage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    is 50 mg twice daily. It is well absorbed orally with a bioavailability of 60 percent and an elimination half-life of 12 hours. Metabolism is through the cytochrome P450 enzyme 1A2 (CYP1A2). The pharmacologic effects of riluzole may be affected by inhibitors of CYP1A2, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    and caffeine, which potentially may decrease the rate of riluzole elimination.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     Riluzole",
"    </a>",
"    is well tolerated, with the most significant adverse effects being gastrointestinal and hepatic. Neutropenia is extremely rare [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/10\">",
"     10",
"    </a>",
"    ]. The most common adverse effects of riluzole are asthenia, dizziness, gastrointestinal disorders, and elevations in liver enzyme activities.",
"   </p>",
"   <p>",
"    Elevation of the liver transaminases can be expected with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/11\">",
"     11",
"    </a>",
"    ]. At least one alanine aminotransferase (ALT) level above the upper limit of normal (ULN) will occur in approximately half of patients treated with riluzole, while elevations greater than three or five times the ULN are seen in 8 and 2 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/12\">",
"     12",
"    </a>",
"    ]. Liver function tests are indicated monthly for the first three months of riluzole treatment and every three months thereafter. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     \"Riluzole: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drugs have been tested for effectiveness in treating ALS since the advent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    as an FDA-approved treatment. While they have shown promise in preclinical in vitro and in vivo models of ALS, they have failed to show efficacy in human clinical trials. These include glutamate antagonists other than riluzole, neurotrophic factors, antioxidants, and immunomodulatory agents. The following illustrates the range of findings in some of these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical trials have found no benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/13\">",
"       13",
"      </a>",
"      ], ciliary neurotrophic factor [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/14\">",
"       14",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/15\">",
"       15",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/16\">",
"       16",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/17-19\">",
"       17-19",
"      </a>",
"      ], talampanel [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/20\">",
"       20",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/21\">",
"       21",
"      </a>",
"      ], valproic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/22\">",
"       22",
"      </a>",
"      ], verapamil [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/23\">",
"       23",
"      </a>",
"      ], or minocycline [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase II randomized controlled trial of 185 patients with ALS showed that the free radical scavenger coenzyme Q10, at up to 2700 mg daily, was safe [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/25\">",
"       25",
"      </a>",
"      ]. However, the trial investigators concluded that coenzyme Q10 treatment was futile and should not be further tested as a possible treatment for ALS.",
"     </li>",
"     <li>",
"      Two preliminary human clinical trials employing recombinant insulin-like growth factor type I (IGF-I) for ALS produced inconclusive results [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/26-28\">",
"       26-28",
"      </a>",
"      ]. A third multicenter placebo-controlled trial of 330 patients with ALS found no evidence of benefit for IGF-1 on any of the primary or secondary outcome measures at two years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several animal models have been developed to investigate the pathogenesis and treatment of ALS. Earlier studies used pure motor neurons cultured in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/30\">",
"     30",
"    </a>",
"    ]. In vitro models of cell death based on superoxide dismutase (SOD1) dysfunction were developed after the discovery of the",
"    <span class=\"nowrap\">",
"     Cu/Zn",
"    </span>",
"    SOD1 gene abnormalities in familial ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], and several mouse and rat models expressing mutant forms of SOD1 exist [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, transgenic rodent models of ALS were developed based upon mutant forms of human TDP-43 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The experimentally induced mutations G93A, G37R, and G85R in the transgenic mouse models have phenotypes similar to human ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/37\">",
"     37",
"    </a>",
"    ]. There are also naturally occurring mouse models including the motor neuron degeneration (Mnd), progressive motor neuropathy (pmn), and wobbler.",
"   </p>",
"   <p>",
"    The transgenic SOD1 mouse model is considered the most accurate representation of the disease process. However, the utility of this animal model for screening potential human ALS treatments is not established. A number of investigators have challenged its validity, since some experimental therapies that are effective in this model have not proven effective in human trials. Nevertheless, limitations in these trials related to dose range and sample size render direct comparison of animal to human studies quite speculative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neurotrophic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trials utilizing insulin-like growth factor-I (IGF-I) and other neurotrophic factors for ALS have been unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/14,28,29\">",
"     14,28,29",
"    </a>",
"    ]. The limitations and short-comings of these agents are related to unfavorable pharmacokinetics, bioavailability, and dose-limiting toxicities, in addition to the possibility that antibody inactivation may occur. However, alternative methods of drug delivery, such as gene therapy or mesenchymal derived cells modified to deliver growth factor, may be warranted (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Gene therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxidative stress has been implicated in the pathogenesis of ALS due to the production of oxygen free radicals resulting in lipid peroxidation, cytoskeletal disruption, and damage to the mitochondria. However, trials utilizing antioxidants have been negative thus far in terms of delaying disease progression.",
"   </p>",
"   <p>",
"    At least two randomized controlled trials have failed to demonstrate significant benefit of vitamin E as add-on therapy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    in ALS. In the earlier study, subjects were randomly assigned to vitamin E 500 mg twice daily or placebo; there was no significant difference in disease progression at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/38\">",
"     38",
"    </a>",
"    ]. In a subsequent 18-month trial, subjects were randomly assigned to either megadose vitamin E at 5000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/39\">",
"     39",
"    </a>",
"    ]. No significant difference was found between the rates of survival of the two groups. No significant adverse events were noted with dosages as high as 5000 mg per day.",
"   </p>",
"   <p>",
"    In another randomized controlled trial testing the free radical scavenger N-acetylcysteine (NAC), there was no significant difference in delay of progression of the disease between the treatment and placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there was a beneficial trend in survival for the patients with limb-onset disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bioenergetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several transgenic mouse models of ALS with SOD1 mutations, early pathologic features include abnormalities in the mitochondria such as swelling and vacuolization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/37\">",
"     37",
"    </a>",
"    ]. The energy buffering agent creatine has been studied as a way to prevent or mitigate mitochondrial dysfunction. In transgenic mouse model data, oral administration of creatine showed dose-dependent benefit, with 1 percent creatine extending survival by 13 days and 2 percent creatine by 26 days [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/41\">",
"     41",
"    </a>",
"    ]. This benefit seen with 2 percent creatine surpassed the extended survival seen with riluzole in this mouse model.",
"   </p>",
"   <p>",
"    Despite the promise of creatine in animal models, human randomized controlled trials failed to demonstrate efficacy for creatine at doses up to 10",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    in the treatment of ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/42\">",
"     42",
"    </a>",
"    ]. The first trial in the Netherlands evaluated 175 patients and found no significant benefit of creatine monohydrate 5 g twice daily for survival compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/43\">",
"     43",
"    </a>",
"    ]. In a second trial, creatine monohydrate 20 mg daily for five days followed by 5 g daily showed no significant benefit compared with placebo in the delay of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/44\">",
"     44",
"    </a>",
"    ]. The doses of creatine used in these trials may have been too low to demonstrate effectiveness. A pharmacokinetic study found that creatine crosses the blood-brain barrier; oral dosages of up to 30 g daily were associated with increased brain creatine concentrations compared with lower dosages [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/45\">",
"     45",
"    </a>",
"    ]. There is an ongoing phase II study of creatine at up to 30",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antiapoptotic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tricyclic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    analog, TCH346 (also called CGP3466) interacts with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in a mechanism that may prevent programmed cell death. It reduces the degeneration of motor neurons in many in vitro models of apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/47\">",
"     47",
"    </a>",
"    ], but it did not have significant effects on survival in transgenic mice. A 24-week phase human trial to evaluate four oral doses of TCH346 in over 500 subjects with ALS found that TCH346 did not slow the rate of disease progression or prolong survival at any of the doses tested [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Current and future trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents are under active investigation for the treatment of ALS, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antisense oligonucleotide therapy for SOD1-associated familial ALS",
"     </li>",
"     <li>",
"      Arimoclomol for familial ALS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"     </li>",
"     <li>",
"      Creatine",
"     </li>",
"     <li>",
"      Dexpramipexole",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"       Memantine",
"      </a>",
"     </li>",
"     <li>",
"      NP001 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stem cell treatments",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although some of these experimental therapeutics for ALS are available as prescription medications for other approved indications, or as over-the-counter medications, the off-label use of these drugs for the treatment of ALS is strongly discouraged. These drugs should be used to treat ALS only in the context of a clinical trial or under the discretion of an experienced physician.",
"   </p>",
"   <p>",
"    A frequently updated list of drug trials can be found online from the",
"    <a class=\"external\" href=\"file://www.alsa.org/\">",
"     ALS Association",
"    </a>",
"    , the",
"    <a class=\"external\" href=\"file://www.alsconsortium.org/\">",
"     Northeast ALS Consortium",
"    </a>",
"    , and",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     ClinicalTrials.gov",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Some agents currently in trial are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Arimoclomol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat shock proteins are involved in protein repair, and thus are cytoprotective. Motor neurons appear to have a high threshold for activation of the heat shock protein pathway, and mutant SOD1 may contribute to reduced antiapoptotic capability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/53\">",
"     53",
"    </a>",
"    ]. Treatment of G93A mice with arimoclomol, a co-inducer of heat shock proteins, delayed disease progression and improved survival by 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/54\">",
"     54",
"    </a>",
"    ]. A trial of arimoclomol in familial ALS is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ceftriaxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     Ceftriaxone",
"    </a>",
"    and other beta lactam antibiotics appear to be active stimulators for expression of the glutamate transporter GLT1, also known as excitatory amino acid transporter type II (EEAT2) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/55\">",
"     55",
"    </a>",
"    ]. These compounds were identified using high throughput screening by the Neurodegeneration Drug Screening Consortium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In vivo evaluation of ceftriaxone in normal rats also revealed upregulation of GLT1 protein expression, and transgenic G93A mice treated with ceftriaxone demonstrated a significant decline of motor neuron loss and hypercellular gliosis after two weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A trial to determine the safety and efficacy of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    treatment in subjects with ALS (NCT00349622",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     ClinicalTrials.gov",
"    </a>",
"    ) is underway [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/57\">",
"     57",
"    </a>",
"    ]. Enrollment is complete and results are expected early 2013.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14942755\">",
"    <span class=\"h3\">",
"     Dexpramipexole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dexpramipexole, the R(+) enantiomer of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    , has a much lower affinity for dopaminergic receptors than pramipexole, thereby minimizing potential dopaminergic side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/58\">",
"     58",
"    </a>",
"    ]. In preclinical studies, dexpramipexole has demonstrated neuroprotective properties, and in preliminary clinical studies, dexpramipexole therapy for ALS was safe and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/59\">",
"     59",
"    </a>",
"    ]. In a phase II placebo-controlled trial involving 102 patients with ALS, dexpramipexole was safe and well tolerated. In addition, dexpramipexole had a significant dose-dependent effect on the rate of functional decline and mortality favoring the higher dose group [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/60\">",
"     60",
"    </a>",
"    ]. Additional randomized controlled trials are needed to determine if dexpramipexole is effective for slowing disease progression in ALS. An ongoing phase III trial of dexpramipexole (300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    versus placebo) is fully enrolled with results expected early in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous clinical trials with neurotrophic factors have shown equivocal to negative results (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Experimental therapy'",
"    </a>",
"    above). Research in a transgenic mouse model found that IGF-I can be delivered directly to respiratory and motor limb muscles to target the affected motor neurons by using the retrograde transport ability of adeno-associated virus (AAV) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/62\">",
"     62",
"    </a>",
"    ]. IGF-I delivered by this vector delays disease onset and prolongs survival by 30 percent in the preclinical model and 18 percent in the postsymptomatic model in the SOD1 mutant mouse model.",
"   </p>",
"   <p>",
"    In a similar method, glial cell line-derived neurotrophic factor (GDNF) gene was injected into lower extremity muscles of a G93A transgenic mouse using a replication defective adenoviral vector [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/63\">",
"     63",
"    </a>",
"    ]. Larger motor neurons were seen in the injected muscles, suggesting gene therapy may delay progression in ALS.",
"   </p>",
"   <p>",
"    Vascular endothelial growth factor (VEGF) is needed for angiogenesis and has been implicated in neuroprotection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Researchers have shown that low levels of VEGF in transgenic mice can cause an ALS-like syndrome. Furthermore, intramuscular delivery of VEGF has shown delayed onset and prolonged survival in SOD1 mice.",
"   </p>",
"   <p>",
"    In a study of intracerebroventricular delivery of VEGF gene therapy in transgenic rats, VEGF delayed disease onset, improved motor performance, and delayed the onset of paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/66\">",
"     66",
"    </a>",
"    ]. This particular route was chosen over intrathecal delivery because of a speculated improved effect on bulbar and cervical motor neurons rather than motor neurons in the lumbar cord. VEGF gene therapy will likely be investigated in human trials in the near future.",
"   </p>",
"   <p>",
"    Another approach to gene therapy employs antisense oligonucleotides to downregulate or silence mutant genes. The antisense strategy targets specific RNA sequences by constructing complementary oligonucleotides that bind to the native mRNA sequences and reduce their translation and subsequent protein expression.",
"   </p>",
"   <p>",
"    In a preliminary study, continuous intraventricular infusion of antisense oligonucleotides to SOD1 reduced both SOD1 protein and mRNA levels throughout the rat brain and spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, this treatment significantly slowed disease progression when initiated near disease onset in a rat model of ALS caused by a SOD1 mutation. A preliminary human trial of an antisense oligonucleotide to SOD1 (ISIS 333611) found that the drug was well-tolerated and achieved predicted levels in cerebrospinal fluid and plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23240/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease-modifying treatment options for amyotrophic lateral sclerosis (ALS) are limited.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"       Riluzole",
"      </a>",
"      is the only drug to have any impact on survival, slowing ALS progression to a modest degree. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Riluzole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ALS, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"       riluzole",
"      </a>",
"      50 mg twice daily (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Patients most likely to benefit from riluzole therapy are those with definite or probable ALS with symptoms present for less than five years, a vital capacity &gt;60 percent of predicted, and no tracheostomy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Riluzole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Guidelines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Dosage and side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since the advent of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"       riluzole",
"      </a>",
"      , no additional disease modifying drugs for ALS have been successfully developed. However, a number of agents are under active investigation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Experimental therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptomatic management of ALS (including respiratory muscle weakness, dysphagia, nutrition, dysarthria, dyspnea, fatigue, muscle spasms, spasticity, muscle weakness, functional decline, sialorrhea, thick mucus, pain, pseudobulbar affect, psychosocial difficulties, and sleep problems) is reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33193?source=see_link\">",
"       \"Symptom-based management of amyotrophic lateral sclerosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/1\">",
"      Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 2001; 58:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/2\">",
"      Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012; 3:CD001447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/3\">",
"      Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/4\">",
"      Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/5\">",
"      Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/6\">",
"      Kennel P, Revah F, Bohme GA, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J Neurol Sci 2000; 180:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/7\">",
"      Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/8\">",
"      Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1997; 49:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/9\">",
"      Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial \"Clinical limits of amyotrophic lateral sclerosis\" workshop contributors. J Neurol Sci 1994; 124 Suppl:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/10\">",
"      Weber G, Bitterman H. Riluzole-induced neutropenia. Neurology 2004; 62:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/11\">",
"      Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249:609.",
"     </a>",
"    </li>",
"    <li>",
"     Rilutek&reg; (riluzole) Tablets. Prescribing information. file://products.sanofi-aventis.us/rilutek/rilutek.html (Accessed on December 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/13\">",
"      Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006; 60:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/14\">",
"      Bongioanni P, Reali C, Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004; :CD004302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/15\">",
"      Miller RG, Moore DH 2nd, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/16\">",
"      Ryberg H, Askmark H, Persson LI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 2003; 108:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/17\">",
"      Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/18\">",
"      Chi&ograve; A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010; 75:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/19\">",
"      Verstraete E, Veldink JH, Huisman MH, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 2012; 83:557.",
"     </a>",
"    </li>",
"    <li>",
"     Press release. Teva provides update on talampanel for the treatment of amyotrophic lateral sclerosis (ALS). www.tevapharm.com/en-US/Media/News/Pages/2010/1555496.aspx (Accessed on December 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/21\">",
"      Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003; 61:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/22\">",
"      Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009; 66:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/23\">",
"      Miller RG, Smith SA, Murphy JR, et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 1996; 19:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/24\">",
"      Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/25\">",
"      Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009; 66:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/26\">",
"      Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/27\">",
"      Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/28\">",
"      Beauverd M, Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012; 11:CD002064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/29\">",
"      Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008; 71:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/30\">",
"      Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995; 65:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/31\">",
"      Pasinelli P, Borchelt DR, Houseweart MK, et al. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci U S A 1998; 95:15763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/32\">",
"      Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2000; 97:13901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/33\">",
"      Flanagan SW, Anderson RD, Ross MA, Oberley LW. Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J Neurochem 2002; 81:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/34\">",
"      Wegorzewska I, Bell S, Cairns NJ, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2009; 106:18809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/35\">",
"      Wils H, Kleinberger G, Janssens J, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A 2010; 107:3858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/36\">",
"      Zhou H, Huang C, Chen H, et al. Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet 2010; 6:e1000887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/37\">",
"      Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/38\">",
"      Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/39\">",
"      Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005; 112:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/40\">",
"      Louwerse ES, Weverling GJ, Bossuyt PM, et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995; 52:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/41\">",
"      Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/42\">",
"      Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2010; :CD005225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/43\">",
"      Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/44\">",
"      Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004; 63:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/45\">",
"      Atassi N, Ratai EM, Greenblatt DJ, et al. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11:508.",
"     </a>",
"    </li>",
"    <li>",
"     Safety and efficacy study of creatine and tamoxifen in volunteers with amyotrophic lateral sclerosis (ALS) (SDALS-001). file://clinicaltrials.gov/ct2/show/NCT01257581 (Accessed on November 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/47\">",
"      Carlile GW, Chalmers-Redman RM, Tatton NA, et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000; 57:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/48\">",
"      Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007; 69:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/49\">",
"      Traub R, Mitsumoto H, Rowland LP. Research advances in amyotrophic lateral sclerosis, 2009 to 2010. Curr Neurol Neurosci Rep 2011; 11:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/50\">",
"      Papadeas ST, Maragakis NJ. Advances in stem cell research for Amyotrophic Lateral Sclerosis. Curr Opin Biotechnol 2009; 20:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/51\">",
"      Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 2011; 10:481.",
"     </a>",
"    </li>",
"    <li>",
"     A study of NP001 in subjects with amyotrophic lateral sclerosis (ALS). file://clinicaltrials.gov/ct2/show/NCT01281631 (Accessed on February 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/53\">",
"      Batulan Z, Shinder GA, Minotti S, et al. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J Neurosci 2003; 23:5789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/54\">",
"      Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004; 10:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/55\">",
"      Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/56\">",
"      Heemskerk J. High throughput drug screening. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 Suppl 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical trial ceftriaxone in subjects with ALS. file://clinicaltrials.gov/ct2/show/NCT00349622 (Accessed on December 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/58\">",
"      Cheah BC, Kiernan MC. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010; 13:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/59\">",
"      Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol 2011; 51:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/60\">",
"      Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011; 17:1652.",
"     </a>",
"    </li>",
"    <li>",
"     Phase 3 study of dexpramipexole in ALS (EMPOWER). file://clinicaltrials.gov/ct2/show/NCT01281189 (Accessed on February 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/62\">",
"      Kaspar BK, Llad&oacute; J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/63\">",
"      Abe K, Manabe Y, Murakami T. [Gene therapy and neurotrophic factor treatment for amyotrophic lateral sclerosis]. Rinsho Shinkeigaku 2001; 41:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/64\">",
"      Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci U S A 2000; 97:10242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/65\">",
"      Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet 2003; 4:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/66\">",
"      Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/67\">",
"      Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23240/abstract/68\">",
"      Miller T, Smith R, Pestronk A, et al. Results of a phase 1, double-blind, placebo-controlled, dose-escalation study of the safety, tolerability, and pharmacokinetics of ISIS 333611 administered intrathecally to patients with familial ALS due to SOD1 gene mutations [abstract]. Neurology 2012; 78:S25.001.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5128 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23240=[""].join("\n");
var outline_f22_44_23240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RILUZOLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dosage and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXPERIMENTAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neurotrophic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bioenergetic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antiapoptotic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Current and future trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Arimoclomol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ceftriaxone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14942755\">",
"      - Dexpramipexole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=related_link\">",
"      Riluzole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33193?source=related_link\">",
"      Symptom-based management of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_44_23241="Paranasal sinus cancer";
var content_f22_44_23241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paranasal sinus cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23241/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23241/contributors\">",
"     Kerstin M Stenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23241/contributors\">",
"     Daniel J Haraf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23241/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23241/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23241/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23241/contributors\">",
"     Marvin P Fried, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23241/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/44/23241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of malignancies can develop in the paranasal sinuses (including the maxillary, ethmoid, sphenoid, and frontal sinuses) (",
"    <a class=\"graphic graphic_figure graphicRef78790 \" href=\"UTD.htm?20/18/20769\">",
"     figure 1",
"    </a>",
"    ). Adenocarcinoma and squamous cell carcinoma of the maxillary sinus and ethmoid sinus are the most common of these tumors.",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation, diagnosis, and management of these tumors are discussed here. Tumors arising in the nasal cavity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13013?source=see_link\">",
"     \"Cancer of the nasal vestibule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=see_link\">",
"     \"Tumors of the nasal cavity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027917\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers arising in the paranasal sinuses are rare, constituting approximately 3 percent of head and neck malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The majority of these tumors arise in the maxillary sinuses and most of the remainder start in the ethmoid sinuses. Cancers of the sphenoid and frontal sinuses are extremely rare. These cancers are more frequent in males than females [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors associated with paranasal sinus cancers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational exposures &mdash; including leather, textile, wood dust, and formaldehyde [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/2-6\">",
"       2-6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Air pollution&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tobacco smoke&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Viruses &mdash; Human papillomavirus (HPV) infection has been associated with paranasal sinus cancer, with some evidence suggesting that it may be involved in the malignant degeneration of inverted papilloma of the paranasal sinus, a rare, usually benign condition [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Correlations have also been suggested between Epstein-Barr virus infection and sinonasal tract lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of paranasal malignancies are squamous cell carcinomas, and most of the remainder are adenoid cystic carcinomas, adenocarcinomas, or mucoepidermoid carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. A wide range of other tumors can originate in this region, including undifferentiated carcinoma, angiosarcomas, rhabdomyosarcomas, lymphomas, olfactory neuroblastomas (esthesioneuroblastomas), melanomas, and meningiomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link\">",
"     \"Pathology of head and neck neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paranasal sinus malignancies tend to be asymptomatic until they invade adjacent structures, at which time symptoms may mimic benign disease. Thus, most patients have advanced disease by the time the diagnosis is established [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/13-17\">",
"     13-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptoms include facial or dental pain, nasal obstruction, and epistaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/15,16,19\">",
"     15,16,19",
"    </a>",
"    ]. When symptoms of persistent nasal discharge and epistaxis occur in patients over age 40, cancer of the paranasal sinuses, nasal vestibule, or nasopharynx should be included in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common symptoms include cranial neuropathy, chronic sinusitis, facial edema, vision loss, headache, rhinorrhea, and hyposmia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. A classic triad of facial asymmetry,",
"    <span class=\"nowrap\">",
"     palpable/visible",
"    </span>",
"    tumor in the oral cavity, and visible intranasal tumor occurs in 40 to 60 percent of patients with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms and signs depend upon the involved site and extent of disease. The bony structures between the nasal cavity, sinuses, orbits and cranial vaults are thin and offer little resistance to cancer spread.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ethmoid sinus, locally advanced lesions may extend into the anterior cranial fossa via the cribriform plate or into the orbit through the lamina papyracea. This may result in anosmia or displacement (typically upward",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      outward) of the globe.",
"     </li>",
"     <li>",
"      In the sphenoid sinus, disease may directly extend through the lateral bony wall into the cavernous sinus. It may also invade the middle cranial fossa directly or via the infraorbital nerve. Affected patients may complain of diplopia, blurred vision, proptosis, paresthesias in the distribution of the trigeminal nerve, or trismus if the pterygoid musculature is invaded. Inferior extension into the oral cavity may also cause painful loose teeth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination should include close attention to the signs and symptoms of orbital extension and base of skull involvement with cranial nerve signs or symptoms. The limited anatomic access of the paranasal sinuses makes early diagnosis difficult.",
"   </p>",
"   <p>",
"    Endoscopic examination is generally necessary to obtain a biopsy for a tissue diagnosis and to assess the extent of local disease. Biopsy of lesions involving the maxillary sinus can usually be obtained on an outpatient basis. Biopsy can be performed intranasally or through the gingivobuccal sulcus if the tumor extends through the anterior maxilla. Adequate examination and biopsy usually require general anesthesia. Ethmoid sinus lesions are biopsied through an endoscopic or transnasal approach in the operating room, as are frontal sinus malignancies via the frontal recess. Frontal sinus trephination is rarely necessary.",
"   </p>",
"   <p>",
"    Imaging studies provide important information for staging and treatment planning. Typically, both CT and MRI are performed and are complementary in evaluating disease extent and in distinguishing tumor from infection, retained secretions, and granulation of scar tissue. CT offers superior definition of bone and bone invasion, while MRI gives superior soft tissue delineation and allows for visualization of cranial nerves, especially when they are involved with disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 TNM staging system developed by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) defines separate T-staging for tumors of the maxillary and ethmoid sinuses (",
"    <a class=\"graphic graphic_table graphicRef82601 \" href=\"UTD.htm?9/42/9902\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/23\">",
"     23",
"    </a>",
"    ]. There is no standard staging system for frontal or sphenoid sinus tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regional lymph node metastases are uncommon at presentation. The incidence of lymph node involvement increases as tumors extend locally to adjacent sites, especially with extension into the oral cavity. One large series found higher rates of cervical lymph node involvement with T2 rather than T3 or T4 tumors of squamous cell histology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/13\">",
"     13",
"    </a>",
"    ]. The retropharyngeal nodes comprise the first echelon lymphatic drainage for sinus malignancies. Other regional nodes that are commonly involved are the periparotid and level 1B nodes (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distant metastases are also uncommon at presentation and subsequently occur most frequently in lung, liver, or bone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/13,24,25\">",
"     13,24,25",
"    </a>",
"    ]. Some centers do routine evaluation for distant metastases with blood tests, chest x-ray or chest CT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SQUAMOUS CELL CARCINOMA AND ADENOCARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma and adenocarcinoma of the paranasal sinuses comprise the majority of cases in most treatment series. The approach to these tumors is discussed in this section. Issues specific to other histologies are discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Other tumor types'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Paranasal sinus cancers generally invade locally early in their natural history and have a high tendency for local recurrence. Local recurrence rates following resection are high in the absence of postoperative RT, even when the original resection is thought to be complete.",
"   </p>",
"   <p>",
"    There are no randomized trials to guide the treatment of these cancers. The available data are derived from single institution, observational series because of the rarity of paranasal sinus cancers and because of their heterogeneity in both histology and site of origin.",
"   </p>",
"   <p>",
"    The majority of patients with both early and locoregionally advanced tumors have been treated with surgical resection and postoperative radiation therapy. Chemotherapy is increasingly used in conjunction with surgery and radiation therapy in an effort to reduce further the risk of local recurrence.",
"   </p>",
"   <p>",
"    Primary treatment using radiation or radiation plus chemotherapy without surgery is reserved for patients with unresectable disease and those who are not fit for major surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the primary treatment modality for cancers involving the maxillary or ethmoid sinuses. Resection is often limited by tumor involvement of the orbit or base of skull, which can result in damage to critical structures such as the eyes, brain, and cranial nerves. However, advances in surgical techniques have resulted in better functional reconstructions and improved quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical resection is indicated for all operable lesions (T1-T4) regardless of nodal status. Surgical margins are positive in about 30 percent of cases after complete resection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Postoperative radiation or chemoradiation is usually recommended for patients who have positive margins and for those with advanced stage lesions irrespective of margin status. (See",
"    <a class=\"local\" href=\"#H6296085\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the past, contraindications to surgical resection included tumor extension to the lateral skull base, intracranial contents, or cavernous sinus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/13,29\">",
"     13,29",
"    </a>",
"    ]. However, with advances in surgical technique and reconstruction, the decision of whether or not to operate depends upon the balance between survival, morbidity, and function rather than technical feasibility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6302248\">",
"    <span class=\"h3\">",
"     Surgical technique",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6302793\">",
"    <span class=\"h4\">",
"     Ethmoid sinus",
"    </span>",
"    &nbsp;&mdash;&nbsp;For ethmoid sinus tumors, the surgical technique depends upon the location and size of the lesion. For smaller lesions, a medial maxillectomy is generally performed with an en bloc ethmoidectomy. If a tumor involves the fovea ethmoidalis or the cribriform plate, more extensive surgery, such as a craniofacial resection via craniotomy or",
"    <span class=\"nowrap\">",
"     transglabellar/subcranial",
"    </span>",
"    approach, is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/27,32\">",
"     27,32",
"    </a>",
"    ]. This latter technique involves resection of the entire ethmoid block with an osteotomy that encompasses the roofs of ethmoid through the cribriform plate regions. Resection is coupled with advanced reconstructive techniques to repair the skull base defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6302800\">",
"    <span class=\"h4\">",
"     Maxillary sinus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maxillary sinus T1 and T2 tumors (",
"    <a class=\"graphic graphic_table graphicRef82601 \" href=\"UTD.htm?9/42/9902\">",
"     table 1",
"    </a>",
"    ) can be successfully resected with standard maxillectomy techniques. In this setting, the sinus walls can usually be removed without sacrificing the orbital periosteum, zygoma, or the palatal mucosa. An extended or radical maxillectomy is used for more advanced (T3, T4) lesions. The orbit is spared whenever possible. The sinus can be exposed through a rhinotomy incision (transfacial) or through a degloving approach (under the lip). The rhinotomy approach may provide better superior exposure. The orbit is spared whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6302814\">",
"    <span class=\"h4\">",
"     Management of the orbit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither clinical examination nor imaging studies can definitively predict whether or not orbital invasion is present [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/33\">",
"     33",
"    </a>",
"    ]. Orbit recurrence has been associated with poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/32,34,35\">",
"     32,34,35",
"    </a>",
"    ]. Therefore, some surgeons advocate orbital exenteration when the tumor transgresses the orbital floor or the periorbita, the dense periosteum surrounding the globe. However, orbital preservation with periosteal resection in the case of incomplete periosteal invasion yields comparable survival and can maintain a functional eye [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/32,33,36-38\">",
"     32,33,36-38",
"    </a>",
"    ]. Orbital exenteration does not improve survival for patients with advanced sinus malignancy that does not transgress the dense periorbita [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6302735\">",
"    <span class=\"h4\">",
"     Endoscopic resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in surgical technique have led to an increasing use of an endoscopic approach for the resection of sinonasal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic techniques are a multidisciplinary collaboration of otolaryngologist and neurosurgeons. They provide superior visualization, with angled endoscopes affording exposure around anatomic corners. The endoscopic method employs piecemeal tumor removal and was initially criticized for its inability to affect an en-bloc resection. Achieving clear surgical margins (regardless of the method) has been found to be the critical oncologic factor and both open and endoscopic techniques appear equally effective in this aspect. Endoscopic sinus surgery has been used both alone and in combination with craniofacial surgery.",
"   </p>",
"   <p>",
"    These endoscopic approaches may offer significant advantages in terms of a lower frequency of surgical complications and decreased morbidity. Advantages include lack of facial incisions, craniotomies or facial bone osteotomies, decreased hospital stay and pain, and faster recovery. Brain retraction is avoidable, so postoperative brain edema and possible encephalomalacia are circumvented [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/39\">",
"     39",
"    </a>",
"    ]. A disadvantage of the endoscopic approach is that of chronic nasal crusting, which is also seen with open approaches. Endoscopic sinus surgery has also been utilized for palliation of symptoms (epistaxis, nasal obstruction, etc) in advanced sinonasal malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/40\">",
"     40",
"    </a>",
"    ]. Contraindications to a pure endoscopic approach include tumors with extensive dural involvement or extension into facial or orbital soft tissues.",
"   </p>",
"   <p>",
"    Several series that included patients with a variety of histologic tumor types have found that this technique can be applied to patients with locally advanced lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Although the short-term oncologic outcomes with endoscopic resection appear to be similar to those with older surgical approaches, there are no direct comparisons with open techniques and longer follow-up from this experience is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of surgical and prosthetic reconstruction is to replace the form and function of facial and anterior skull base defects caused by surgery. Advances in tissue transfer techniques (particularly microvascular free flaps) provide reconstructive options in addition to maxillofacial prostheses. Optimal esthetic, functional, and quality of life outcomes are superior with combined approaches rather than single techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/45/8919?source=see_link\">",
"     \"Management of acquired maxillary defects: Prosthetic rehabilitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6302598\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious postoperative complications associated with craniofacial resection can include meningitis, hemorrhage, wound infection and abscess, cerebrospinal fluid leak, pneumocephalus, trismus, and blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/31,32,47-49\">",
"     31,32,47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical mortality and complication rates can be significant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. A multi-institution analysis of 1193 patients observed postoperative mortality and complication rates of 5 and 36 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/49\">",
"     49",
"    </a>",
"    ]. The risk of complications and mortality is increased substantially for patients older than 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6296085\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paranasal sinus cancers have a high tendency for local recurrence in the absence of postoperative RT, even when the original resection was thought to be complete. Postoperative RT is widely used and has been effective in decreasing the incidence of local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/26\">",
"     26",
"    </a>",
"    ]. The use of RT as primary therapy without surgery is generally limited to patients with unresectable disease, as well as to those who are not candidates for major surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6301996\">",
"    <span class=\"h3\">",
"     RT complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older reports of experience with RT, based upon single institution patient series treated over very prolonged periods, found a high frequency of significant complications, particularly to the eye.",
"   </p>",
"   <p>",
"    Radiation retinopathy is strongly correlated with the dose of radiation to the retina. This relationship was analyzed in a study of 186 patients who received a significant dose of radiation to the retina as part of curative therapy for head and neck cancer. Approximately two-thirds of the patients in that series were treated for cancer of the nasal cavity or paranasal sinuses, and most of the remainder had a primary nasopharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation retinopathy developed in 31 eyes in 30 patients, resulting in blindness in 26 and decreased vision in the other 5 eyes. Radiation retinopathy developed in 25 of the 30 eyes that received 60 Gy or more to the retina. In contrast, only 3 of 72 eyes (4 percent) that received less than 50 Gy developed radiation retinopathy.",
"   </p>",
"   <p>",
"    Other serious complications of RT can occur include osteoradionecrosis and brain necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6302012\">",
"    <span class=\"h3\">",
"     Contemporary RT techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in RT techniques have led to the development of highly conformal techniques that permit the delivery of therapeutic doses of radiation to paranasal sinus tumors while minimizing the dose of radiation to uninvolved normal tissues.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Widely used conformal techniques include three-dimensional conformal RT and intensity modulated RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/53\">",
"     53",
"    </a>",
"    ]. Although proton beam RT is less widely available, it may offer additional advantages in delivery maximal tumor doses while minimizing radiation to the retina and brain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link&amp;anchor=H163948839#H163948839\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'Three-dimensional conformal RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have undergone a complete resection of their tumor, the dose of postoperative radiation is generally approximately 60 Gy when given on a once daily schedule. For patients with positive tumor margins and those that are unresectable, the prescribed doses are approximately 66 Gy and 70 Gy, respectively, when given in 2 Gy fractions once daily. There are no randomized trials that define the dose of radiation in these patient populations, and these schedules are based upon more extensive data from other head and neck cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H1493366803#H1493366803\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Dose and schedule of RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with squamous histology and a positive margin or extracapsular lymph node spread, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    chemotherapy to radiation provides a recurrence and survival advantage in other head and neck subsites, and should be considered in this situation for paranasal sinus tumors.",
"   </p>",
"   <p>",
"    Observational series indicate that these highly conformal techniques have comparable efficacy to earlier series, but with a substantially decreased incidence of blindness and other serious eye complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      As an example, 85 patients with paranasal sinus tumors were treated postoperatively over an 18 year period at a single institution [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/55\">",
"       55",
"      </a>",
"      ]. Among the 53 patients treated with contemporary conformal techniques and planning, there were no grade 3 or worse eye complications. Disease control was comparable to other series.",
"      <br/>",
"     </li>",
"     <li>",
"      Similarly, in another center, 84 patients were treated with IMRT including 73 immediately following surgery and 11 for a local recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/56\">",
"       56",
"      </a>",
"      ]. The five-year rates of overall survival and disease-specific survival were 59 and 67 percent, respectively, which was similar to that in other series. There were no cases of blindness, although one patient developed radiation-induced retinopathy and neovascular glaucoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6296135\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy is used in conjunction with radiation therapy and surgery in many other head and neck cancers, and these techniques are being tried in patients with cancer of the paranasal sinuses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In these patients, chemotherapy has been used as a component of multimodality therapy with RT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery in a variety of ways. There are no randomized trials in these patient populations, and no definitive conclusions can be drawn about the role of chemotherapy. The potential roles of chemotherapy are illustrated by three large series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy was given to 49 patients, including 38 with T3 or T4 disease (",
"      <a class=\"graphic graphic_table graphicRef82601 \" href=\"UTD.htm?9/42/9902\">",
"       table 1",
"      </a>",
"      ), all of whom had resectable, previously untreated disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/57\">",
"       57",
"      </a>",
"      ]. Chemotherapy was followed by surgery and postoperative RT in 19 of 21 responders and 23 of 28 nonresponders. The three year overall and event-free survival rates were 69 and 57 percent, respectively.",
"     </li>",
"     <li>",
"      In a series of 39 patients with stage IVB disease (",
"      <a class=\"graphic graphic_table graphicRef82601 \" href=\"UTD.htm?9/42/9902\">",
"       table 1",
"      </a>",
"      ), 35 patients were managed with chemotherapy plus definitive RT and four were treated with definitive RT alone [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/58\">",
"       58",
"      </a>",
"      ]. Management did not include surgical resection. With a median follow-up of over seven years, the five-year disease-free and overall survival rates were approximately 15 percent.",
"     </li>",
"     <li>",
"      Another series reported the results of 46 patients treated with induction chemotherapy followed by surgery and radiation or concomitant chemotherapy with radiation in 22 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/59\">",
"       59",
"      </a>",
"      ]. The remainder had definitive radiation or concomitant chemotherapy and radiation with surgery for salvage. Overall 67 percent had a partial to complete response, 9 percent had stable disease and 24 percent had progressive disease. The two year survival was 77 percent for patients who responded and 36 percent for those with progressive disease on induction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Smaller series of systemic, platinum-based chemotherapy also suggest that these approaches have activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/15,60,61\">",
"     15,60,61",
"    </a>",
"    ], but their role remains undefined.",
"   </p>",
"   <p>",
"    Intraarterial chemotherapy has yielded promising results in small series, but its use by this route remains experimental [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/62-64\">",
"     62-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6303274\">",
"    <span class=\"h2\">",
"     Management of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical lymph node metastases are uncommon at presentation. In a series of 704 consecutive patients with paranasal sinus cancer treated over a 25 year period, 5 percent had cervical node disease at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/13\">",
"     13",
"    </a>",
"    ]. The cumulative incidence of lymph node involvement either at presentation or within five years was approximately 14 percent. Neck dissection and postoperative RT are recommended for all patients with cervical lymph node involvement either at presentation or subsequently.",
"   </p>",
"   <p>",
"    Prophylactic treatment (neck dissection or RT) of the N0 lymph node negative (",
"    <a class=\"graphic graphic_table graphicRef82601 \" href=\"UTD.htm?9/42/9902\">",
"     table 1",
"    </a>",
"    ) neck is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/26\">",
"     26",
"    </a>",
"    ]. Factors weighing against prophylactic treatment include the low incidence of subsequent relapse, the observation that most such relapses are associated with other sites of involvement, and the lack of impact on overall survival from prophylactic treatment.",
"   </p>",
"   <p>",
"    Other groups have attempted to identify patient subsets that might benefit from prophylactic treatment. As an example, in a series of 146 patients with maxillary sinus cancer, 126 had clinically negative lymph nodes at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/65\">",
"     65",
"    </a>",
"    ]. Among the 36 patients with squamous carcinoma or undifferentiated carcinoma who were not treated prophylactically, 13 (36 percent) had a cervical lymph node relapse, compared with 3 of 45 (7 percent) who received prophylactic neck irradiation. Although there was also a difference in the frequency of distant metastases between these two groups, the difference was not significant on multivariate analysis.",
"   </p>",
"   <p>",
"    Prophylactic selective neck dissection has acceptable morbidity. It also provides valuable staging and prognostic information. For these reasons, we suggest prophylactic neck treatment for patients with T3 or T4 disease. We suggest ipsilateral neck dissection for patients with T3 or T4 disease who will be undergoing definitive resection of the primary site, and for those same patients who are managed with definitive RT (with or without chemotherapy), we suggest prophylactically irradiating the ipsilateral N0 neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6296142\">",
"    <span class=\"h2\">",
"     Recurrent and metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with locoregionally recurrent disease are treated with multimodality therapy, including resection, reirradiation, and concurrent chemotherapy and RT. Distant metastatic disease is typically treated with chemotherapy alone. There are insufficient data to differentiate the management of these patients from that of other head and neck cancer cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=see_link\">",
"     \"Treatment of locally recurrent head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"     \"Treatment of metastatic and recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6296149\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results in large series vary, depending upon case mix and the time period that was analyzed. In general, five-year overall survival rates around 50 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/13-17,66-68\">",
"     13-17,66-68",
"    </a>",
"    ], with significant variation depending upon stage and histology (",
"    <a class=\"graphic graphic_table graphicRef57100 graphicRef66398 \" href=\"UTD.htm?24/33/25118\">",
"     table 2A-B",
"    </a>",
"    ). Factors associated with a better prognosis include lower T stage, the absence of lymph node involvement, and adenocarcinoma rather than squamous cell carcinoma or undifferentiated carcinoma. Primary tumors arising in the maxillary sinus appear to have a better prognosis than those arising in the ethmoid sinus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6296156\">",
"    <span class=\"h2\">",
"     Posttreatment follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be monitored for evidence of recurrence following treatment, although a survival benefit has not been demonstrated for posttreatment surveillance (",
"    <a class=\"graphic graphic_table graphicRef54259 \" href=\"UTD.htm?15/34/15915\">",
"     table 3",
"    </a>",
"    ). In general, the intensity of follow-up is greatest in the first two to three years, which is the period of greatest risk for disease recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OTHER TUMOR TYPES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Adenoid cystic carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoid cystic carcinomas can arise in minor salivary glands of the paranasal sinuses. These tumors tend to spread locally through bony destruction and perineural and perivascular invasion. Adenoid cystic carcinomas have characteristically high rates of local recurrence and distant metastases (typically lung and bone), which can occur as late as 10 to 20 years following initial treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=see_link\">",
"     \"Salivary gland tumors: Treatment of locoregional disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary surgery followed by radiation therapy is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6304283\">",
"    <span class=\"h2\">",
"     Sinonasal undifferentiated carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinonasal undifferentiated carcinoma is associated with a poor outcome. Multimodality approaches with surgery, platinum-based chemotherapy, and radiation therapy are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Nevertheless, the importance of surgical resection was demonstrated by a single institution series of 21 cases, which observed a better five-year local control rate with gross tumor resection compared with subtotal resection (74 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/73\">",
"     73",
"    </a>",
"    ]. The five-year rate of overall survival for the entire group was 43 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathology of head and neck neoplasms\", section on 'Sinonasal undifferentiated carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Inverted papilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inverted papilloma is a benign, locally aggressive neoplasm, which is associated with squamous cell carcinoma in about 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for inverted papilloma is primarily surgical resection, which is increasingly accomplished using endoscopic approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Radiation is added if it is associated with squamous cell carcinoma or if is incompletely resected. Local recurrence is common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathology of head and neck neoplasms\", section on 'Schneiderian papillomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6304224\">",
"    <span class=\"h2\">",
"     Olfactory neuroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Olfactory neuroblastomas, also known as esthesioneuroblastomas, arise from the olfactory epithelium and invade into the paranasal sinuses. The management of olfactory neuroblastoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12008?source=see_link\">",
"     \"Olfactory neuroblastoma (esthesioneuroblastoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoma of the paranasal sinuses is most commonly a diffuse large B cell lymphoma, though nasal-type",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell non-Hodgkin lymphoma is also seen. Combination chemotherapy and radiation therapy are suggested; the role of CNS prophylaxis is debated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Head and neck'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinonasal melanoma of the paranasal sinus has a particularly poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/27\">",
"     27",
"    </a>",
"    ]. Primary treatment is surgical, and postoperative radiation is sometimes used for close or positive margins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23241/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4010?source=see_link&amp;anchor=H3306310#H3306310\">",
"     \"Mucosal melanoma\", section on 'Mucosal melanoma of the head and neck'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180178974\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paranasal sinus cancers are rare tumors that encompass multiple histologies. Treatment needs to incorporate information about both histology and anatomic site of origin. (See",
"      <a class=\"local\" href=\"#H1027917\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adenocarcinoma and squamous cell carcinoma of the maxillary sinus and ethmoid sinus are the most common of these tumors. Aggressive surgical resection remains the mainstay of treatment. Combined modality approaches (radiation therapy, chemotherapy) have been added to improve local control, which remains the determining factor in survival. Adverse prognostic factors include advanced T stage, squamous cell histology, positive surgical margins, and brain or orbit involvement. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management of squamous cell carcinoma and adenocarcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with early (stage I or II) paranasal sinus cancer, we recommend surgical resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who are not candidates for a major surgical procedure, definitive RT is an appropriate alternative. We suggest postoperative RT for patients with T1 and T2 lesions with close or positive margins, high-grade histology, and other adverse prognostic features including perineural, lymphatic, and perivascular invasion (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with locoregionally advanced (stage III and IV) paranasal sinus cancer, we recommend multimodality therapy including both surgical resection and RT rather than surgical resection or RT alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with stage III and IV disease and a clinically negative neck (N0), we suggest prophylactic treatment of the neck nodes with either lymph node dissection or RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6296085\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6303274\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with clinical involvement of the cervical lymph nodes, we recommend neck dissection with postoperative RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6303274\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Induction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concurrent chemoradiation therapy approaches may have a role in the management of patients with paranasal sinus cancer. However data are too limited to make definitive recommendations, and such treatment should be undertaken only after joint surgical, radiation oncology, and medical oncology evaluation. (See",
"      <a class=\"local\" href=\"#H6296135\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of patients with other tumor histologies is tumor-specific. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other tumor types'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Persky MS, Tabaee A. Cancer of the nasal vestibule and paranasal sinus: Surgical management.. In: Head and neck cancer, Third, Harrison LB, Sessions RB, Hong WK (Eds), Lippincott, Williams, and Wilkins, Philadelphia 2009. p.454.",
"    </li>",
"    <li>",
"     Barnes L, Tse LLY, Hunt JL, et al. Tumours of the nasal cavity and paranasal sinuses: Introduction. In: Pathology and Genetics of Head and Neck Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D.  (Eds), IARC, Lyon 2005. p.9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/3\">",
"      't Mannetje A, Kogevinas M, Luce D, et al. Sinonasal cancer, occupation, and tobacco smoking in European women and men. Am J Ind Med 1999; 36:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/4\">",
"      Bonneterre V, Deschamps E, Persoons R, et al. Sino-nasal cancer and exposure to leather dust. Occup Med (Lond) 2007; 57:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/5\">",
"      Battista G, Comba P, Orsi D, et al. Nasal cancer in leather workers: an occupational disease. J Cancer Res Clin Oncol 1995; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/6\">",
"      Luce D, Leclerc A, B&eacute;gin D, et al. Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. Cancer Causes Control 2002; 13:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/7\">",
"      Calder&oacute;n-Garcidue&ntilde;as L, Delgado R, Calder&oacute;n-Garcidue&ntilde;as A, et al. Malignant neoplasms of the nasal cavity and paranasal sinuses: a series of 256 patients in Mexico City and Monterrey. Is air pollution the missing link? Otolaryngol Head Neck Surg 2000; 122:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/8\">",
"      Zheng W, McLaughlin JK, Chow WH, et al. Risk factors for cancers of the nasal cavity and paranasal sinuses among white men in the United States. Am J Epidemiol 1993; 138:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/9\">",
"      Kim JY, Yoon JK, Citardi MJ, et al. The prevalence of human papilloma virus infection in sinonasal inverted papilloma specimens classified by histological grade. Am J Rhinol 2007; 21:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/10\">",
"      Alos L, Moyano S, Nadal A, et al. Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. Cancer 2009; 115:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/11\">",
"      Feng YF, Wu QL, Zong YS. Correlation of immunophenotype of sinonasal non-Hodgkin's lymphoma to Epstein-Barr virus infection. Ai Zheng 2007; 26:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/12\">",
"      Mitarnun W, Suwiwat S, Pradutkanchana J. Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand. Asian Pac J Cancer Prev 2006; 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/13\">",
"      Cant&ugrave; G, Bimbi G, Miceli R, et al. Lymph node metastases in malignant tumors of the paranasal sinuses: prognostic value and treatment. Arch Otolaryngol Head Neck Surg 2008; 134:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/14\">",
"      Myers LL, Nussenbaum B, Bradford CR, et al. Paranasal sinus malignancies: an 18-year single institution experience. Laryngoscope 2002; 112:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/15\">",
"      Guntinas-Lichius O, Kreppel MP, Stuetzer H, et al. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol 2007; 33:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/16\">",
"      Blanco AI, Chao KS, Ozyigit G, et al. Carcinoma of paranasal sinuses: long-term outcomes with radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/17\">",
"      Harbo G, Grau C, Bundgaard T, et al. Cancer of the nasal cavity and paranasal sinuses. A clinico-pathological study of 277 patients. Acta Oncol 1997; 36:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/18\">",
"      Chen AM, Daly ME, Bucci MK, et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys 2007; 69:141.",
"     </a>",
"    </li>",
"    <li>",
"     Cummings Otolaryngology-Head and Neck Surgery, 4th, Cummings CW Jr, Haughey BH, Thomas JR (Eds), Mosby, St. Louis 2004.",
"    </li>",
"    <li>",
"     Comprehensive Management of Head and Neck Tumors, 2nd, Thawley SE, Panje WR, Batsakis JG, et al (Eds), WB Saunders, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/21\">",
"      Loevner LA, Sonners AI. Imaging of neoplasms of the paranasal sinuses. Neuroimaging Clin N Am 2004; 14:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/22\">",
"      Das S, Kirsch CF. Imaging of lumps and bumps in the nose: a review of sinonasal tumours. Cancer Imaging 2005; 5:167.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/24\">",
"      Bogaerts S, Vander Poorten V, Nuyts S, et al. Results of endoscopic resection followed by radiotherapy for primarily diagnosed adenocarcinomas of the paranasal sinuses. Head Neck 2008; 30:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/25\">",
"      Jansen EP, Keus RB, Hilgers FJ, et al. Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys 2000; 48:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/26\">",
"      Robbins KT, Ferlito A, Silver CE, et al. Contemporary management of sinonasal cancer. Head Neck 2011; 33:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/27\">",
"      Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study. Head Neck 2005; 27:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/28\">",
"      Porceddu S, Martin J, Shanker G, et al. Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck 2004; 26:322.",
"     </a>",
"    </li>",
"    <li>",
"     Jesse RH, Butler JJ, Healey JE, et al. Paranasal sinuses and nasal cavity. In: Cancer of the head and neck, MacComb WS, Fletcher GH (Eds), Williams &amp; Wilkins, Baltimore 1967. p.329.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/30\">",
"      Vrionis FD, Kienstra MA, Rivera M, Padhya TA. Malignant tumors of the anterior skull base. Cancer Control 2004; 11:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/31\">",
"      McKay SP, Shibuya TY, Armstrong WB, et al. Cell carcinoma of the paranasal sinuses and skull base. Am J Otolaryngol 2007; 28:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/32\">",
"      Howard DJ, Lund VJ, Wei WI. Craniofacial resection for tumors of the nasal cavity and paranasal sinuses: a 25-year experience. Head Neck 2006; 28:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/33\">",
"      Tiwari R, van der Wal J, van der Waal I, Snow G. Studies of the anatomy and pathology of the orbit in carcinoma of the maxillary sinus and their impact on preservation of the eye in maxillectomy. Head Neck 1998; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/34\">",
"      Van Tuyl R, Gussack GS. Prognostic factors in craniofacial surgery. Laryngoscope 1991; 101:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/35\">",
"      McCaffrey TV, Olsen KD, Yohanan JM, et al. Factors affecting survival of patients with tumors of the anterior skull base. Laryngoscope 1994; 104:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/36\">",
"      Carrau RL, Segas J, Nuss DW, et al. Squamous cell carcinoma of the sinonasal tract invading the orbit. Laryngoscope 1999; 109:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/37\">",
"      Imola MJ, Schramm VL Jr. Orbital preservation in surgical management of sinonasal malignancy. Laryngoscope 2002; 112:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/38\">",
"      Essig GF, Newman SA, Levine PA. Sparing the eye in craniofacial surgery for superior nasal vault malignant neoplasms: analysis of benefit. Arch Facial Plast Surg 2007; 9:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/39\">",
"      Snyderman CH, Carrau RL, Kassam AB, et al. Endoscopic skull base surgery: principles of endonasal oncological surgery. J Surg Oncol 2008; 97:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/40\">",
"      Tabaee A, Nyquist G, Anand VK, et al. Palliative endoscopic surgery in advanced sinonasal and anterior skull base neoplasms. Otolaryngol Head Neck Surg 2010; 142:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/41\">",
"      Nicolai P, Battaglia P, Bignami M, et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. Am J Rhinol 2008; 22:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/42\">",
"      Batra PS, Luong A, Kanowitz SJ, et al. Outcomes of minimally invasive endoscopic resection of anterior skull base neoplasms. Laryngoscope 2010; 120:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/43\">",
"      Hanna E, DeMonte F, Ibrahim S, et al. Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg 2009; 135:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/44\">",
"      Futran ND, Mendez E. Developments in reconstruction of midface and maxilla. Lancet Oncol 2006; 7:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/45\">",
"      Cordeiro PG, Santamaria E, Kraus DH, et al. Reconstruction of total maxillectomy defects with preservation of the orbital contents. Plast Reconstr Surg 1998; 102:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/46\">",
"      Genden EM, Okay D, Stepp MT, et al. Comparison of functional and quality-of-life outcomes in patients with and without palatomaxillary reconstruction: a preliminary report. Arch Otolaryngol Head Neck Surg 2003; 129:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/47\">",
"      Kellman RM, Marentette L. The transglabellar/subcranial approach to the anterior skull base: a review of 72 cases. Arch Otolaryngol Head Neck Surg 2001; 127:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/48\">",
"      Solero CL, DiMeco F, Sampath P, et al. Combined anterior craniofacial resection for tumors involving the cribriform plate: early postoperative complications and technical considerations. Neurosurgery 2000; 47:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/49\">",
"      Ganly I, Patel SG, Singh B, et al. Complications of craniofacial resection for malignant tumors of the skull base: report of an International Collaborative Study. Head Neck 2005; 27:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/50\">",
"      Janecka IP, Sen C, Sekhar LN, et al. Cranial base surgery: results in 183 patients. Otolaryngol Head Neck Surg 1994; 110:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/51\">",
"      Ganly I, Gross ND, Patel SG, et al. Outcome of craniofacial resection in patients 70 years of age and older. Head Neck 2007; 29:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/52\">",
"      Monroe AT, Bhandare N, Morris CG, Mendenhall WM. Preventing radiation retinopathy with hyperfractionation. Int J Radiat Oncol Biol Phys 2005; 61:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/53\">",
"      Brizel DM, Light K, Zhou SM, Marks LB. Conformal radiation therapy treatment planning reduces the dose to the optic structures for patients with tumors of the paranasal sinuses. Radiother Oncol 1999; 51:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/54\">",
"      Resto VA, Chan AW, Deschler DG, Lin DT. Extent of surgery in the management of locally advanced sinonasal malignancies. Head Neck 2008; 30:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/55\">",
"      Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys 2007; 67:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/56\">",
"      Madani I, Bonte K, Vakaet L, et al. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009; 73:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/57\">",
"      Licitra L, Locati LD, Cavina R, et al. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol 2003; 14:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/58\">",
"      Hoppe BS, Nelson CJ, Gomez DR, et al. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys 2008; 72:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/59\">",
"      Hanna EY, Cardenas AD, DeMonte F, et al. Induction chemotherapy for advanced squamous cell carcinoma of the paranasal sinuses. Arch Otolaryngol Head Neck Surg 2011; 137:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/60\">",
"      Lee MM, Vokes EE, Rosen A, et al. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am 1999; 5:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/61\">",
"      Brasnu D, Laccourreye O, Bassot V, et al. Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. Arch Otolaryngol Head Neck Surg 1996; 122:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/62\">",
"      Samant S, Robbins KT, Vang M, et al. Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg 2004; 130:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/63\">",
"      Yoshimura R, Shibuya H, Ogura I, et al. Trimodal combination therapy for maxillary sinus carcinoma. Int J Radiat Oncol Biol Phys 2002; 53:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/64\">",
"      Nishino H, Miyata M, Morita M, et al. Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy for maxillary sinus carcinoma. Cancer 2000; 89:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/65\">",
"      Bristol IJ, Ahamad A, Garden AS, et al. Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys 2007; 68:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/66\">",
"      Dulguerov P, Jacobsen MS, Allal AS, et al. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001; 92:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/67\">",
"      Dirix P, Nuyts S, Geussens Y, et al. Malignancies of the nasal cavity and paranasal sinuses: long-term outcome with conventional or three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/68\">",
"      Bhattacharyya N. Factors affecting survival in maxillary sinus cancer. J Oral Maxillofac Surg 2003; 61:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/69\">",
"      Wiseman SM, Popat SR, Rigual NR, et al. Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose Throat J 2002; 81:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/70\">",
"      Enepekides DJ. Sinonasal undifferentiated carcinoma: an update. Curr Opin Otolaryngol Head Neck Surg 2005; 13:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/71\">",
"      Mendenhall WM, Mendenhall CM, Riggs CE Jr, et al. Sinonasal undifferentiated carcinoma. Am J Clin Oncol 2006; 29:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/72\">",
"      Rischin D, Porceddu S, Peters L, et al. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck 2004; 26:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/73\">",
"      Chen AM, Daly ME, El-Sayed I, et al. Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2008; 70:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/74\">",
"      Mendenhall WM, Hinerman RW, Malyapa RS, et al. Inverted papilloma of the nasal cavity and paranasal sinuses. Am J Clin Oncol 2007; 30:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/75\">",
"      Melroy CT, Senior BA. Benign sinonasal neoplasms: a focus on inverting papilloma. Otolaryngol Clin North Am 2006; 39:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/76\">",
"      Lawson W, Patel ZM. The evolution of management for inverted papilloma: an analysis of 200 cases. Otolaryngol Head Neck Surg 2009; 140:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/77\">",
"      Guillemaud JP, Witterick IJ. Inverted papilloma of the sphenoid sinus: clinical presentation, management, and systematic review of the literature. Laryngoscope 2009; 119:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/78\">",
"      Dragonetti A, Gera R, Sciuto A, et al. Sinonasal inverted papilloma: 84 patients treated by endoscopy and proposal for a new classification. Rhinology 2011; 49:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/79\">",
"      Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/80\">",
"      Hausdorff J, Davis E, Long G, et al. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Cancer J Sci Am 1997; 3:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/81\">",
"      Logsdon MD, Ha CS, Kavadi VS, et al. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/82\">",
"      Laskin JJ, Savage KJ, Voss N, et al. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma 2005; 46:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23241/abstract/83\">",
"      Thompson LD, Wieneke JA, Miettinen M. Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol 2003; 27:594.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3401 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23241=[""].join("\n");
var outline_f22_44_23241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H180178974\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1027917\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT OF SQUAMOUS CELL CARCINOMA AND ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6302248\">",
"      - Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6302793\">",
"      Ethmoid sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6302800\">",
"      Maxillary sinus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6302814\">",
"      Management of the orbit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6302735\">",
"      Endoscopic resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6302598\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6296085\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6301996\">",
"      - RT complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6302012\">",
"      - Contemporary RT techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6296135\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6303274\">",
"      Management of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6296142\">",
"      Recurrent and metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6296149\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6296156\">",
"      Posttreatment follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OTHER TUMOR TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Adenoid cystic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6304283\">",
"      Sinonasal undifferentiated carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Inverted papilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6304224\">",
"      Olfactory neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H180178974\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3401|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/18/20769\" title=\"figure 1\">",
"      Paranasal sinus anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/42/9902\" title=\"table 1\">",
"      TNM stage sinonasal sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/47/19197\" title=\"table 2A\">",
"      Survival by histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/52/12109\" title=\"table 2B\">",
"      Survival by T and N stg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/34/15915\" title=\"table 3\">",
"      NCCN followup guide HNC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13013?source=related_link\">",
"      Cancer of the nasal vestibule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/45/8919?source=related_link\">",
"      Management of acquired maxillary defects: Prosthetic rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4010?source=related_link\">",
"      Mucosal melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12008?source=related_link\">",
"      Olfactory neuroblastoma (esthesioneuroblastoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28313?source=related_link\">",
"      Salivary gland tumors: Treatment of locoregional disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=related_link\">",
"      Treatment of locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39206?source=related_link\">",
"      Tumors of the nasal cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_44_23242="Coagulopathy associated with trauma";
var content_f22_44_23242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coagulopathy associated with trauma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23242/contributors\">",
"     Mitchell Cohen, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23242/contributors\">",
"     Matthew E Kutcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23242/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23242/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23242/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/44/23242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/44/23242/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/44/23242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H62323431\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma remains a leading cause of death and disability in adults in spite of advances in resuscitation, surgical management, and critical care [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/1\">",
"     1",
"    </a>",
"    ]. Between 25 to 35 percent of injured civilian trauma patients develop a biochemically evident coagulopathy upon arrival in the emergency department, in spite of improved efficiency of trauma systems, military and civilian, in reducing the time interval between acute injury and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Coagulopathy may be the result of physiologic derangements such as acidosis, hypothermia, or hemodilution related to fluid or blood administration; however, an acute coagulopathy can also occur in severely injured patients independent of, or in addition to, these factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Several terms are used in the literature to refer to this condition, including acute traumatic coagulopathy (ATC), early coagulopathy of trauma (ECT), trauma-induced coagulopathy, and the acute coagulopathy of trauma-shock (ACoTS) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/2,3,5,6\">",
"     2,3,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology, diagnosis and treatment of coagulopathy associated with trauma will be reviewed here. The general principles of shock management in the trauma patient and the treatment of excessive anticoagulation related to medical treatment are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62326298\">",
"    <span class=\"h1\">",
"     IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulopathy in trauma patients, and specifically acute traumatic coagulopathy (ATC), is associated with higher transfusion requirements, longer intensive care unit and hospital stays, more days requiring mechanical ventilation, and a greater incidence of multiorgan dysfunction. Compared with patients who do not have coagulopathy, those with coagulopathy have a threefold to fourfold greater mortality, and are up to eight times more likely to die within the first 24 hours following injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/2-4,7,8\">",
"     2-4,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injury to brain tissue may predispose to acute traumatic coagulopathy and about one-third of patients with traumatic brain injury (TBI) have a coagulopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62326162\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of coagulopathy in the injured patient is multifactorial with overlapping contributions depending upon the injury and nature of resuscitation. Normal coagulation is a balance between hemostatic and fibrinolytic processes which permit control of bleeding following mild injury while preventing inappropriate intravascular thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Etiologies that upset this balance include the classic elements of the &lsquo;vicious triad&rsquo; which includes acidosis related to tissue injury and shock, hypothermia from exposure and fluid administration, and hemodilution due to fluid or component blood product administration. Systemic consumption of clotting factors manifesting as disseminated intravascular coagulation (DIC) may occur early after injury due to inadequate clotting factor repletion in the face of ongoing consumption, or later in the hospital course triggered by secondary insults (eg, sepsis). Frequently complicating these etiologies but mechanistically different, acute traumatic coagulopathy (ATC) is a biochemical response to injury and shock leading to hyperfibrinolysis and",
"    <strong>",
"     hypo",
"    </strong>",
"    coagulability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83047596\">",
"    <span class=\"h2\">",
"     Acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate tissue perfusion in patients with hypovolemic shock due to bleeding leads to metabolic (lactic) acidosis, which can be exacerbated by excessive chloride and component blood administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H16#H16\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Hypovolemic shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acidosis causes demonstrable clotting dysfunction in experimental models at pH&lt;7.2 by interfering with the assembly of coagulation factor complexes involving calcium and negatively-charged phospholipids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. As an example, the activity of the factor",
"    <span class=\"nowrap\">",
"     Xa/Va/phospholipid/prothrombin",
"    </span>",
"    (&ldquo;prothrombinase&rdquo;) complex is reduced by 50, 70, and 90 percent at a pH of 7.2, 7.0, and 6.8, respectively. However, correction of acidosis alone does not always correct the associated coagulopathy, indicating that tissue injury causes coagulopathy via additional mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299161\">",
"    <span class=\"h2\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia in injured patients is graded into mild (36 to 34",
"    <sup>",
"     &ordm;",
"    </sup>",
"    C), moderate (34 to 32",
"    <sup>",
"     &ordm;",
"    </sup>",
"    C), and severe (&lt;32",
"    <sup>",
"     &ordm;",
"    </sup>",
"    C) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/15\">",
"     15",
"    </a>",
"    ]. Nearly two-thirds of trauma patients have a temperature below 36",
"    <sup>",
"     &ordm;",
"    </sup>",
"    C on presentation; 9 percent of trauma patients have a temperature at or below 33",
"    <sup>",
"     &ordm;",
"    </sup>",
"    C [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/11,16-19\">",
"     11,16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothermia following injury is due to cold exposure at the time of injury, during transport, and during the trauma examination compounded by the administration of cold intravenous fluids. Patients who require surgery are at a greater risk for hypothermia due to further physical exposure in the operating room, additional fluid administration, and the effects of general anesthesia. Injured patients with hypothermia generally have worse outcomes compared with non-injured patients with hypothermia; however, hypothermia alone is a weak independent predictor of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. Acidosis and hypothermia are synergistic with increased mortality when both are present, compared with one or the other [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of hypothermia on clotting includes platelet dysfunction and impaired enzymatic function. Overall thrombin generation in activated in vitro clotting systems is generally preserved at a temperature of 33",
"    <sup>",
"     &ordm;",
"    </sup>",
"    C; however, impairment of tissue factor activity, platelet aggregation, and platelet adhesion are evident at temperatures between 33 to 37",
"    <sup>",
"     &ordm;",
"    </sup>",
"    C [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. It is important to note that",
"    <strong>",
"     no",
"    </strong>",
"    effects on standard coagulation tests are seen in hypothermia-induced coagulopathy without special sample handling due to the standard practice of pre-warming blood samples to 37",
"    <sup>",
"     &ordm;",
"    </sup>",
"    C prior to analysis, which corrects the defect.",
"   </p>",
"   <p>",
"    Specific measures to correct hypothermia include controlling physical exposure, the administration of warmed fluids, and passive rewarming with blankets and forced-air devices. Rapid identification and control of bleeding is vital to preserve normal temperature. Continuous temperature monitoring is essential to ensure that mild hypothermia does not worsen. In the case of moderate or severe hypothermia and coagulopathy, central rewarming may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299168\">",
"    <span class=\"h2\">",
"     Resuscitation-associated (dilutional) coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resuscitation-associated coagulopathy (RAC) refers to alterations of the coagulation system induced by large volumes of fluid or unbalanced component blood administration during the management of shock [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/22\">",
"     22",
"    </a>",
"    ]. Trauma resuscitation historically focused on the treatment of hypotension and acidosis with aggressive crystalloid resuscitation followed by packed red blood cells (PRBC). At that time, treatment of coagulopathy was initiated only in response to abnormal standard coagulation tests. Similarly, platelet transfusion was generally not performed until laboratory evidence of thrombocytopenia was present.",
"   </p>",
"   <p>",
"    Computer modeling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/23\">",
"     23",
"    </a>",
"    ], in vitro experiments [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/24\">",
"     24",
"    </a>",
"    ], and clinical studies in healthy volunteers have found that large volume resuscitation with crystalloid, colloid, and packed red blood cells leads to dilution of plasma clotting proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/25\">",
"     25",
"    </a>",
"    ]. A retrospective study of 8724 injured patients found a positive correlation between prehospital fluid resuscitation volume and coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/4\">",
"     4",
"    </a>",
"    ]. Coagulopathy was present on admission in more than 50 percent of patients who received &gt;3L of intravenous fluid prior to arrival, but coagulopathy was also present in 10 percent of patients administered &lt;500 mL and in 32 patients who had received no prehospital fluids, which appears to reflect the frequently overlapping contribution of acute traumatic coagulopathy (ATC). (See",
"    <a class=\"local\" href=\"#H122599087\">",
"     'Acute traumatic coagulopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another factor contributing to resuscitation associated coagulopathy is the effect of storage time on packed red blood cells which undergo progressive functional and structural changes over time. The &lsquo;storage lesion&rsquo; includes decreased pH, chelation of calcium, low 2,3 diphosphoglycerate levels, and decreased clotting factor concentration. Transfusion of older blood can further impair microvascular perfusion, and has inflammatory and immunomodulatory effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link&amp;anchor=H6#H6\">",
"     \"Use of red blood cells for transfusion\", section on 'Physiologic changes with storage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The median duration of storage of a unit of red blood cells in the United States is about 15 days, which is relatively old, with even older units frequently allocated to high-use facilities such as trauma centers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, the storage lesion is particularly relevant for massively transfused trauma patients. Several studies suggest that an older storage age of transfused PRBCs may be linked to higher morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] but this remains an area of controversy and current investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83047881\">",
"    <span class=\"h2\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is a systemic process producing consumptive coagulopathy in concert with diffuse microvascular thrombosis (",
"    <a class=\"graphic graphic_table graphicRef63831 \" href=\"UTD.htm?34/15/35067\">",
"     table 1",
"    </a>",
"    ). In trauma patients, tissue-injury-induced exposure of tissue factor and activation of the extrinsic coagulation cascade leads to thrombin generation proportional to injury severity. In addition, systemic embolism of tissue-specific thromboplastins from sites of injury (including bone marrow lipid material, amniotic fluid, and brain phospholipids) may predispose patients to DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122599087\">",
"    <span class=\"h2\">",
"     Acute traumatic coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute traumatic coagulopathy (ATC) is an impairment of hemostasis and activation of fibrinolysis that occurs early after injury and is biochemically evident prior to, and independent of, the development of significant acidosis, hypothermia, or hemodilution. The risk of ATC increases with hypotension, higher injury severity scores, worsening base deficit, and head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/3,7,8\">",
"     3,7,8",
"    </a>",
"    ]. Once established, ATC is often compounded by other etiologies. (See",
"    <a class=\"local\" href=\"#H83047596\">",
"     'Acidosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H299161\">",
"     'Hypothermia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H299168\">",
"     'Resuscitation-associated (dilutional) coagulopathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with ATC frequently meet criteria for DIC and some authors have argued that acute traumatic coagulopathy (ATC) may represent an early, partially-compensated stage of DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/22,34,35\">",
"     22,34,35",
"    </a>",
"    ]. However, the concept of DIC as a final common pathway for several different phenomena is insufficient to explain the hematologic abnormalities post-injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7,36,37\">",
"     7,36,37",
"    </a>",
"    ]. Coagulopathy in the absence of thrombocytopenia and hypofibrinogenemia, as seen in ATC, argues against consumption as a necessary underlying mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/13\">",
"     13",
"    </a>",
"    ] Although D-dimer levels are frequently elevated and fibrinogen levels depleted in acutely injured patients, indicating intravascular fibrin deposition and active fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/38\">",
"     38",
"    </a>",
"    ], functional thrombin generation (assayed by the presence of prothrombin fragments and thrombin-antithrombin complexes) remains intact [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7,39-41\">",
"     7,39-41",
"    </a>",
"    ]. Furthermore, ATC occurs only when tissue injury is combined with systemic hypoperfusion. Thus, it is most likely that ATC is mechanistically distinct from DIC but that these frequently overlap. Exploring this distinction is an area of ongoing research. (See",
"    <a class=\"local\" href=\"#H83047881\">",
"     'Disseminated intravascular coagulation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3046566840\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18982251\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial observations in hypoperfused trauma patients found a correlation between acute traumatic coagulopathy (ATC) and elevated levels of activated protein C (aPC), reduced levels of non-activated protein C, and elevated soluble thrombomodulin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7\">",
"     7",
"    </a>",
"    ]. Activation of the thrombomodulin-protein C system is a principle pathway mediating ATC, a mechanism that is distinct from clotting factor consumption or dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7,42\">",
"     7,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under normal circumstances, tissue injury leads to thrombin generation, fibrin deposition, and clot formation via the extrinsic pathway (",
"    <a class=\"graphic graphic_figure graphicRef75450 \" href=\"UTD.htm?12/20/12610\">",
"     figure 1",
"    </a>",
"    ). The enzymatic pathways making up the coagulation cascade are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initiation of the clotting process is localized to the site of tissue injury. Systemic coagulation due to the escape of thrombin from the injury site is inhibited by circulating antithrombin III, or by the binding of thrombin to constitutively-expressed thrombomodulin on nearby undamaged endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protein C, a systemic anticoagulant, is proteolytically converted from an inactive zymogen to activated protein C (aPC) by the complex of thrombin with thrombomodulin. Activated protein C is a serine protease that proteolytically inactivates factors Va and VIIIa and depletes plasminogen inhibitors (",
"    <a class=\"graphic graphic_figure graphicRef81428 \" href=\"UTD.htm?30/24/31118\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70156 \" href=\"UTD.htm?33/3/33851\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. In this manner, aPC can serve a protective function by inhibiting thrombosis during periods of decreased flow.",
"   </p>",
"   <p>",
"    Sustained hypoperfusion is associated with increased circulating soluble thrombomodulin levels, which can increase the availability of thrombomodulin-bound thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, thrombin can be diverted from a predominantly procoagulant role to a pathologic, anticoagulant role via excess activation of protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7\">",
"     7",
"    </a>",
"    ]. Although the precise biochemical mechanisms are still under investigation, the importance of protein C in this process has been confirmed. Inhibition of protein C by an antibody-mediated mechanism in an animal model has been shown to prevent the development of ATC in response to trauma and hemorrhagic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With widespread protein C activation, thrombin generation is inhibited, impairing clot formation, and fibrinolysis is enhanced causing degradation of existing clot. Consumption of endogenous plasminogen activator inhibitor-1 (PAI-1) by ATC-mediated aPC destabilizes the fibrinolytic balance, leading to uninhibited tissue plasminogen activator (tPA)-mediated conversion of plasminogen to plasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/45\">",
"     45",
"    </a>",
"    ]. Diversion of thrombin to protein C activation may also reduce activation of thrombin-activatable fibrinolysis inhibitor (TAFI), further enhancing fibrinolytic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/46\">",
"     46",
"    </a>",
"    ]. These mechanisms lead to the hyperfibrinolytic state seen in trauma patients with ATC, which is reflected in increased levels of tissue plasminogen activator (tPA), decreased plasminogen activator inhibitor (PAI-1), and increased D-dimer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activated protein C also has antiinflammatory and cytoprotective effects. Profound activation and consumption of protein C can deplete protein C stores, potentially leading to infectious and later thrombotic sequelae. These effects are mediated via binding of aPC to a protease-activated receptor-1 (PAR-1) and endothelial protein C receptor (EPCR) that are likely independent of the role of aPC as an anticoagulant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/47\">",
"     47",
"    </a>",
"    ]. The importance of these mechanisms is suggested by separate murine models in trauma and sepsis. In these experiments, selective antibody-mediated inhibition of the anticoagulant function of aPC reduced the rate of coagulopathy, but not mortality, while inhibition of anticoagulant and cytoprotective functions increased mortality after a challenge with",
"    <span class=\"nowrap\">",
"     trauma/hemorrhagic",
"    </span>",
"    shock [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/42\">",
"     42",
"    </a>",
"    ], or injection of lipopolysaccharide (LPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These animal model results are supported by a recent study of 203 critically-injured trauma patients, for whom early coagulopathy was linked to high levels of activated protein C, and later, protein C depletion as early as six hours after injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients who demonstrated protein C depletion had a significantly increased risk of acute lung injury, ventilator-associated pneumonia, multiorgan failure, and death. A smaller prospective study that also identified protein C depletion in trauma patients found elevated markers of endothelial injury and coagulopathy, and noted a threefold higher risk of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytoprotective functions of aPC may also play a role in pulmonary capillary endothelial barrier function as suggested by in vitro studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], and in human studies that found that persistently low protein C levels in critically-injured, mechanically-ventilated trauma patients are associated with increased rates of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/53\">",
"     53",
"    </a>",
"    ]. Ongoing studies are evaluating the interactions of the protein C system, innate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] and cellular immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], and endothelial activation and barrier permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/52,58-60\">",
"     52,58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recently identified importance of ATC-associated depletion of protein C stores after traumatic injury suggests a potential mechanism for later hypercoagulability and risk of thromboembolic complications after trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/49,61,62\">",
"     49,61,62",
"    </a>",
"    ]. Although this phenomenon has not been studied in the trauma population, a prothrombotic state associated with protein C depletion has been reported in septic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/44\">",
"     44",
"    </a>",
"    ]. In one observational study, injured patients with coagulopathy on admission had a significantly higher risk of thromboembolic complications, but a link to protein C depletion was not specifically investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/63\">",
"     63",
"    </a>",
"    ]. However, the potential link between protein C depletion and late hypercoagulability after trauma requires further investigation. Despite initial trials demonstrating the efficacy of recombinant aPC supplementation in sepsis, the recent PROWESS-SHOCK trial failed to show a survival benefit in severe sepsis, and the drug was voluntarily withdrawn from the market [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]; as such, there is no role for protein C replacement in trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3046566840\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely injured trauma patients are routinely screened with standard laboratory evaluation, including complete blood count, serum electrolytes, arterial blood gas analysis, and standard coagulation tests. These laboratory studies provide an assessment of acidosis and hemodilution, indicate the severity of shock (as measured by base deficit",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lactate), guide specific component blood product administration, and serve as a baseline for the assessment of ongoing hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Readily obtainable coagulation tests (prothrombin time, international normalized ratio, and activated partial thromboplastin time) are the current standard for establishing a definitive diagnosis of coagulopathy. Fibrinogen and D-dimer levels are also available in most clinical laboratories, and should be drawn in patients with evidence of hemorrhage or shock since these are surrogate markers of clotting factor consumption and hyperfibrinolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these assays are commonly relied upon to evaluate bleeding risk in trauma patients, these tests were originally designed to screen for heritable coagulopathies such as hemophilia, and subsequently used to monitor anticoagulant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/66\">",
"     66",
"    </a>",
"    ]. The normal ranges are derived from the general population and correlate poorly with bleeding risk in elective general and vascular surgical operations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/67\">",
"     67",
"    </a>",
"    ]. Additionally, the results from standard laboratory analysis can take up to 30 minutes and may not accurately reflect the patient&rsquo;s evolving coagulation status; the delay in the availability of results may make them irrelevant in the face of exsanguinating hemorrhage. As a result, there has been a trend toward the use of point-of-care laboratory testing (thromboelastography) and clinical scoring systems to guide management of the severely injured patient. (See",
"    <a class=\"local\" href=\"#H3046566855\">",
"     'Thromboelastography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with prolonged clotting times due to known bleeding diatheses or pharmacological anticoagulation are not traditionally defined as having ATC, although ATC physiology may exacerbate any preexisting coagulation disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link\">",
"     \"Correcting excess anticoagulation after warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18982722\">",
"    <span class=\"h2\">",
"     Standard coagulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical studies have used several diagnostic criteria to identify clinically relevant coagulopathy following injury. These include prothrombin time (PT)&gt;18 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/39\">",
"     39",
"    </a>",
"    ], international normalized ratio (INR)&gt;1.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/68\">",
"     68",
"    </a>",
"    ], activated partial thromboplastin time (PTT)&gt;60 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/39\">",
"     39",
"    </a>",
"    ], or any of these values at a threshold of 1.5 times the laboratory reference value [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/69\">",
"     69",
"    </a>",
"    ]. The prevalence of prolonged PT is higher, but prolongation of the PTT is more specific.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trauma registry study involving 20,103 patients, the PT and PTT were prolonged in 28 and 8 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/3\">",
"       3",
"      </a>",
"      ]. The adjusted odds ratios for mortality were 1.35 for PT and 4.26 for PTT prolongation.",
"     </li>",
"     <li>",
"      A five-center international retrospective study of 3646 trauma patients identified patients with significantly greater transfusion requirements and increased mortality using a more liberal cutoff &gt;1.2 of prothrombin time ratio (an inter-center standardized version of the INR) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/70\">",
"       70",
"      </a>",
"      ]. This lower INR value may be a more appropriate cutoff for patients with more severe injury (injury severity scale [ISS]&gt;15) and shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decreased platelet count",
"    <span class=\"nowrap\">",
"     (100,000/&micro;L)",
"    </span>",
"    and decreased platelet function also contribute to coagulopathy and poor outcome following trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/71\">",
"     71",
"    </a>",
"    ]. Little information about platelet function is evident from the platelet count alone. In one study, serial functional analyses demonstrated increased platelet activation and function in survivors following traumatic injury, while non-survivors had significant dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/72\">",
"     72",
"    </a>",
"    ]. Instrumentation available to assess platelet function includes the platelet function analyzer (PFA-100), and the electrical impedance whole blood aggregometer (Multiplate&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. However, these devices have not been clinically evaluated in trauma and resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link\">",
"     \"Platelet function testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unknown whether ATC might exist in patients with normal-range values of",
"    <span class=\"nowrap\">",
"     PT/INR",
"    </span>",
"    and PTT. A careful study of markers of coagulopathy and inflammation in 80 trauma patients identified that increasing injury severity correlated with elevated markers of endothelial cell and glycocalyx damage, protein C activation, and clotting factor consumption even when INR and PTT values were in the normal range, suggesting that the biochemical derangement of ATC lies on a continuum dependent upon injury and shock severity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/41\">",
"     41",
"    </a>",
"    ]. Similarly, there have been anecdotal reports of injured patients with clinically relevant hyperfibrinolysis identified using thromboelastography, but without prolonged PT or PTT. Thus, patients who present with the combination of significant injury (ISS&gt;15) and a base deficit (&lt;-6) should be closely monitored and aggressively treated for clinical coagulopathy even in the face of normal standard coagulation tests, pending further clinical studies.",
"   </p>",
"   <p>",
"    Because ATC can occur in patients who have normal platelet and fibrinogen levels, specific platelet or fibrinogen levels are not included in current diagnostic criteria; however, when abnormalities are present, thrombocytopenia and hypofibrinogenemia certainly contribute to clinical hemorrhage and should be corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/2,3,7\">",
"     2,3,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H62323474\">",
"     'Treatment'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3046566855\">",
"    <span class=\"h2\">",
"     Thromboelastography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboelastography assesses the viscoelastic properties of clot formation in fresh or citrated whole blood in real-time. The test synthesizes information obtained from multiple coagulation tests (PT, PTT, thrombin time, fibrinogen level, and platelet count) into a single read out (",
"    <a class=\"graphic graphic_figure graphicRef80241 \" href=\"UTD.htm?31/11/31929\">",
"     figure 3",
"    </a>",
"    ) providing information regarding clot initiation, clot strength, and fibrinolysis simultaneously. Until recently, the bulk of its clinical use has been as a point-of-care adjunct during cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/75\">",
"     75",
"    </a>",
"    ] and liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/76\">",
"     76",
"    </a>",
"    ]. As a functional test of clot formation and lysis, it is conceptually well-suited to monitor the progress or resolution of coagulopathy after injury.",
"   </p>",
"   <p>",
"    Thromboelastography parameters have been validated against standard laboratory tests [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/77,78\">",
"     77,78",
"    </a>",
"    ], thrombin-antithrombin complex levels for TEG&reg; [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/79\">",
"     79",
"    </a>",
"    ], and euglobin clot lysis times for RoTEM&reg; [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/80\">",
"     80",
"    </a>",
"    ]. Specific elements of the clotting cascade can be interrogated by performing tests in the presence of specific clotting activators or inhibitors (",
"    <a class=\"graphic graphic_table graphicRef55087 \" href=\"UTD.htm?3/13/3292\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H25#H25\">",
"     \"Platelet function testing\", section on 'Thromboelastography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Representative tracings compared with normal are given for each of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary fibrinolysis &ndash; (",
"      <a class=\"graphic graphic_figure graphicRef58281 graphicRef51767 \" href=\"UTD.htm?18/39/19058\">",
"       figure 4A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Secondary hyperfibrinolysis &ndash; (",
"      <a class=\"graphic graphic_figure graphicRef58281 graphicRef70388 \" href=\"UTD.htm?23/22/23906\">",
"       figure 4A, 4C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thrombocytopenia &ndash; (",
"      <a class=\"graphic graphic_figure graphicRef58281 graphicRef80926 \" href=\"UTD.htm?22/35/23090\">",
"       figure 4A, 4D",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Clotting factor consumption &ndash; (",
"      <a class=\"graphic graphic_figure graphicRef58281 graphicRef60690 \" href=\"UTD.htm?23/54/24418\">",
"       figure 4A, 4E",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypercoagulability &ndash; (",
"      <a class=\"graphic graphic_figure graphicRef58281 graphicRef58977 \" href=\"UTD.htm?24/55/25458\">",
"       figure 4A, 4F",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple studies have used thromboelastography to diagnose immediate hypocoagulability and later hypercoagulability following moderate injury despite normal-range standard coagulation tests [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Studies involving trauma patients have correlated thromboelastography parameters with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. In one of these studies, the mortality rate for a group of patients who demonstrated hyperfibrinolysis was significantly greater (77 versus 41 percent) compared with the group that did not demonstrate hyperfibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/85\">",
"     85",
"    </a>",
"    ]. Cut-off values for RoTEM&reg;-based parameters correlate with standard laboratory transfusion cut-off values [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/87\">",
"     87",
"    </a>",
"    ]. The use of thromboelastography in trauma as a guide to transfusion is discussed below. (See",
"    <a class=\"local\" href=\"#H184662298\">",
"     'Thromboelastography-based transfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3046566862\">",
"    <span class=\"h2\">",
"     Factor levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although coagulation factors are not commonly assessed in injured patients, coagulation factor depletion due to hemodilution and unbalanced component blood transfusion exacerbates coagulopathy associated with trauma. Fibrinogen (factor I) is the first factor to become depleted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/88\">",
"     88",
"    </a>",
"    ]. Of the commonly numbered coagulation factors, V and VIII are the most labile and may become selectively depleted during trauma resuscitation, particularly in the setting of low plasma to red blood cell unit transfusion ratios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168701765\">",
"    <span class=\"h2\">",
"     Clinical scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid clinical assessment of the trauma patient provides information that helps predict the potential for coagulopathy and empiric need for massive transfusion based upon the mechanism and severity of injuries, hemodynamic status of the patient, and evidence of active hemorrhage (eg, positive focused assessment with sonography for trauma [FAST], or brisk bleeding from a chest tube) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/89-91\">",
"     89-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several clinical scoring systems have been evaluated for this purpose, but are not widely used. These include the Trauma-Associated Severe Hemorrhage (TASH) score [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/91\">",
"     91",
"    </a>",
"    ], McLaughlin score [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/92\">",
"     92",
"    </a>",
"    ], and Assessment of Blood Consumption (ABC) score [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/89\">",
"     89",
"    </a>",
"    ]. A retrospective review compared these clinical scores in 596 patients. Significantly higher TASH (13 versus 6), McLaughlin (3.4 versus 2.4) and ABC (2 versus 1) scores were seen in patients who required massive transfusion compared with patients who did not, but no significant predictive differences were identified between these scores [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/89\">",
"     89",
"    </a>",
"    ]. None of these scoring systems include coagulation parameter measurements, highlighting the fact that massive hemorrhage is generally due to active bleeding requiring surgical or interventional control, not as a result of coagulopathy. &nbsp;",
"   </p>",
"   <p>",
"    The utility of any clinical scoring system requires the demonstration that mortality is reduced as a result of a high score triggering a transfusion protocol, and that earlier activation of these protocols is associated with a further decrease in mortality. There are no prospective trials that demonstrate such a survival benefit; however, significant reductions in overall blood product use and hospital costs have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that many massive transfusion protocols call for the early use of plasma and increased transfusion ratios (1:1:1), a sensitive scoring system may allow the early identification of patients at risk for ATC and more precise transfusion triggers, but these scoring systems have not been designed or validated as diagnostic tests for coagulopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62323474\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of acute traumatic coagulopathy (ATC) predicts significantly higher transfusion requirements in the first 24 hours of hospitalization. In one study, patients with ATC on admission received an average of 10 units of blood, compared with the 2 received by those with normal clotting studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7\">",
"     7",
"    </a>",
"    ]. The need for blood transfusion and number of units transfused is a predictor of systemic inflammation, acute respiratory distress, and mortality following traumatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/95-97\">",
"     95-97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although red blood cell transfusion improves perfusion and oxygen carrying capacity, there is an increasing awareness that traditional transfusion protocols produce or exacerbate resuscitation-associated coagulopathy. Resuscitation protocols continue to vary widely between trauma centers and ratios of plasma:PRBC range from 1:1 to 1:10 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/23,98-100\">",
"     23,98-100",
"    </a>",
"    ]. With low plasma ratios, treatment of coagulopathy becomes delayed, and ultimately a greater volume of blood is required. The recognition of this problem has led to a widespread re-evaluation of transfusion protocols, particularly in patients who demonstrate acute traumatic coagulopathy.",
"   </p>",
"   <p>",
"    Although no prospective, randomized trials are yet available to provide a definitive approach to transfusion for the trauma population, patients with acute traumatic coagulopathy are at risk for massive transfusion and they appear to benefit from a resuscitation protocol using fresh frozen plasma, packed red blood cells, and platelets (1:1:1 ratios) given early and aggressively, while limiting crystalloid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. However, the value of this approach is controversial, and benefits remain to be proven in randomized trials. Not all investigators feel there is a clear survival benefit to 1:1:1 resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/68,103,104\">",
"     68,103,104",
"    </a>",
"    ]. The retrospective nature of these studies introduces selection and survival biases, with patients who have died early in the resuscitation effort often excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/105\">",
"     105",
"    </a>",
"    ]. Patients may have had longer survival not because they received more plasma, but rather received more plasma because they survived long enough to do so [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/106\">",
"     106",
"    </a>",
"    ]. The initial management of the severely injured patient is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184662298\">",
"    <span class=\"h2\">",
"     Thromboelastography-based transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion protocols based upon thromboelastography parameters including clotting time, clot formation time, amplitude, and clot lysis index (",
"    <a class=\"graphic graphic_table graphicRef74954 \" href=\"UTD.htm?41/10/42156\">",
"     table 4",
"    </a>",
"    ) have been suggested for standard and rotational thromboelastography based upon single center experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/83,87,90,107-109\">",
"     83,87,90,107-109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although thromboelastography-guided transfusion triggers are preliminary, the authors feel that thromboelastography is a promising technology. As institutional experience and clinical guidelines accrue, the rapid turnaround and multifaceted information provided by point-of-care thromboelastography will likely provide improved criteria for transfusion in acutely injured patients. Thrombelastography-guided &ldquo;thrombostatic&rdquo; resuscitation protocols will likely emerge as the new standard, but only single-center studies are currently available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example protocol from Denver Health Medical Center, providing normal ranges and transfusion cutoffs, is given in the table (",
"    <a class=\"graphic graphic_table graphicRef56058 \" href=\"UTD.htm?42/44/43723\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. Examples of the utility of thromboelastography in trauma are given below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Denver group found that TEG&reg; &ldquo;G&rdquo; values and thrombin generation parameters obtained six hours after arrival were significantly associated with survival, while the INR was not [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective evaluation of TEG&reg; used in 44 combat patients found that maximal amplitude (MA) correlated more strongly with 24-hour transfusion requirements than standard laboratory values [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another retrospective study of 832 patients requiring massive transfusion (21 percent trauma patients), patients whose transfusion was guided by TEG&reg; parameters received more plasma and platelets, and had significantly better 30-day survival (32 versus 20 percent) compared with retrospective controls transfused using standard laboratory measurements [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83049587\">",
"    <span class=\"h2\">",
"     Pharmaceutical hemostatic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to repletion of coagulation factors by transfusion, several pharmaceutical hemostatic agents are available for the treatment of severe coagulopathy in the injured patient including recombinant factor VIIa, prothrombin complex concentrate, antifibrinolytic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recombinant factor VIIa &ndash; Recombinant factor VIIa was initially developed and approved for the treatment of hemophilia and congenital factor deficiencies [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/115\">",
"       115",
"      </a>",
"      ]. The recognition of injury-exposed tissue factor binding to activated factor VII as the principle trigger of clot formation after trauma led to interest in using recombinant factor VIIa for the management of acute traumatic coagulopathy.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"       Recombinant human factor VIIa",
"      </a>",
"      is an adjunctive treatment for coagulopathy associated with trauma but should be reserved for salvage therapy. When used, it is important to correct acidosis, hypothermia, thrombocytopenia, and hypofibrinogenemia prior to its use. The dosing of recombinant factor VIIa in trauma patients is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link&amp;anchor=H21#H21\">",
"       \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Managing post-traumatic hemorrhage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prothrombin complex concentrate &ndash; Prothrombin complex concentrate (PCC) is a factor concentrate enriched for factors II, VII, IX, and X originally developed for hemorrhagic complications of hemophilia B [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/115\">",
"       115",
"      </a>",
"      ]. The clinical use of PCC has been well studied in the reversal of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation, since PCC is preferentially rich in the vitamin K-dependent clotting factors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/116\">",
"       116",
"      </a>",
"      ]. Some centers have used PCC to correct coagulopathy after trauma and preliminary studies in animal models of hemorrhagic shock are promising, but PCC has not been thoroughly evaluated in trauma patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/117\">",
"       117",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H14#H14\">",
"       \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Prothrombin complex concentrates'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antifibrinolytic therapy &ndash; An interest in antifibrinolytic therapy has been renewed because of the presence of enhanced fibrinolysis following severe trauma, [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/7,118-122\">",
"       7,118-122",
"      </a>",
"      ]. Antifibrinolytic therapy may be appropriate for patients with ongoing hemorrhagic shock who have an elevated D-dimer and depleted fibrinogen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage (CRASH-2) trial, an absolute mortality reduction of 1.5 percent was identified in patients receiving empiric",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/119\">",
"       119",
"      </a>",
"      ]. The coagulation status (standard parameters or thromboelastography) of the patients enrolled was not specified. Enrollment criteria included adult trauma patients within eight hours of injury with significant hemorrhage (systolic blood pressure &lt;90 mmHg or heart rate &gt;110 beats per min, or both), or those who were considered to be at risk of significant hemorrhage.",
"     </li>",
"     <li>",
"      The subsequent Military Application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       Tranexamic acid",
"      </a>",
"      in Trauma Emergency Resuscitation (MATTERs) study evaluated outcomes in 896 patients who were treated with tranexamic acid or not [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/123\">",
"       123",
"      </a>",
"      ]. For the first half of the study, patients received tranexamic acid at the discretion of the treating surgeon, and thereafter, the drug was administered as part of a major hemorrhage protocol or clinical practice guideline to patients requiring emergency blood products or patients with evidence of hyperfibrinolysis. Unadjusted mortality rates were significantly reduced for treated (17 versus 24 percent) versus nontreated casualties. In a subgroup of patients requiring massive transfusion, greater reductions in mortality were seen for those who were treated (28 versus 14 percent).",
"     </li>",
"     <li>",
"      Further studies of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      in patients with demonstrable ATC are needed to identify appropriate treatment criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/119\">",
"       119",
"      </a>",
"      ]. Other antifibrinolytic agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"       aprotinin",
"      </a>",
"      , but these have not been evaluated in patients with traumatic coagulopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/120\">",
"       120",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H20853214#H20853214\">",
"       \"Initial evaluation and management of shock in adult trauma\", section on 'Antifibrinolytic agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      &ndash; Desmopressin was developed for the treatment of inherited bleeding diatheses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/124\">",
"       124",
"      </a>",
"      ], and to counteract uremic bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/125\">",
"       125",
"      </a>",
"      ]. There is insufficient clinical evidence to support the use of desmopressin in the trauma population except in those patients with preexisting bleeding diatheses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/126\">",
"       126",
"      </a>",
"      ]. Preliminary animal studies show that desmopressin administration improves but does not completely correct hypothermia or acidosis-induced platelet dysfunction, but clinical validation of these experimental data needs to be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/127,128\">",
"       127,128",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link&amp;anchor=H7704093#H7704093\">",
"       \"Platelet dysfunction in uremia\", section on 'Desmopressin (dDAVP)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18982992\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reliance upon standard serial laboratory measurements is not compatible with the timely correction of coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/129\">",
"     129",
"    </a>",
"    ]. Thromboelastography provides more comprehensive information in real-time and readily identifies hyperfibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/44/23242/abstract/84\">",
"     84",
"    </a>",
"    ]. Serial thromboelastography, when available, should be used to monitor the patient&rsquo;s coagulation status, and to guide transfusion and the correction of coagulopathy. (See",
"    <a class=\"local\" href=\"#H3046566855\">",
"     'Thromboelastography'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H184662298\">",
"     'Thromboelastography-based transfusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Where thromboelastography is not available, serial",
"    <span class=\"nowrap\">",
"     PT/INR,",
"    </span>",
"    PTT,",
"    <span class=\"nowrap\">",
"     hemoglobin/hematocrit,",
"    </span>",
"    platelet count, and fibrinogen levels should be obtained on arrival and following transfusion to verify an appropriate response to blood products",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmaceutical hemostatic agents, before and after operative interventions, and as dictated by the patient&rsquo;s clinical course.",
"   </p>",
"   <p>",
"    Serial measurements of arterial blood gas for pH and base deficit are indicated for monitoring the resolution of acidosis and tissue hypoperfusion in response to resuscitation. During the course of operative intervention and ongoing shock resuscitation, central temperature monitoring (eg, via Foley catheter or esophageal temperature probe) should be performed until normothermia is reestablished.",
"   </p>",
"   <p>",
"    In the massively resuscitated patient, the early institution of intermittent intraabdominal pressure transducer is also appropriate to monitor for the development of abdominal compartment syndrome and the need for abdominal decompression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link&amp;anchor=H20#H20\">",
"     \"Abdominal compartment syndrome\", section on 'Measurement of intraabdominal pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62326854\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coagulopathy is associated with greater transfusion requirements, longer intensive care unit and hospital stays, more days of mechanical ventilation, and a greater incidence of multiorgan failure and mortality. The identification and early correction of coagulopathy is important to decrease fluid and transfusion requirements, decrease complications and improve survival. (See",
"      <a class=\"local\" href=\"#H62326298\">",
"       'Impact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of coagulopathy in the injured patient is multifactorial with overlapping contributions from acidosis related to tissue injury and shock, hypothermia related to exposure and fluid administration, hemodilution due to fluid or component blood product administration. In severely injured patients, an additional biochemical process that remains incompletely characterized underlies &lsquo;acute traumatic coagulopathy&rsquo;. Consumption of clotting factors manifesting as disseminated intravascular coagulation (DIC) may contribute upon presentation or later in the hospital course. (See",
"      <a class=\"local\" href=\"#H62326162\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute traumatic coagulopathy (ATC) is an impairment of hemostasis and activation of fibrinolysis that occurs in response to severe injury and is biochemically evident prior to, and independent of, the development of significant acidosis, hypothermia, or hemodilution. Acute traumatic coagulopathy is mediated primarily by activation of the thrombomodulin-protein C system. (See",
"      <a class=\"local\" href=\"#H122599087\">",
"       'Acute traumatic coagulopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard coagulation tests including prothrombin",
"      <span class=\"nowrap\">",
"       time/international",
"      </span>",
"      normalized ratio",
"      <span class=\"nowrap\">",
"       (PT/INR),",
"      </span>",
"      activated partial thromboplastin time (PTT), fibrinogen level, and platelet count are part of the initial laboratory evaluation of trauma patients. In patients without pre-existing coagulation defects, a prolonged prothrombin time (PT)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      activated partial thromboplastin time (PTT) greater than 1.5 times normal on admission defines the presence of acute traumatic coagulopathy. Clinically relevant ATC can occur in patients who have normal platelet and fibrinogen levels. (See",
"      <a class=\"local\" href=\"#H3046566840\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thromboelastography is emerging as an important tool for identifying patients with acute traumatic coagulopathy and for real-time monitoring of ongoing resuscitation efforts in injured patients. Thromboelastography measures the viscoelastic properties of clot formation providing information on clot initiation, clot strength, and fibrinolysis. Additional clinical evaluation is ongoing in an effort to establish guidelines for more widespread use. (See",
"      <a class=\"local\" href=\"#H3046566855\">",
"       'Thromboelastography'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For patients diagnosed with acute traumatic coagulopathy, we suggest plasma-based resuscitation, targeting ratios of packed red blood cells, fresh frozen plasma, and platelets approaching 1:1:1 over protocols with lower ratios (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Injured patients with acute traumatic coagulopathy are more likely to require massive transfusion and benefit from early matched transfusion. We prefer to use thromboelastography to guide transfusion and monitor patients rather than treatment and follow-up guided by standard coagulation tests. (See",
"      <a class=\"local\" href=\"#H62323474\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H3250855#H3250855\">",
"       \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion of blood products'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmaceutical hemostatic agents available as adjuncts for the treatment of severe coagulopathy in the injured patient include recombinant factor VIIa, prothrombin complex concentrate, antifibrinolytic agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"       aprotinin",
"      </a>",
"      ) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H83049587\">",
"       'Pharmaceutical hemostatic agents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H17#H17\">",
"       \"Initial evaluation and management of shock in adult trauma\", section on 'Developing treatments for hemorrhage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/1\">",
"      Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/2\">",
"      Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003; 54:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/3\">",
"      MacLeod JB, Lynn M, McKenney MG, et al. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/4\">",
"      Maegele M, Lefering R, Yucel N, et al. Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury 2007; 38:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/5\">",
"      Spivey M, Parr MJ. Therapeutic approaches in trauma-induced coagulopathy. Minerva Anestesiol 2005; 71:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/6\">",
"      Hess JR, Brohi K, Dutton RP, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008; 65:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/7\">",
"      Brohi K, Cohen MJ, Ganter MT, et al. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg 2007; 245:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/8\">",
"      Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. J Trauma 2008; 64:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/9\">",
"      Engstr&ouml;m M, Sch&ouml;tt U, Romner B, Reinstrup P. Acidosis impairs the coagulation: A thromboelastographic study. J Trauma 2006; 61:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/10\">",
"      Martini WZ. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma 2009; 67:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/11\">",
"      Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/12\">",
"      Hess JR. Blood and coagulation support in trauma care. Hematology Am Soc Hematol Educ Program 2007; :187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/13\">",
"      Martini WZ, Dubick MA, Pusateri AE, et al. Does bicarbonate correct coagulation function impaired by acidosis in swine? J Trauma 2006; 61:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/14\">",
"      Martini WZ, Dubick MA, Wade CE, Holcomb JB. Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs. Crit Care Med 2007; 35:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/15\">",
"      Tsuei BJ, Kearney PA. Hypothermia in the trauma patient. Injury 2004; 35:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/16\">",
"      Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/17\">",
"      Farkash U, Lynn M, Scope A, et al. Does prehospital fluid administration impact core body temperature and coagulation functions in combat casualties? Injury 2002; 33:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/18\">",
"      Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/19\">",
"      Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008; 65:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/20\">",
"      Shafi S, Elliott AC, Gentilello L. Is hypothermia simply a marker of shock and injury severity or an independent risk factor for mortality in trauma patients? Analysis of a large national trauma registry. J Trauma 2005; 59:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/21\">",
"      Dirkmann D, Hanke AA, G&ouml;rlinger K, Peters J. Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth Analg 2008; 106:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/22\">",
"      Schreiber MA. Coagulopathy in the trauma patient. Curr Opin Crit Care 2005; 11:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/23\">",
"      Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma 2003; 54:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/24\">",
"      Brazil EV, Coats TJ. Sonoclot coagulation analysis of in-vitro haemodilution with resuscitation solutions. J R Soc Med 2000; 93:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/25\">",
"      Coats TJ, Brazil E, Heron M. The effects of commonly used resuscitation fluids on whole blood coagulation. Emerg Med J 2006; 23:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/26\">",
"      Tinmouth A, Fergusson D, Yee IC, et al. Clinical consequences of red cell storage in the critically ill. Transfusion 2006; 46:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/27\">",
"      Fukuda T, Nakashima Y, Harada M, et al. Effect of whole blood clotting time in rats with ionized hypocalcemia induced by rapid intravenous citrate infusion. J Toxicol Sci 2006; 31:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/28\">",
"      Levy JH. Massive transfusion coagulopathy. Semin Hematol 2006; 43:S59.",
"     </a>",
"    </li>",
"    <li>",
"     Whitaker, B, Sullivan, M. The 2005 Nationwide Blood Collection and Utilization Survey Report 2005. AABB. file://aabb.org/programs/biovigilance/nbcus/Documents/05nbcusrpt.pdf (Accessed on December 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/30\">",
"      Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/31\">",
"      Spinella PC, Carroll CL, Staff I, et al. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care 2009; 13:R151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/32\">",
"      Dzik W. Fresh blood for everyone? Balancing availability and quality of stored RBCs. Transfus Med 2008; 18:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/33\">",
"      Hess JR, Lawson JH. The coagulopathy of trauma versus disseminated intravascular coagulation. J Trauma 2006; 60:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/34\">",
"      Gando S. Acute coagulopathy of trauma shock and coagulopathy of trauma: a rebuttal. You are now going down the wrong path. J Trauma 2009; 67:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/35\">",
"      Levi M. Disseminated intravascular coagulation. Crit Care Med 2007; 35:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/36\">",
"      Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008; 36:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/37\">",
"      Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/38\">",
"      Gando S, Tedo I, Kubota M. Posttrauma coagulation and fibrinolysis. Crit Care Med 1992; 20:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/39\">",
"      Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 2007; 13:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/40\">",
"      Shaz BH, Winkler AM, James AB, et al. Pathophysiology of early trauma-induced coagulopathy: emerging evidence for hemodilution and coagulation factor depletion. J Trauma 2011; 70:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/41\">",
"      Johansson PI, S&oslash;rensen AM, Perner A, et al. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care 2011; 15:R272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/42\">",
"      Chesebro BB, Rahn P, Carles M, et al. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 2009; 32:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/43\">",
"      Cadroy Y, Diqu&eacute;lou A, Dupouy D, et al. The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium. Arterioscler Thromb Vasc Biol 1997; 17:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/44\">",
"      Esmon CT. Protein C pathway in sepsis. Ann Med 2002; 34:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/45\">",
"      Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276:15567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/46\">",
"      Bajzar L, Jain N, Wang P, Walker JB. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med 2004; 32:S320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/47\">",
"      Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/48\">",
"      Xu J, Ji Y, Zhang X, et al. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock. J Thromb Haemost 2009; 7:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/49\">",
"      Cohen MJ, Call M, Nelson M, et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 2012; 255:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/50\">",
"      Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011; 254:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/51\">",
"      Finigan JH, Boueiz A, Wilkinson E, et al. Activated protein C protects against ventilator-induced pulmonary capillary leak. Am J Physiol Lung Cell Mol Physiol 2009; 296:L1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/52\">",
"      Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280:17286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/53\">",
"      Cohen MJ, Bir N, Rahn P, et al. Protein C depletion early after trauma increases the risk of ventilator-associated pneumonia. J Trauma 2009; 67:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/54\">",
"      Ganter MT, Brohi K, Cohen MJ, et al. Role of the alternative pathway in the early complement activation following major trauma. Shock 2007; 28:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/55\">",
"      Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/56\">",
"      Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/57\">",
"      Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/58\">",
"      Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007; 110:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/59\">",
"      Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105:3178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/60\">",
"      Schuepbach RA, Feistritzer C, Fern&aacute;ndez JA, et al. Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost 2009; 101:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/61\">",
"      Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? J Trauma 2003; 54:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/62\">",
"      Selby R, Geerts W, Ofosu FA, et al. Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism. Thromb Res 2009; 124:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/63\">",
"      Knudson MM, Collins JA, Goodman SB, McCrory DW. Thromboembolism following multiple trauma. J Trauma 1992; 32:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/64\">",
"      Silva E, de Figueiredo LF, Colombari F. Prowess-shock trial: a protocol overview and perspectives. Shock 2010; 34 Suppl 1:48.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit. file://www.fda.gov/Drugs/DrugSafety/ucm277114.htm (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/66\">",
"      Owen CA Jr. Historical account of tests of hemostasis. Am J Clin Pathol 1990; 93:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/67\">",
"      Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Ann Intern Med 2003; 138:W15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/68\">",
"      Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma 2008; 65:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/69\">",
"      Hoyt DB, Dutton RP, Hauser CJ, et al. Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice. J Trauma 2008; 65:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/70\">",
"      Frith D, Goslings JC, Gaarder C, et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost 2010; 8:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/71\">",
"      Hess JR, Lindell AL, Stansbury LG, et al. The prevalence of abnormal results of conventional coagulation tests on admission to a trauma center. Transfusion 2009; 49:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/72\">",
"      Jacoby RC, Owings JT, Holmes J, et al. Platelet activation and function after trauma. J Trauma 2001; 51:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/73\">",
"      Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/74\">",
"      Velik-Salchner C, Maier S, Innerhofer P, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008; 107:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/75\">",
"      Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/76\">",
"      Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost 1995; 21 Suppl 4:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/77\">",
"      Jeger V, Zimmermann H, Exadaktylos AK. Can RapidTEG accelerate the search for coagulopathies in the patient with multiple injuries? J Trauma 2009; 66:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/78\">",
"      Cotton BA, Faz G, Hatch QM, et al. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma 2011; 71:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/79\">",
"      Schreiber MA, Differding J, Thorborg P, et al. Hypercoagulability is most prevalent early after injury and in female patients. J Trauma 2005; 58:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/80\">",
"      Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/81\">",
"      Kaufmann CR, Dwyer KM, Crews JD, et al. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997; 42:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/82\">",
"      Park MS, Martini WZ, Dubick MA, et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009; 67:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/83\">",
"      Carroll RC, Craft RM, Langdon RJ, et al. Early evaluation of acute traumatic coagulopathy by thrombelastography. Transl Res 2009; 154:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/84\">",
"      Sch&ouml;chl H, Frietsch T, Pavelka M, J&aacute;mbor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/85\">",
"      Theusinger OM, Wanner GA, Emmert MY, et al. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg 2011; 113:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/86\">",
"      Tauber H, Innerhofer P, Breitkopf R, et al. Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth 2011; 107:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/87\">",
"      Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/88\">",
"      Hiippala ST, Myllyl&auml; GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/89\">",
"      Nunez TC, Voskresensky IV, Dossett LA, et al. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? J Trauma 2009; 66:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/90\">",
"      Schreiber MA, Perkins J, Kiraly L, et al. Early predictors of massive transfusion in combat casualties. J Am Coll Surg 2007; 205:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/91\">",
"      Y&uuml;cel N, Lefering R, Maegele M, et al. Trauma Associated Severe Hemorrhage (TASH)-Score: probability of mass transfusion as surrogate for life threatening hemorrhage after multiple trauma. J Trauma 2006; 60:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/92\">",
"      McLaughlin DF, Niles SE, Salinas J, et al. A predictive model for massive transfusion in combat casualty patients. J Trauma 2008; 64:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/93\">",
"      Cotton BA, Au BK, Nunez TC, et al. Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. J Trauma 2009; 66:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/94\">",
"      O'Keeffe T, Refaai M, Tchorz K, et al. A massive transfusion protocol to decrease blood component use and costs. Arch Surg 2008; 143:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/95\">",
"      Charles A, Shaikh AA, Walters M, et al. Blood transfusion is an independent predictor of mortality after blunt trauma. Am Surg 2007; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/96\">",
"      Dunne JR, Malone DL, Tracy JK, Napolitano LM. Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. Surg Infect (Larchmt) 2004; 5:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/97\">",
"      Silverboard H, Aisiku I, Martin GS, et al. The role of acute blood transfusion in the development of acute respiratory distress syndrome in patients with severe trauma. J Trauma 2005; 59:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/98\">",
"      Cotton BA, Gunter OL, Isbell J, et al. Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. J Trauma 2008; 64:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/99\">",
"      Alam HB, Rhee P. New developments in fluid resuscitation. Surg Clin North Am 2007; 87:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/100\">",
"      Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007; 62:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/101\">",
"      de Biasi AR, Stansbury LG, Dutton RP, et al. Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma (CME). Transfusion 2011; 51:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/102\">",
"      Brown LM, Aro SO, Cohen MJ, et al. A high fresh frozen plasma: packed red blood cell transfusion ratio decreases mortality in all massively transfused trauma patients regardless of admission international normalized ratio. J Trauma 2011; 71:S358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/103\">",
"      Sperry JL, Ochoa JB, Gunn SR, et al. An FFP:PRBC transfusion ratio &gt;/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008; 65:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/104\">",
"      Scalea TM, Bochicchio KM, Lumpkins K, et al. Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. Ann Surg 2008; 248:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/105\">",
"      Rajasekhar A, Gowing R, Zarychanski R, et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Crit Care Med 2011; 39:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/106\">",
"      Snyder CW, Weinberg JA, McGwin G Jr, et al. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma 2009; 66:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/107\">",
"      Kheirabadi BS, Crissey JM, Deguzman R, Holcomb JB. In vivo bleeding time and in vitro thrombelastography measurements are better indicators of dilutional hypothermic coagulopathy than prothrombin time. J Trauma 2007; 62:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/108\">",
"      Martini WZ, Cortez DS, Dubick MA, et al. Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. J Trauma 2008; 65:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/109\">",
"      Sch&ouml;chl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14:R55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/110\">",
"      Kashuk JL, Moore EE, Sawyer M, et al. Postinjury coagulopathy management: goal directed resuscitation via POC thrombelastography. Ann Surg 2010; 251:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/111\">",
"      Stahel PF, Moore EE, Schreier SL, et al. Transfusion strategies in postinjury coagulopathy. Curr Opin Anaesthesiol 2009; 22:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/112\">",
"      Kashuk JL, Moore EE, Wohlauer M, et al. Initial experiences with point-of-care rapid thrombelastography for management of life-threatening postinjury coagulopathy. Transfusion 2012; 52:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/113\">",
"      Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma 2008; 64:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/114\">",
"      Johansson PI, Stensballe J. Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang 2009; 96:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/115\">",
"      Limentani SA, Roth DA, Furie BC, Furie B. Recombinant blood clotting proteins for hemophilia therapy. Semin Thromb Hemost 1993; 19:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/116\">",
"      Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:204S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/117\">",
"      Dickneite G, D&ouml;rr B, Kaspereit F, Tanaka KA. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma 2010; 68:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/118\">",
"      Kashuk JL, Moore EE, Sawyer M, et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg 2010; 252:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/119\">",
"      CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/120\">",
"      Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001; :CD001886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/121\">",
"      Mangano DT, Tudor IC, Dietzel C, et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/122\">",
"      McMichan JC, Rosengarten DS, Philipp E. Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: a clinical study. Circ Shock 1982; 9:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/123\">",
"      Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 2012; 147:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/124\">",
"      Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/125\">",
"      Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/126\">",
"      Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/127\">",
"      Hanke AA, Dellweg C, Kienbaum P, et al. Effects of desmopressin on platelet function under conditions of hypothermia and acidosis: an in vitro study using multiple electrode aggregometry*. Anaesthesia 2010; 65:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/128\">",
"      Ying CL, Tsang SF, Ng KF. The potential use of desmopressin to correct hypothermia-induced impairment of primary haemostasis--an in vitro study using PFA-100. Resuscitation 2008; 76:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/44/23242/abstract/129\">",
"      Ho AM, Karmakar MK, Dion PW. Are we giving enough coagulation factors during major trauma resuscitation? Am J Surg 2005; 190:479.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15147 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-9070587B58-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23242=[""].join("\n");
var outline_f22_44_23242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H62326854\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62323431\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62326298\">",
"      IMPACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62326162\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83047596\">",
"      Acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299161\">",
"      Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299168\">",
"      Resuscitation-associated (dilutional) coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83047881\">",
"      Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H122599087\">",
"      Acute traumatic coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18982251\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3046566840\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18982722\">",
"      Standard coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3046566855\">",
"      Thromboelastography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3046566862\">",
"      Factor levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168701765\">",
"      Clinical scoring systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62323474\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184662298\">",
"      Thromboelastography-based transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83049587\">",
"      Pharmaceutical hemostatic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18982992\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62326854\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15147\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15147|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/20/12610\" title=\"figure 1\">",
"      Tissue factor and coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/24/31118\" title=\"figure 2\">",
"      Regulation of fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/11/31929\" title=\"figure 3\">",
"      TEG tracing interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/55/7039\" title=\"figure 4A\">",
"      Normal thromboelastography and parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/37/16991\" title=\"figure 4B\">",
"      Primary hyperfibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/6/20591\" title=\"figure 4C\">",
"      Secondary hyperfibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/6/19567\" title=\"figure 4D\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/52/21327\" title=\"figure 4E\">",
"      Clotting factor consumption and hypofibrinogenemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21551\" title=\"figure 4F\">",
"      Hypercoagulability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15147|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/15/35067\" title=\"table 1\">",
"      Acute versus chronic DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/3/33851\" title=\"table 2\">",
"      Components fibrinolytic system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/13/3292\" title=\"table 3\">",
"      Various types of thromboelastograms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/10/42156\" title=\"table 4\">",
"      Thromboelastography definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/44/43723\" title=\"table 5\">",
"      Thromboelastography-guided transfusion parameters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_44_23243="Three-point checklist";
var content_f22_44_23243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The three-point checklist of dermoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Asymmetry",
"        </strong>",
"       </td>",
"       <td>",
"        Asymmetry in distribution of dermoscopic color and/or structures in one or two perpendicular axes. The contour or silhouette of the lesion does not factor into whether the lesion is symmetric or not.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Atypical pigment network",
"        </strong>",
"       </td>",
"       <td>",
"        Pigment network with thick lines and irregular holes.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Blue-white structures",
"        </strong>",
"       </td>",
"       <td>",
"        Blue-white veil and/or white scar-like depigmentation and/or blue pepper-like granules.",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Interpretation: A total score of 2 or 3 points is considered positive, and the skin lesion should be removed or submitted for further evaluation.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Soyer HP, Argenziano G, Zalaudek I, et al. Three-point checklist of dermoscopy. A new screening method for early detection of melanoma. Dermatology 2004; 208:27. Copyright &copy; 2004 S. Karger AG, Basel. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23243=[""].join("\n");
var outline_f22_44_23243=null;
var title_f22_44_23244="Clinical features malabsorption";
var content_f22_44_23244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms of malabsorption",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Malabsorption of",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calories",
"       </td>",
"       <td>",
"        Weight loss with normal appetite",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat",
"       </td>",
"       <td>",
"        Pale and voluminous stool, diarrhea without flatulence, steatorrhea",
"       </td>",
"       <td>",
"        Stool fat &gt;6 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein",
"       </td>",
"       <td>",
"        Edema, muscle atrophy, amenorrhea",
"       </td>",
"       <td>",
"        Hypoalbuminemia, hypoproteinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbohydrates",
"       </td>",
"       <td>",
"        Watery diarrhea, flatulence, acidic stool pH, milk intolerance, stool osmotic gap",
"       </td>",
"       <td>",
"        Increased breath hydrogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12",
"       </td>",
"       <td>",
"        Anemia, subacute combined degeneration of the spinal cord (early symptoms are paresthesias and ataxia associated with loss of vibration and position sense)",
"       </td>",
"       <td>",
"        Macrocytic anemia, vitamin B12 decreased, abnormal Schilling test, serum methylmalonic acid and homocysteine increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Folic acid",
"       </td>",
"       <td>",
"        Anemia",
"       </td>",
"       <td>",
"        Macrocytic anemia, serum and RBC folate decreased, serum homocysteine increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B, general",
"       </td>",
"       <td>",
"        Cheilosis, painless glossitis, acrodermatitis, angular stomatitis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron",
"       </td>",
"       <td>",
"        Microcytic anemia, glossitis, pagophagia",
"       </td>",
"       <td>",
"        Serum iron and ferritin decreased, total iron binding capacity increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium and vitamin D",
"       </td>",
"       <td>",
"        Paresthesia, tetany, pathologic fractures due to osteomalacia, positive Chvostek and Trousseau signs",
"       </td>",
"       <td>",
"        Hypocalcemia, serum alkaline phosphatase increased, abnormal bone densitometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin A",
"       </td>",
"       <td>",
"        Follicular hyperkeratosis, night blindness",
"       </td>",
"       <td>",
"        Serum retinol decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin K",
"       </td>",
"       <td>",
"        Hematoma, bleeding disorders",
"       </td>",
"       <td>",
"        Prolonged prothrombin time, vitamin K-dependent coagulation factors decreased",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23244=[""].join("\n");
var outline_f22_44_23244=null;
var title_f22_44_23245="ACC AHA AVR in chronic AR";
var content_f22_44_23245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81155%7ECARD%2F57010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81155%7ECARD%2F57010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA Guideline Summary: Indications for aortic valve replacement or repair (AVR) in chronic aortic regurgitation (AR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or",
"general agreement that aortic valve replacement or repair (AVR) is",
"indicated in patients with chronic AR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Symptomatic patients with severe chronic AR, irrespective of left ventricular ejection fraction (LVEF).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; If the presence of symptoms in patients with severe chronic AR is equivocal, the development of symptoms during an exercise test.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Asymptomatic patients with severe chronic AR and an LVEF &le;50 percent at rest.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with severe chronic AR who undergo coronary artery bypass graft surgery (CABG) or surgery on the aorta or other heart valves.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence",
"or opinion is in favor of the usefulness of AVR in patients with",
"chronic AR in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &bull;&nbsp; Asymptomatic patients with severe chronic AR and a normal LVEF (LVEF &gt;50 percent) who have severe left ventricular dilatation (end-diastolic dimension &gt;75 mm or end-systolic dimension &gt;55 mm). Lower threshold values can be considered for patients of small stature.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence",
"or opinion is less well established for the usefulness of AVR in",
"patients with chronic AR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients with moderate chronic AR who undergo CABG or surgery on the ascending aorta.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &bull;&nbsp; Asymptomatic patients with severe chronic AR and an LVEF &gt;50 percent in whom the end-diastolic dimension is &gt;70 mm or the end-systolic dimension is &gt;50 mm, and there is evidence of progressive left ventricular dilatation, declining exercise tolerance, or an abnormal hemodynamic response to exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that AVR is NOT indicated in patients with chronic AR",
"in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        &bull;&nbsp; Asymptomatic patients with mild, moderate, or severe chronic AR and an LVEF &gt;50 percent at rest in whom the degree of left ventricular dilatation is not moderate or severe (end-diastolic dimension &lt;70 mm or end-systolic dimension &lt;50 mm).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Indications for aortic valve repair or replacement (AVR) in adolescents or young adults with chronic aortic regurgitation (AR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that aortic valve repair or replacement (AVR) is indicated in",
"adolescents or young adults with chronic AR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Severe AR with symptoms of angina, syncope, or dyspnea on exertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Asymptomatic severe AR with a left ventricular ejection fraction (LVEF) less than 50 percent on serial studies separated by one to three months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Asymptomatic severe AR with progressive left ventricular enlargement to an end-diastolic dimension more than four standard deviations greater than normal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Coronary angiography before aortic valve surgery when a pulmonary autograft (Ross procedure) is considered when the origin of the coronary arteries was not identified by noninvasive testing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or",
"opinion is less well established for the usefulness of AVR in",
"adolescents or young adults with chronic AR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Asymptomatic adolescents with severe AR who also have moderate aortic stenosis (peak left ventricle-to-peak aortic gradient greater than 40 mmHg at cardiac catheterization).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Asymptomatic adolescents with severe AR who develop ST depression or T wave inversion over the left precordium.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23245=[""].join("\n");
var outline_f22_44_23245=null;
var title_f22_44_23246="Reduced dialysis delivery";
var content_f22_44_23246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure showing the effect of dialyzer blood flow on urea clearance in the presence of low cardiac output, recirculation, and low mass transfer coefficient for urea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 258px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of increasing dialyzer blood flow (Qb) on total body urea clearance (Ktb) during hemodialysis. The top curve (Kd) represents the ideal curve in which all of the dialysis prescription is delivered. The lower curves reflect the progressive decrease in Ktb induced by the sequential addition of a low cardiac output (Qco = 5 L/min); plus a high access blood flow (Qac = 50% Qco); plus 15 percent access recirculation; plus a low rate of urea equilibration from the tissues (low MTCurea).",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23246=[""].join("\n");
var outline_f22_44_23246=null;
var title_f22_44_23247="GH peaks adult stim tests";
var content_f22_44_23247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Peak serum growth hormone concentrations with arginine/GHRH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 402px; background-image: url(data:image/gif;base64,R0lGODlhIQKSAeYAAP///4CAgAAAAH9/f8DAwBAQEHBwcPDw8EBAQKCgoDAwMJCQkL+/v7CwsD8/P2BgYAAzmSAgIP9/f+Dg4FBQUP8AAL/M5dDQ0D9msn+ZzP8/P/8PDx8fH5+fn/+fn/8fH//v709PTy8vL+/v79/f329vb/+vr/9PT4+Pj6+vrw8PD/+/v8/Pz//Pz3+Z/38AAP/f3/9vb/+Pj/8vL19/v19fX5+y2N/l8i9ZrI+l0v9fXx9Mpe/y+M/Y6w8/n6+/32+MxT9MZk9yuH8vL38PD39PT7/M/x8zWV9mcn8/Pw8mUgAZTI8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAhApIBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyLChw4cQI0qcSBEfgQAYM2rcyLGjx48gQ4ocSbKkyZMoU6pcybJlAAIV6wVwMKCmzZs4c+rcybOnz59AgwodSrSo0aNIkyZ1EIDeRZdQo5KEmSvAgJj9BjSdN1Op169DmeqyipWfVnpkr52terWsvrXy/9Jag3tLrtt7dOHZpZa31t679Pq6+ytN8CzCgOMZZocY2uJYjRO7e6wusicGDEYIYsGAxKIODliwcNDhEuVXliWvO40uNScBAlAAIAG7baIBAjoPYGB6Ky7XqtGxPveXgVfeh2BzAFCitiDQDmQDYBHCgYPcJHYDYFA9uqABHVA4qKEZ0XBWwCXDkCHBA4hPMTRIim9IQwxT58v9xQ27v///APZnWyECcCBACioYeFVzJYQQGwkqqDDAdZgJcNUANUwoQGmwiWBgDbf5VteAwR3iQQUoViCfIxpUwKKLkbRoSHuOqGhJfuTsF+COPJI4iAAOhBAhblclWBOQKGwIAP9uFV41AgohiGAhAEACMEKV5oloS3p3wVDBBisA0IIEAIAQnw4tAACDBCbER+YKH1QgwQorSNCCB2GacIIGMggiIyFmaqABmR6QCUChALRoggY6vCcBjYcK2meZMkh64gcSwBDooI/gOE5xxyECZAoClEAklRzY1AGTS+bGwJQiqIBCkldhieUhnqLCpVsyVHAfITNsIEGwMKyAogYbVOCBB8lqUOiXcppQwQkx+JoojIN8IGwMH1zrp4st6lDtCdfKV20MJ1TQZ4sxxLBBtRto0IK2EnDbqZbv7HpJlZmd6uBuq74aAgMUvlorBww0V6sDgtxqSK6n6AtQnY9WbPH/xRWHKYgEchLSgrXSymAsmdKS+SfHJgiS7nvBekvIBhvokKnLMv45A4w2boApx/JWoIMgMABgIwAwyxy0IxCDI3Elt546Qg0qCCAhc1JL2SQAHcB23cINM5zlWD4yRDHGZGc8yIkrqjkyACOvvfbJFWj8Z83YCtLCCXFuAMPc4ML4p40V7Nze2oMMfXfeRzOS9DdLE7M4KY1XFOegexL9wQrptuB2x4qOGbcgvbI5rcuDOLtCi3dP627fK/RKrtDypTsnojCbYMIMQl++N56oI43vYGFH8/gokVMEQ7qB99nCzR94wHbHa5uQLHufC7L6Ce/9OQjyzYsZ5wk3X9vs/3uwl6lDssKKibx8HFeQeuDO+45W8I79fhj9JQJz5+ilDM9N8cHwXygAmD9YtOgDaeqf/RiDP2cIEBQELCA2HpiNCPqCgp6woARHYYEewAKD19AgL0DICRE2BAMYsIAghIABGwDABijEAA082AMMAEEQQMCAB3OIQiDcYBIWyMAPAQABDDzCBhn4BAmrYUJdLFETTVwIBCBAgxdOMYkZKCIQIOADHligiILAAARUKEYaAMEHPvCgIW6gQkF40QJDzGIbC2GBOQ4CjmGEACHqyANMPHEaXQGLIAeZE7GwZYOGmCIEbiBGCGDRkQAQYx3BGMkxVlKFP6CkIL6IAx9AAP8HfVQkBIDwxSkaEYw92MEU00jEHXgSAj/I4hUt8EpL3miB2CAAVR7xFKn48pca2eWIEFmIIu6ABlSEZBYzwANVslGUUySjLae4RyoCIIsutAEPfqBKHiAzBx4EIw52wIMeWBMCO/hBDop4AxyMkZGW/MEQK/HHX2CEmACIojyM4IJ++vOfAPWnEQhRxCxiYJnXFGUSv7iDDGRAldJsIzXvCMkvMlOMndSjHAUBRmie0ohENKIYBWEDRWKgj7cMxz2Jqc948DOgMP3nQAfBTgzEUplUxCMAvghSSV4SAOusIkWTuE4kwrKSCZWoEXdATkH8kJJgHOlOb/ADIUAypUr/w6VkWooQTSIUoRTtqSUx6k5QVnMHGN0mOt2px5IeM6RW9AEG0ApXuCITBznAgFxdqUZ6atUaK0UkVw+SARduMgMqDKIdb1BYkgrxhQ7NwA8M8UUaZCAHKI2lDZDo2Mk2FgA3yMFlf/jZxvJAtD0I7Wj9+FcmtvYug8XnUIVRT18EdoOxlS1oEUvb1+7iAgsIQAIOIIgDJEC4xF3EbSWYW906zre68A8CBKEAASBAAApgxHIL2Fzn9jYZCQDABGADgAYIgAIAoIAAGjCIXmoEAdDFSne9C4zamoIABhBAUwKg33z2VxDuzQh88Tlf+l4wvrlIwHUN4N/9/jcR202F/y4nLAkDTLcQCGAwKZ7CXkFMILgdroSCiTsBAkwAwg008Dbse4rrEmABAmBwfhegXAR34j+SuK4hhOsIHS+CAMklBAH805QJFKAA1dUwJSJwYf4usMAq3gWLRUEABQQgvwKYwHgjQIAIZLnGr4ANhQlxAAsP+LiCQPN1G4CABxAXI+EFgIIRQGMAHGABCKBzl/ULEzxn+MSDQEABDABoD8MkAdYFwIwBUAABBDmfceZxPjMsaQAMOdIP3nGKozxBG9diAtUVQAQ6nAAvRyDOiogwKmCDAAoIEwARKMCVIwAAH+v4ug/IL3qvO938GkC9NF6wAQqQgEYjIAEPiHEAFP/wagVbN8RypkAB2OviWgtAmImmUq/Py98LA+ABBRiEk1HM6XFMeSye3gQFApDsAhSa0QV4QABObGsBWJu69tY2oyOAEeteQAAP8PC908vtVw/iAtdFryAMoABiWxsm1f7RhRMt6oZd+AAxFnemC8FVzJS7F+euSro7EXFBXIACXnZ3vQfuY4rzG85DFpGPD/CAUEMbwOpVwM3Jq172VvcChMg2xSd+YUQDXRDjRgRXa/LxEY58Gaq+r5Xb/ehjE+C6Jz/vsO3tYhgrPNHqfQmaj9yABmR3zRd4wALwK4A6p9nLD9hlANatXlojmgLmpXXQR43o6Va3AX2nbnY1Dt//l2gaEiRAwQBQUJ4RrKoD5SkE0+1hnJsgZzJPV0bUSwFq2Cjg6INQr6jDewEvU6C61jZ2chNN80bLGgBZT3QDGh1c1ytZEPJ+dHm97O+FN/rzBDpyBJgMey/zGvYCQLV/+4MvLl2nQ4KQ0nVEgKtNq6Py1tHOO0L+m8zT4gJ3t0W229uAi2Qc3LpXrvUFkYIRjMBADCBVCADgoBQIovITWv9q9C8O7tfF+7NwXREAerMwfmkGG/FGXAugfI0gMQaSHVNyKtthEzShCJhRHpzhGZuQGYiQeIvnGSSAGZihgbQwefDgf1sCgA2hL0lSAq1yIVMiefgDG7JBGzGoCblx/whZwwEOEDWtIiC2YILbp4LGsHlbxX/NASIA0IJUIx2EIISGoBxUE4PQIR0lYB01wAITmAI14AD2lxyXF3QCUB4wWAMjGIT8Fw4o6BdEuBBc4iCpshu0gTAP+DAzaCAIoiBU0yCxAQCpUgIJ0ioq8HwkiDXWIQAi4AAuSAgGwgE1AHmtQhMDUIiyAIXtsIa0YISJwSX/cRUd0IilYYeKACRCIiFTYiS4wTAJ04P2xirNEYaVJwAZEoqDMBr9IQIjwB+wEYaVmIbggImH0YYKsXQz6IWlcioFoirylwJS0iq8wSpRyIuCoBkjkALwJ4G3YInsAIyyoImAQYyjqIq5OP8l/8IAq0Ik1tiKOQiNghCCr4ICDKCFhKACJRB/ETKOkiiNH+SL38CNkCGMCQGOidA0U/I0USMhIyAlHGAgztiQg6CLWlMINWAgAhACWgiR/CgK2rgaACkM3tgNdxZqnrcA6dcKAokPG6kO/ggLH7kNxTZoE4ZfZNeNGYk0NUkOKZkOK4kaHYkMiGYA6VdmyQcZN6k4Rdl/R5kNO+kKLYkNiMaAhYBoN7cKJ6kM+FcT+qhESdlpKtWTxXAAg8YIw1aSurKV5mGWsYB9NJGVnpCTwuGV9gSXw7AABUCWZFYAboceaCmKz+CWneCX5rCUJimXwqAAt6cIDIcaeymDjlH/lC3AHiawAolTffIgmOhBmMFwbY4wZIo5CoA5DJ9ZCCBgAhJwQDIjKOgjKDGQMg+5mNNgmVSJmcCgmY3AmUzpmq3ZmJDgAXijImxCPoVQLKQZL0cTmuYmm+hmDrTJCLZpkrj5Hc/pCp/pAR/wATKQQI5gJuljnP2HnCKnnAaHCM2pl54Zna3gl9TZPZSwAjMwA0Vgng7knd1nDobpCIl5m+Wpm4lgAtUZP5cgAURQBMCJeV1pDnRpl4MAlnlJldHJnb+Qkszin5kwAESwARK6jfL5f+YAlod5CGPZmRoJn6uwkeeDnZpQE/ypARqDoQVqDk+pCFLJkg0qoqpgiSAA/z4DeqJtIQPEyaJZhQ4/GZT5BZUMKgnxOAgi6HF86UAkAgIzgD1aOQggIAExM5mBmaEpmA6zB5O61ADDNm00CQkskIo/4h+U2ZcD0gIxEwpQCAPnIwE5epwtig4h6R8KQJL3AwnP5zVU4iqXh38ViKZnY6Ehegh7swGTUg6wqQpNKV/89yp8qjUDg6QUSKOpMHkgQKiFigin8wGsKac/mg512h93iqCpsCuQOgghgCFSQ4lLYqmoMHkn8DqbmgjM8ivdOacuemQGEJNfOpXkCQmpWggUsqTNwHTSE6dtmWIwMAMaoKwrhqVsCKQxJqRDKaNimiQikBkMIAKsqgKRl/+baJqpn1qrigAC57Oi3rCopyqtuvCiiRCjIOoIz7eLJCAliCiPjImms4of68csidoN7Kor7ooLHCqWdTmvoOCgFzQEGwCtywoJ8wKlAluw3WixtnCgjKCgChulffkC5ZqfkHCjCFSxyfBhAYCnlhaT2oWxtVCfjXCfzimyzlAERRCrvsijF6oWLnsJ1+V5DWOmYFYOy/lj+Taz5roMJvAClsqwbBMzECs8PWsJDXAAB+BlMCFmuiRkHTFgRBuehzCeRZq0yaCmQ9C0GQkCGjADVkqplqcMAysJXnZirOZqXMsRXrsNozqSRasIYsuoM9oMThoDTksJhWs9GxCy91f/E9nHlgE0tZcAYxq2bu32bofQqMvwkr06YVu3oInwt6cauMygA/JxuJJgugAgPYZypnALuZWQXwGHYX27Y65bCkFqCAdQXURqCDIbrGwKq6PAo++Buo2gltpXCctDsfvauslQdxihS1MnAAmbarU7CvB6CDC2XovAsfhJtsXwMQlEvIxwlcdbCSRrotDJDHHrCP8xb6EGfEN7DQebCGApvQj6od37u8qQqYkqvqxApRfqv7GwvqWAucegsTAKG547CPKavwsLvKDAKE8IwZywAu8ywepbve2aDTC7CIimANa6u6FLs8YQAzMwoALMCs36rOm7DAQMORoMCrOLCDDG/6UE4KUzSZQkTAzSg74pzAroWrI/LJ0xHDFF7AkzHLZtJ5LYpbI67L3AAAKeaqzHoLNDfJ5HXMBZ/Bpgawig6xeiWwylybrJYMFEQMELu8XEo8Y42MWF8MWZGMbD4CVt+6rNAANDMARR+7i6Wg0dvAi9+xtyLAycQsZwW6HoWwwvvMbZgMCKwL1gs8PAwJ/QesXSOQAnsrOgycYDxMmYML+IOb2RDMW8IMWKK67qexVq+jPHsMiiYMDHcL2H0MCjLKz66njgEa6oHAxjbAjG67i01RZOyrbG4Mqd7JLVirtDalv6N6a3In2IaMi+QMeHQL7AHEADkq6K7MmfAMvIsP+lm3vDv2pP+ren7FeR9Hcgi8u4aGwJhayUJAKwz9XH2LC3TWyqYBwJw3oqEgio7UwJlLxiPjIvjfJdoSpYj4ol/HyDu+wL6qkN2qi2xFxf3JxBFf0pCe01TNgcTtjQvECdAks/7qKuTkfP+cMlLKCtmTGHDFCHy+vQmjwNv4wIzLK6JX3QuFXO/sEbn1ggtIjBvwDS2mDNiTCxe1yJF11CSa1Sg7wLD50ONzoDiRyESw1FVc04TZ0LQt0OVHrKJXjVmODNElGVTh3T6CA9ykvVJl0iZK3V3RIPN5q4uGDMEATW3dDWuPDU8IDWR12jdm0JYh0ReG0LWz0Pce3VWLz/1sEx2LWg1/PA17NA193819vA2LNQ2PZw2Eit2Kph2bLg2PYA2a8g2RZNYFlNC5idD5pNxJx9hJLc2GZ9D6K9zjZxzVjlCgbQoRvMUqctC6nND6s9gROylhppsXnGk6b92rMA2v0w23bsmcbtbZeZ3KQMC7/9D8FtyQ8pn3OWZ4Im3bGpDvZcqnla3a/A3AAB2dr9HfLJX/8B3oxK2Zygub6aw9hq3q1w3QJx2Ou9JPJZYjFJAAQY3nq7AExsZUysX7onlCJclsoNC+g9ELbT36TdCYFNDPStS8kGGwaQbAswzlGpvR0bsYT91g1B4fJJaNOaDbd7gISWX2FpZ8tc/wj4i7SVkKT62N+TEOEFgeKqwGoNvtvXIMvXO+MHeHOQ7LuUgGNUHAv6fRA+ngp3lnIPMOAEbg2gbGcxTl1H9mg1vnCDZ+NL7qfSDOGxbRBRvgoEAG7YNVyVgLIqa1zI1bLY4MgAYOfrhZd3uaBwbArFI6l/Wqm18OQEMdNsWrDGVV1uvAg/i134dl1hDmHyrQh/DACVfm2BHMh9XsA3uao10Kq0HajLfeYDQdSHLgsXYLmQULVXe23mhV49115dO+kD+Wp9e21im+tHq+SWUKwvbd0m3nTszQoXEOCaMLfjlnSWNuvYcOu2rku7bmnRvumQU5Pd+q26/NyfTer0hf+CjY6Aqh4Jkttg5E69zf7sdmbg/+HEYhvIgGsJ99oh+grUTh7swu7frNBmGBEB0ha7lAC7gjDui2bu1+Ds9J1f/JXD45nkY6u/sUCu9/6EWFoAVDF3FlYJzvsSW7Zn4U4IFw4Mla4ASZZcYIlkDK5okf7lDf/AsoAuES/xrIBkN6wA8AXfj9C+cmZqQZ5PtE7DoqxobVcI4y5nyafnR37fDv8KFlzHTYeC7g0bDUAB/h7f9bzl9XuYWweUQJ+wJ4/0LA/hAfvya/gUVk71TnmtdAljqCaV4MxfD4DDYPrESd8Kvfzy203sMVn2BKsNQVqfPzkBM34ATz+S+BwxvW3/CuBr9zC/Ct9u83uvDVvadhreH5sL9+UX7WGK36PwzoqP76twXPuu24+vDXf2Hwhup3hK7SvvsawgA/au+NwYAI5vxN6QxF6M+XL/9asAA2BilbatqFha7LpEAa6m91pc+4veXrjv9ayvCtTiwv+8yfkOILMPw95Q6Yng7rnf/KiQrMjARhaABEEQWXVU/n2FCUrKvJ/PETt/zN1g54jA8Jk/96egpoidCel/CeXvUDwECDgQED4YGEdBGRlAho07g5A7jYZAipYWmJg9AJwAAwOdoaKjpKWiDAymqqujAwGssLGys7SqAa+1ubq7sgcFBqwGBQe8xbagxqqfybQg/x8yzKbLqjyZFjaWQoY+gziUipmi06w91haWioyTj5BLR5MYleg55pi549GtuPn8/aW3/gIGTCAggSqCDQQWC4BMID6FoWboUFgOSaIM2hpBGjRJiCUbmG7MeuhvABJz6BTRgIdB0MZuLGlcItnPFcSbzADi3KmLoAFiog4YKMizFkOINBXqmJGsmoUcGVZiGCQJkSKQmXgERHUzaa16T2c2dLivqFlYOs+qVdWgwC8CcBsIK5BwLdqxuUZ0GNBhBCmv/mR8APEVqiF2hmTSs6CVE2C7xbjifJzMJuQLCYDaTQu5M6cDCxQIGC1AwQLNnv/hrSVCgAMBIv6uFuhhQ/+LWE9pCMIh84eFTawkpx5Oi7Ixy3YJCCgQALVZzsSjSyd1dFcKASEAhBCQotVsfzE2eFCVezcNetPT+xNO1jOBAAjKPpevvn7q6roGCAClHxmDTwM48F0+MMwwAwyjlAcBb+jZ5+CD4tAHYT/QTWghTvjds58nGwLw3ycCArCCBCSWaOKJKKaI4gYxhGKBbgueZ8GFNDqIHE8JIKDjjsBAVmGNQOaTYS0oCFACACUIgEIrAibxwpNQRinllFRKycQQAH4ShBJBZOnll2CGKeaYZJZp5plopqlmmKl0JSFEAZBGGgKd/RjknQsNCAsJAnDAAAcCkDDKhyAKuGaaDhj/eqiaiS66aKOOnglppGi2qdCNO00AlwIKwHVBnW/iKapResLSAaAcdMCKcbywelyp/Li6i6ytwnpcqDfpOJydo/Yay5BI2VrrTrQWU2wtx94jbKu4BqQpAZx6Cqqv1JJaVLKyYFvcspVxm5+3s4KLbLP+xCmnAHT6SG617HICrELsrWcpRPHSO+9W9wpUb03r8pPjjjr2uFm/7VL7bsEIJ5wPpgrbQnDDdx4M8cQUr/owMxMEcEHGt0wwbcUFSwzyyCMzfFMAERyg3GgXU9gyyQ6KDPPMCpsMEQLAKAdfugPT7KvMzHzYHSd68eUXM0X3FRALKBhN9F5K91M0Mkkf/21M0UMDUHXQLHRCQtMoWJ3CACgIyozNCuEMwAV0GsDzWrz6fCHQxjAgJzKtvRYbM3nDFpCcDnDS9975sKCCaxwI7prfV7fW2pEADG4MC/oFzslro+2dpAgqqGD2rWc9UMCnAExQwAMfy40n3cWQkEoHrgFwXXbbZc3L7Npx54+qfAogO3a5254MoF1zgnvtxhR5JKAkHK87L5hbLvsIIwDKwAgCqACA8me/XMzKOo5GQOqqB8m6MR2EoEJ3/XEobisbtr9ekvzF3yEzLPQJaHbty9+qkQB4zX/s975Q2E16nWDeAT0Uu8p4rxgJKMBoCmAQ8pWvRucbCWnaVALOqf+qf/f7X/0KuIoOvOZIICThoGDDgNbshYDG6J0DDjfAEdatgZ3g3gIX6MDkjO8+DwQZaERDGtM4Ry0ZlIXrUGE1AIxmewBM0pKSF0UlKUSA3JNi4WLXnyxacXJ8ARQUj6TFyOAQSQKoASfyFxvc9VB1cbtgBN8CFwLMpS6bUSEsBhACPvYJAHzyE/OSEcg/BaofLRxAkgJVyEHmA1ApaA0DGnlI9DFgO0ei5Od0wTQW+mU7HPhEKiC5HVW9UW5xVJ1PjigUouTxJikAlGuKd6o+mTIZtUyVP0jQmj4NLZe3jAYLWqMCUwKTGaMJZSeOWQzMjSYV5wLFMLMHuVP6LJX/PiNIBUuBkFde8JvsQhvIsDkzXwjMFMI44k6SCM521kecClmABEfztl0QgHQAqCNcWEFOmMlTnUEpwALgpkd3GhQy8BTIcnhUjAvEiWfn4mcQG6aAc6rCAAog6EE3WqOEBiQCEw0FAujZCfHtcxX9JJkAfsgK5WiUozCFkEf9QQCQ3mKb9kRXSdFFAZbm8xZAvUV8NrrSWLgUiQWNqVLboxYikvR7OuUEBQLwgOV4jBPvCapQQ4qnIZ5rNKLxqSqOehZ2LvWsblqLAHoqLajWEwAjFesoUsquOUZgOQawowTvShdYkPU5SWUXC1BBWBaYsHgCYYEDgonWUsy0HwZA/x0zLrCA0hBAZQqg6nIA2gm6Ussnlf1JJ1q5HFdeNKNINagzR+OA/2xylwPIlynsFtiCPZYfI51TMXIrvgkQUQH4NIVne6VNbZKCIAIVAB5J4YuBptadg61BGhkw2AEIai8pcEAJRlADBxTvktptogEHkIIQhGAEAeJdbAGAXfN2bS+cgK90Q4ReB4RgaOV1QA1kO7Hb5sNtDFUXycxpTnQKwADpROcwXmpQ+eknFa/hAKBUEOHfhSBJ2flL9ojJuUDRNoB9ak3iXnM534k4cJwbQGsMix0+1vZC/kXYcEX1z3+awhcCkKdzR9FNBrvTwQKAsO8+TOLtfEKMGoZm4P8eTGTfRc53JAYxA6XpmgFIl2yw4QvNYsyMBAQVp0jkKo0qCgAyX3SCqA1FK8EM2I0CWchTlvJrsuTYIDtxyUFucomlLOUPHxBAqQjQaKpZMjHXgrdR7dnIilrUsSpXgnmNyx3r9OJqvbnPGyJxkULAgBSosUjzevCdOYSKTDu5yNgpweEYeF8AdK4DDEBBB1BQAgbALsMk43IyLlBHClpwYoyWqyhcqhynluY0njErxS5NYj17Qpa0S1woRM3FPJt6zyzYX2tKrD0WbMeXsRzNeWem63wggAK/hliwV0FsJ09H2WctZmNjZWhaeDkAQ3nrfFQ6vkabot3qgbdSSYD/63l3by2IXm6YSUZmM6MzoxgNeKUNTvFYlLuhdbyqgEdW4wWXornNlXjFR36tes9CV7syOYQI/AsFC8Xj7544yWceIbjpG24qh1BxTRsKhPQ4PQKnudCVkXNY5Dtg6Z4YaA+smVYuYChsjk7Qh071mqsF0TfnyYx71ZYC8NUActmrWxQe86qbHXRwLPqEvPpVIz5o6men+sV5IRQEXIACZN/3yNgOVmRjUOZxN/jcd0EB8T0A3Ruv2BwjDZdJ0ygAiqKU5CdP+cpb/vKYz/zlHaD2VeQYAe/J+jo7P51VjmLNNMqqVlfP+ta7/vWwj73sZ0/72tv+9rjPve53z3vX/wsbJ8oF/bmTrot7dmICCwiA30OB/ADkfSA857FyA0/9uIvO69Evq5gdmmjeppkTpiuAaCwakAKvIsHVT7/QD1D4lhOfFrnlWQMOcIC7+nQoA5Wgc1Sve7HaeBUhp34CSHMbk2yGphxvdVcaB1dFFVeiYC5fFYESKADy4XDn930DmIFnhQAP0ACjEVwLxwwIKAqhJQoO6IChAIETuIIsIwr+xm7upoEyGFPBFwEKIFmKlgwj2AlDgYOdUHgJIRogyH+5J1Yv6GgzmIQwtVKnAx/vNwuUZVnEUHg2NT4jBQAEgXcCEAHA93uj8FdKGIbfpAB3tQAPIHoYImaI1m9y8v8KVwgAwlAaIPg3XjhsMSiGeCg3BCB+prNjOEcxFnh6oSEnbvcZg1hEy5eHihh3W0cj/8djbgF2B6ZXfbV4+uR4i5iJVNeIF2J+omB66NdKVSVaQQF1mniKNMeJF2JcPedKP8cJo3gQ04eKtAgknDV6IGN6AFBgqKdmXgdzpIB+tTiM6kGKCYB4OUgxXZdXUIeJnSBPfagKAUiM1BgdCBABBFB4aHgypJcefHds6kRmEXda1ViOw3EBd4UuCxiCM3OEo1BUYPiFd2iO9HgW7LeNaegz7uiC4xOPdliPAFkUEYiPCqGKeLKPoQCP8/iPAdmQNwMwSJd4MIOQJdWPCxn/Cv7okBopY91oH4E4CuKIgaMwjhtZkvlwdwGWjCTziKQAjQIljS9pkjKZDMZGkAJhkHfiicz1i7cojDP5k7lQEL7zAB3pMHLDiqUQi6bwikDZlLKwUtjoNjqITwfgZZkhUarEdKfXg1pZitnnlGCpCiBVVWvVUA/VCaIxUiI5V0XpIMtYR2HXV28paWMXlnYJCxdwAexHAbcIC/HHCR6IbkDYCUS4VRf0jYW4i4fYd315l46pMpBpDDsYJ69AmYTJekNFM4iZiI7ZmbtAECv1kbUwmRQIAJZplDNjiXXkjJ7ZmrNgg9johG7FCSWIfyjVltKhi2pmiq7Zm7GwUqAn/5W8EIWdcgATsIU1JQDryJYwg5THNYu+GZ2lEAEPkFnutwtriIV3FQFR94C4ORw6WQo+KZ3kCQAeOEHLqXcgw5IfF5Pl+Z4OtQDpqZ4Vc4OLCY6iQJLvGZ0Zw5kqCWx4dYl1SZgXuZ+OaToT1Jj5mIsC8ACsxJv5VKAGapehZZsGyKAU2WMZOaF2KZuZ+YTVYk4UCYcLtqEcCpYBUAA64nVqI5EN80+iOVovqZ+bqaDlWKO9qYJP9Z8JQ2bsmZ8KMI2q2XgDupFDSonPB5bPok9zSJ8NU1ThaYfop5ujBaENSaWfYaUniosU02jOaYez+KWfCJ0AKaatmKRbWi7fCf8Z/oalu1hVFRSlIwmM5iin+UmnNKIpDYmTEPKCc0kAYfdEtImnp+ee9PijheqHGCShw8inDxKIm1mdaEl+4rmW1BijI2mpncFr6dl8BhEn7zGfteioDoKoAbVjI4qRjEqLqUqg03EBEkQfyDV8cWIAEWCTikiq9mGnoSCMrYpVq4qKvxqh00FE8nGcKdNZvhMn9air9mGmnfCKw2qitTitwVoUKToU8lFZCiBBA8WsFMCF9Oisz9qVuxl9ynWfiQmsAWmt0XEBynWaytqBEpQxy9FX47qmnvGncUl2okFHRIqvnKCf5oipQCp151IWleWGw0qL5OogODqmyrmVrjT/jYdKqKcaHc9SVQ/gMTqFrF1now6rrxZCEPJEqVg4feN5o9fpckBXmk6ULgmwnU2arxtVYNAqDJWFpsQIrZzAlGlakCQLIf/npsf5lfTopr0YtAtqUBYImoQYh5pKj/zKmtPRADy7kQ9ri+p6GotnbKNRVTIZsfWRolmrkVtLI6qZY3NhrlUqqEwLEQfwABFQszOZtiVrrkVVWUgLADtLj2Q7Ib6FACLrkHirc+h6Wb8AtMCKsad4pFZbH7Dqgx06tMQRpRVlYysLh92qqLSotFqqHj7blIdbqngqT2ZmsZ8hUASLiqPLuNEhOnbrlKXrkZSKYyzVuulErXjIqzzo/7hnkQA4eAAIoACiiqKWOxwIabKueqbEOoym6oueaxd3hTro6KC+Wbv1QZGjIVpk1Yu8K4YG26tTWxTnuVbMIZ3aqx7cOxcGUFmAionhG4bumhpYR57rmx4UWVGB27qaWL+dsTJyQrmtmb/FirJ+63H+u4uGKqx1qKqpQZbnQsCdacDSYaq82MC/W7gzCMB2cbTnwp0yqU8PbJrJmxo6iZgUQKiwm4njy4PlixMSTE/d2ZARdZvlw4pDyrcCm6V9m4nRK6PTWxQ4Nho91ZQmVcIWXHoHFlpNNxTztAB02cPD6LsDC7wYErbHq5H0dMSXuXofqjptYVl0iS5gi5/m+P+6ZkyI/qkQIMXB9ThVVVUAGleY8HHCl1sAFGBsnBKgBMCxRZrGbuvDfhywZxu3poCCwoXHw8GeuglyoUuNVTtPpHiuNYzIpAAtmoXFS3zAY8pm49jCtYiYonHJoozJzPdbs+su8dF6P2THQPXKryfLvodVs2zLtfxTuZxVDapVp4PLt1BVQBUBJXrLuuzKwMx6tIzMx6zMybx6y+zMzQzNz6xV0UzN02zN1RxU4+MLNhUAfIxsorPLxmzHJTxaKbprBJCeKnNVHHPOVXfHzAzLt3DN2pzN3LzNsazP9czPAUDL6BvCp8F/wgxUL0nP/+zP9pzP+LzPDd3PD53QEb3/0A6N0BQN0Rat0AkMzngVVHe0h62MzRmNz+c8AaIDt7sAqzCLkYWHC15WeKtsdp0sHRMUadTpjH+1wPRYUaBbEDp9E398w7xgrO/YgtoZVho408RBENjLCVAKoX81v8PYoD/sE9fKDw2AaKSxEL+w0ikIswfmgfA8dEqdGsh1Tm06i/op1dV6YMGA0jgxsxNoez4Frw0gr1+NC1Vlf0kd0iJdzoBNzoI9z+XMoswBVA36ysR8CyqqVb4z0pAd2IQ92NIc2ZT915d9zxndvbl8npP92Qz9iYUngXT91W04V16dhPJc2ZLN2pnN0JbNzCnK2N+c2Lasoovt2BOt0bvd/9ux7dqgjdnBrdmtTc3oUs4jNdywLc3MdZ9wTQsb26Aemy5B/QBjzYiMDBlmxoqBGIcK99Pl6NZGd9X+MAG2utXGcJpRJdSqnd12kdY/8YhzG32q265YzMDkLRB/XACeWdad4aduwbHxO09zCsen2L2KGc7EMBT5LbcV7N5qJVab6YFjesjESNUnHYFdPRSo7DKqk6Fa+b2RHJAVRZYAq1dhC94dbhQQ3lQIbJ6RSLcDTsUaKU8TBLBxOUFDvOK64N+QEcSBW5JHmxk6yjJ8u8U8Pgs+bhdWTKIGXo58mwCQ6xajseNJTgtLbhdqbOEknlwN6hzzDVZXngxZruWDvP+LIz6TB4ZcOH5HoDnm6d3idjHJNL6R33hgv3AARU6BCy4ATw7n7iLnTN61f/65AT7abShPJ/7ROQbou1Dmji4LoBWJDYDopIFRhKhZVRXDkU4dgt7psijlB5Yx8xSBjDcXiA7qWP7pKEzoDWlOxSVB1n3Gd7VNrUTgqi4LkD4cU17n1OiSBgC1X2Xj52JEqZ7rv8LqkNHTl0yLmevlbAUXNT1PD1BVOY7eyI6V7rTl9RiafLVgd46+fRjmJ53taKHsatHkm1utK+N1wLB4EmgAK0ztpbUWxhcUTAqYylfoi7jrPPGNCsgK9T3V5zkUBGB6o0HMEthXuXUW3PdWAqz/U8IQAF6steiuEEcqQb5OvvS4VuJD1dtUWk837MSAXA1uDH9ph51ifOItk/5+E1iqXGnOrgVLGiuD1g9AEOnIxlAntmexg6qqoh0LABGAbhOA5NW42sIN3Ey/9E5P3K1nikTYy6JRF3YszBct0b/99Mv92hVd3FCv3F9PzrxFlgYg0cvB0RNonRTI9WN/z6UA9J1wAUSplmvzrzGd9H4d9k3P926P0WB/C0PRI1NPlBRfzKuH9by99X7f+F0v9oDv9ZEP+Vp/CywoJ6dT7CNPGn3/+KGdyYlGCs9tki8vEKbaaANP8+UItVr9VQjWoArfCRLs8Nx6WTFrmlM1Urhq/46lHxCY6nA6reKLCJozfPlU7ju3Pvo3Iyf9RicNkI58SbsX3w8U+X8ZmfpKhdCzV8LhLidTxeAJH4HdqsfLwenZ3vv+QJHml5HrrlR7fvkJuwoRRBo9Bf4avoLjn2PiZ+7aDggAgoOEhYaHiImKi4yLAgSKCQIJAAQCh5INjZucnZ6foIYBAqSlpqeopQGRAgUCEQUTCwqptagGBa4IpKG9vr/AwcLDxJ4Bq8XJyo+LkgYNl4QHBpPK1te/BMfb3N3e3JCIkrsJCrCmBdS2tgkPArvY8fLz9PWbx/b5igoGjA2uBQgIbICrgCZ9CBMCO1DgQToApAwEcEWKIq1UD/8WmFrg7h0vhSBDigSJb2S+BQUOMJrwypSCBSpNypwJAOXEA5IWAOBXimKpjj0pkHpAK9ckVzSTKk2KM0CCmIpKLr3GsN8iXFCn2mv61JCsABcEHRAoMCw9fvwYMntECuaCCKdcSaqVABeFCFrz6q1Ha5cCRlL3EpNEKVEmwXw9/iV0IRdcTZZKIajHlgDKtdCY7Wx1qgHcUoKoxaKIuLTpX9AoABB6MFHg07+cZRVLrTBsa6lXC2ituwFLvJYUlKVsiQDafgKEam6LCi7pSq0WKL9NvTqiUauwD9LmDQEy673+pSNLMBdv8MK0ax+0SxMvSwUQPJhAvDLKAxUFWCX/dbFUgsgCLGYJLqChZyBs6gnwHXfdeHdgKAfM4hJMDw6T4HcASBIfLxc8EIBf9RVXFS3iqYRKARp9JoBO0LnTUYUw6qVRP9Sw6BqGMeao0IwA1FhIA069U8hH8xzHjCS0EOAMRLRc1M9cpDRAQANABafjlTP9RgBc9EWFI5ZgyqMllxBNNkEDDZAIQAAUfCgkPTa5Es5cT+ongDufxYInKgpAY4mNYQaqTwJwRWDbjYImig2hrxQmZGR9CuIZKRTMhg1DDuk3SGYGEABURT49BwBDC1jikKWKpirSa6q2CuY4rUBlzjo9KbBYjympA6irvCLEaq/APqjhnTGhpBFn/yrydyeKgmSiVkrBRlvPr9JWe9s/FXUKJUaTYPsAAdRQQOBu1pZrDbXmpqtXhP31BNM0d7YCl1DJmnKouvj2gm6+/CYlXqcuFqTJtqVQgKY7BvWr8Cf7LuwwSOzGJeWUF0WgnLuoPqwxIR9+4/HHIIcs8sgkl2zyySinrPLKLLfssjfjouNTTxK9bPPN34SzsTwM4uzzzyYj4B3QRBdt9NFBD4300i3rvPPTwDQMNU1ST201v1VfveqXWneNNddey5R12GTzOnbZ9pyN9tqBqs12PG6/LTeMcc+dTN12510d3noHw3ffgAv2d+ChDE744UkJhLg9ii/u+OOQRy755P+UV2755ZhnrvnmnHfu+eeghy766NQ1tUCXxVyAwL2Ij6WzQCpdQFZMExDQpeKuE2AW6Z43ZgonozidiCVgBx5ZWHNBsot/ayooyHumRLA775rDpdMEVi2AgMHNBtAABRRcMMEuDyQwQQBTUtIhAgaoRHzkkT2wGTO76N5K88hAPxkBuWRMveQXCFAhqGEA1gBgFxGghfTgwg/4vGMCBVDARP7yPshZAi4XpN9aLjGKoelPEO7Y1f8oZ4nJECKCo0rOAaNBi+ZBYkCC0IgmqCE751lQQbmgQP1W+AChyG8Up4COCdczQsuxBFoAoM+bhASPFboQOsgIngsr+DjiUaP/ATv0i3dUsp4PAsAdrCui5PAUAIf0ZhQ6aSI8sCMQGwaQAlsqABThp6CxrFB5mhFEFy8RHG0IUIyXmwZA5HcAoTzEiU6cwLyoyCgFhIWKjqNiFvOIv+fxsScP8B8gN8nJTnryk6AMpShHScpSmjKU7CuE6sIoxgQgYHqnDN2bBnE+4SECkplrojZQx4hZxnJu66MAJZyiR0q8o2NJPAYkDvAh7iXRANuj0jFHBU0H9S0B6JOP+3SIAJ1sSUECCQB9JvAA+TzSe+Uc2CvEOQ2hFe+XUGOJBHtYpudNphUFXNEFaLEKBRQgALS4AEP+WU4FTgYWATAAXvpGvnCtyUPk/0iALrD5CAhKMBfN25AAsNeKVyJUofAkWwAjYAAKLfGek8HP/hQUQO+4IwAaKUztbJgLD/HSbk1sYYQowE9EBk8jEH2EFKkBiTfVVJwhJRsWXfGXk9aznsQr4Tb8+Do33qUVN5WbGi/hzwVoZBVNDN4oPHSM8zFDim+6wFVjkdSueUpKGHWFAdxxT+GEcI65+M8CEhBA4SQAjsnRxOoIsAtYavURGlHNK8DlvPZcIHh9lZIBHnvWtUTAdoMtbFu1NoGLODJDuaDGPSlilfeplRQR0ESaSAHW+ynHUIBD4DtUMpddrAJbC5DiagNkVkhIEYinbdRmEcdYEeYyGsMdJVEpEKDJyjUxudCNrnSnS93qWve62M2udrfL3e5697vgDa94x0ve8pr3vOhNr3rXy972uve98I2vfOdL3/ra9774za9+98vf/vr3vwAOsIABGQgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Growth hormone concentrations in patients with multiple pituitary hormone deficiencies (MPHD) and in age- and gender-matched control subjects following the administration of a combination of arginine and growth hormone-releasing hormone (GHRH). The median peak GH level in each group is denoted with a horizontal bar. The dashed lines and superscripts indicate diagnostic cut-points as follows: a) using a maximum response of 4.1 ng/mL, the combination of specificity (91 percent) and sensitivity (95 percent) is maximized, whereas using b) a maximum response of 4.6 ng/mL or c) a minimum response of 1.5 ng/mL, sensitivity and specificity are 95 percent, respectively. The inset illustrates the time course of the mean serum growth hormone concentration in response to the stimuli in the two groups of subjects.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87:2067.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_44_23247=[""].join("\n");
var outline_f22_44_23247=null;
